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We live in an ageing society and thus the number of older people is increasing rapidly 
around the world (1). The ageing process makes people more prone to certain health 
conditions and many older people experience multiple health problems. Furthermore, 
the percentage of people with chronic diseases increases with age. What is more, due 
to an increase in life expectancy, the increasing prevalence of chronic health prob-
lems result in an equally increasing loss of healthy life years (2). Moreover, with aging 
accumulation of DNA damage and alterations in epi-genetic and cellular mechanisms 
occur that affect the trajectory of healthy ageing (3). Nutrients and nutritional status 
could also influence these epi-genetic and cellular mechanisms (4). Hence, cumula-
tive effects of ageing and inadequate nutritional status result in a further increased 
risk of negative health outcomes.
Accordingly, nutritional status and body composition changes as a result of ageing, 
and there are many factors that influence nutritional status during ageing. These 
include gender, genetic variation in individuals, physical functional status (such as 
physical activity, strength and endurance), socio- economic status, cognition, nutri-
tion and medical health status, such as chronic or acute health conditions and the use 
of medication (figure 1) (5).
Furthermore, an age-related set of clinical syndromes characterized as “frailty”, 
results in an increased risk of worse health outcomes, such as falls, disability, 
hospitalization and mortality (6). It is possible that improving nutritional status in 
older people could help to inhibit the ageing process and reverse frailty (7). Poor 
nutritional status of the ageing population is caused partly by low intake of macro- 






Figure 1. Factors that influence nutritional status as people age (5)
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associated with frailty (8). Community-dwelling older adults face health problems, 
and micronutrient deficiencies (deficiencies in vitamins and minerals) are similarly 
more common among this group due to inadequate diet, and age-related changes in 
the absorption, distribution, metabolism and/or excretion of nutrients (9). A common 
approach to measure vitamin deficiencies is measuring dietary intake or biomarkers 
in blood, urine or tissue (figure 2).
In the Netherlands older adults regularly use dietary supplements to prevent vitamin 
deficiencies (10). The dietary supplements that are most frequently used by older 
adults are multi-vitamins including B-vitamins, vitamin D and calcium (11). The global 
use of dietary supplements, such as vitamins and minerals has become a routine part 
of many people’s lives, including many older people. For example, in the US the 
national Health and Nutrition Examination Survey showed that in 2011-2014, 70% of 
the older population used dietary supplements, and in the Netherlands around 45% 
of this part of the population used dietary supplements in 2010-2012 (12, 13). It has 
been shown that the use of supplements in the Netherlands is increasing with age 
(11). Yet, the role of dietary supplements on health, especially in the elderly, is not 
completely understood. Dietary supplements could play a role in optimizing health, 
however it could further be harmful and have negative effects on health (14).
Figure 2. Nutrition and measuring nutritional status, effect on body tissue and dietary exposures
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Role of Genetic Factors in nutritional status
Genetic variation in individuals may play a role in nutrition and could result in dif-
ferences in nutritional processes such as absorption, food metabolism, micronutrient 
metabolism and gut microbiome composition. Moreover, the genetic factors affect 
food preference(15, 16). An approach used in genetic research to associate specific 
genetic variations with particular diseases is called genome-wide association studies 
(GWAS) (17). GWAS helps us to increase our understanding of the genetic variation 
and diseases. With GWAS we are able to improve our knowledge of subtle differ-
ences between individuals, including behavioural characteristics and health (18). For 
example, different Loci for serum calcium concentrations were identified with GWAS 
(19). These Loci then could be used as a combined genetic score, like polygenetic risk 
score (PRS). Additionally, PRS can be applied as effect-modifier in association analysis 
or in Mendelian Randomisation studies to understand causality in the association 
between micronutrients (e.g. calcium) and disease (e.g. cancer). By using genetic 
variations as natural experiments, MR studies provides evidence about assumed causal 
relationships between a modifiable risk factor and the outcome of interest (20).
MICRONUTRIENTS AND HEALTH
Due to inadequate intake of nutrients and changes in absorption in our digestive 
system, micronutrient deficiencies, like vitamin D deficiency, are common in older 
persons (9).
Concomitant with age-related changes in body composition, the incidence of obesity 
increases too among older populations (21). These changes in body composition are 
further associated with lower micronutrient status, such as in the case of vitamin D, 
vitamin B12 and folic acid, for example (22, 23). So, in the older populations, changes 
in body composition as well as micronutrient deficiencies are more common. How-
ever, the association between intake and circulating levels of these micronutrients 
and body composition in older adults is unclear.
The commonly used measure of body composition, BMI (as weight in kg divided by 
square height in meters) may underestimate the prevalence of body composition 
among older adults. Ageing is associated with height loss due to changes in the bones, 
joints and muscles loss (24), therefore, in studies involving older people measuring 
fat mass and fat-free mass provides a better insight into the actual body composition 
and the prevalence of obesity. However, for a better insight into body composition, 
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especially in an ageing population, other measures than BMI are needed. For example, 
the DXA scan (or other alternatives such as Bod Pod) that measure the body fat and 
fat free mass, is considered a better alternative (figure 2) (25).
Vitamin deficiencies appear to play a role in several chronic and common diseases 
in older persons. Community-dwelling older persons are at risk of vitamin B12 and 
vitamin D deficiency However, the role of vitamin B12 and folic acid in common 
diseases in older adults, such as osteoporosis, cancer and cardiovascular disorders 
remains unclear. It is possible that hyperhomocysteinemia is an important factor in 
this relationship.
Homocysteine concentration is negatively associated with vitamin B12 and folate 
concentrations, as depicted below, and an effective method to reduce homocyste-
ine concentration is the provision of B-vitamins (26, 27). The association between 
hyperhomocysteinemia and the risk of cardiovascular disease and fractures has been 
observed consistently (28, 29) and showed that elevated homocysteine level appears 
to be a strong predictor of ischemic heart disease, stroke and fractures. Consequently, 
observational studies have shown an association between B-vitamin intake (dietary 
and supplements) and lower risks of fractures and cardiovascular disease, however 
with conflicting results that may be explained by bias such as confounding. Thus, to 
assess the effect of B-vitamin intake (dietary and supplements) on the risk of frac-
tures and cardiovascular disease, randomized controlled trials are needed. Several 
intervention trials have been performed to investigate the effect of treating these 
common conditions with B-vitamins, but again with conflicting results (30, 31). Due 
to few RCT’s, in 2008 the B-PROOF (B-Vitamins for the PRevention Of Osteoporotic 
Fractures) trial was designed to investigate the effect of B-vitamins on different 
outcomes in an older population using a multicentre RCT design (more details below). 
After 2-3 years of supplementation with vitamin B12 and folic acid, a reduced risk 
of osteoporotic fractures was observed in only a subgroup of compliant persons aged 
80 years and over (32). In addition, the B-vitamin intervention was observed to have 
no effect on the overall incidence of coronary heart disease, with the exception of a 
significantly reduced risk of cerebrovascular events among females (33). Unexpect-
edly, we found as well a higher self-reported incidence of cancer in the intervention 
group compared to the control group (32). In view of the relative short duration of the 
B-PROOF intervention, it was additionally speculated if longer follow up would reveal 
more consistent effects.
Thus, additional research questions arose following the B-PROOF trial: what is the 
long-term effect of the B-PROOF intervention on cancer risk? What is the long-term ef-
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fect of the intervention on osteoporotic fractures and cardiovascular diseases? Other 
more general questions included: what is the effect of micronutrients supplementa-
tion (i.e. B-vitamins, vitamin D and calcium) on age related disease in the general 
population? Who benefits from taking supplements? What are the risks of excessive 
and over the counter micronutrient- and dietary supplements? In this thesis, we 
aimed to address these questions. In order to answer them, some pathophysiological 
background is needed first, which we will further explain in the next section, by 
starting with vitamin B12, folate, calcium and vitamin D and their potential influence 
on ageing and related-diseases.
B-VITAMINS IN ONE-CARBON METABOLISM
Vitamin B12 & Folate
Vitamin B12 (cobalamin) is water-soluble and naturally present in products derived 
from animals, such as meat, milk, cheese, fish, and eggs. Together with folic acid, 
vitamin B12 plays a role as an important co-factor in the one-carbon metabolism. 
Cells require one-carbon units for DNA synthesis and methylation (figure 3). In the 
methionine cycle, vitamin B12 is involved in the synthesis of methionine from ho-
mocysteine (both amino-acids) by two intermediates, namely S-adenosylmethionine 
(SAM) and S-adenosylhomocystine (SAH). Homocysteine is an amino acid that is not 
available from food but is made after the demethylation of methionine, which is an 
essential amino-acid available from food (34). So, methionine and homocysteine are 
necessary for DNA synthesis by the methyl group released when SAM converts to SAH 
(35).
Vitamin B12 in food is attached to animal protein (haptocorin) and is released from 
this protein by gastric acid and pepsin in the stomach to free vitamin B12. Vitamin 
B12 is absorbed in the intestine and in the small intestine vitamin B12 binds with the 
intrinsic factor (IF) (which is produced in the stomach) and absorption is facilitated by 
mucosa in the small intestine. It is transported to other tissues via the blood. Vitamin 
B12 that is not used immediately is stored in the liver (36). The daily recommended 
intake of vitamin B12 for adults is 2.8 micrograms and currently no limited upper 
intake level has been defined for vitamin B12 (37).
Folate is a water-soluble B-vitamin too, which is naturally present in grains and green 
leafy vegetables. The bioavailability of natural folate is lower than in its synthetic 
form, folic acid, which is used in supplements (38). The metabolism of folate starts in 
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the intestine in its bounded form. It is absorbed in the jejunum, and the hydrolysed 
folate attached to methyl groups is delivered to the liver and other body cells via the 
blood. The methyl group is in the one-carbon metabolism removed from 5-methyl-THF 
in the synthase reaction. The enzyme 5-methyl-THF together with vitamin B12 as co-
factor is needed before homocysteine can be converted into methionine, which serves 
as a methyl group donor through transformation to SAM, and can be used to methylate 
DNA, for example (figure 3) (38). In the Netherlands, the daily recommended intake 
of folate for adults is 300 micrograms and 400 micrograms for pregnant women in 
order to prevent major birth defects in the baby’s brain and spine, like neural tube 
defects. The European Food Safety Authority (EFSA) specifies an upper limit on the 
intake of folic acid from supplements of 1,000 micrograms per day, because vitamin 
B12 deficiency is not detected if the intake of folic acid is too high (39).
Calcium & Vitamin D
Calcium is a mineral needed in cellular metabolism and is, together with phosphate, 
incorporated in hydroxyapatite which is crucial for the structure and maintenance of 
the bones and teeth (40). Calcium plays a key role in the optimal functioning of bone, 
tooth formation, muscles and nerves, blood clotting, the transport of other minerals 
and hormone excretion (41). Furthermore, it plays a role in cell signalling and fluid 
balance (42).
As a dietary component, calcium is naturally present in milk, dairy products, veg-
etables, nuts and legumes. It is absorbed in the gut with the aid of a controlling 
hormone, 1.25-Dihydroxyvitmin D3 (1.25(OH2)D3), the active form of vitamin D (43). 
Figure 3. One-carbon metabolism
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Most calcium in the body is deposited in the skeleton and less than 1% is found in the 
blood, soft tissues and extracellular fluid (41). Circulating calcium in serum exists in 
3 forms, whereby 5-15% is complexed calcium bound to anions, 30-50% is bound to 
albumin, and the remaining circulates as free ionized calcium (Ca2+) (44).
The Health Council of the Netherlands recommends 950 milligrams of calcium daily for 
men aged between 25-69 years and women aged 25-50 years. The daily recommended 
intake for persons older than 70 years is 1,200 milligrams daily; for women aged 
51-69 years it is 1,100 milligrams. Pregnant women and lactating women, need 1,000 
milligrams of calcium daily (45). The upper limit on intake from food and supplements 
is 2,500 milligrams daily, due to the elevated risk of kidney stones, renal insufficiency, 
vascular and soft issue calcification and hypercalciuria (45).
Vitamin D is a fat-soluble vitamin that is naturally present in fat fish, and in lower 
amounts in meat and eggs. Additionally, it is fortified in margarines. Sunlight is the 
most important source of vitamin D (3), which enables the synthesis of 1.25(OH2)
D3 in the skin, produced by 7-hydrocholesterol through exposure to ultraviolet B. In 
the liver, 25-hydroxylation of vitamin D results in the formation of 25-hydroxyvitamin 
D (25(OH)D), which is considered a more longer term reliable measure of vitamin D 
status, reflecting vitamin D reservoirs in persons with normal kidney function (45).
As mentioned, vitamin D is important for calcium homeostasis (46). The daily recom-
mended intake of vitamin D is 10 micrograms for adults and 20 micrograms a day for 
everyone aged above 70 years. The upper daily limit for vitamin D is 100 micrograms 
a day. High intake of vitamin D is not that common in healthy people, however, it can 
result in symptoms of malaise, drowsiness, loss of appetite and obstipation (45).
Diet and medication: Diuretics as an example
In addition to the increased use of dietary supplementation, effects of use of medica-
tions and polypharmacy on nutritional status are as well a growing concern among 
older population (47). A frequently prescribed medication group to treat heart failure 
and hypertension, especially in older people is diuretics (48, 49). A study in 2015 
showed that between 33 and 47% of older people aged 50-90 years or older used 
diuretics. The potential adverse effects of diuretics may have serious impact on older 
persons. Recently, recognition of the relevance of food-drug interactions in clinical 
practice has further been growing (40). Interestingly, it has been widely documented 
that diuretics can have various effects on bone health (50-52). Thiazide diuretics have 
been shown to have a protective effect in protecting bone mass and in decreasing the 
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risk of fractures (51). In contrast, loop diuretics may have a negative impact on bone 
turnover by increasing urinary calcium excretion (53). Calcium and vitamin D have 
been hypothesized to play a role in the association between the use of diuretics and 
bone health (54). Thus, knowledge of the food-drug interaction regarding diuretics 
and the use of vitamin D and calcium supplementation in relation to the effects on 
bone health may be therefore relevant.
STUDY POPULATIONS AND METHOLOGY
For this thesis, the data from the B-PROOF trial and the Rotterdam study was used. 
For the initial B-PROOF study, the inclusion criteria were, age >65 years, a homocyste-
ine level >12 µmol/L and <50 µmol/L and creatinine level <150 µmol/L. Initially 2,919 
older persons participated. For the second follow-up study after 5-7 years, 1,298 par-
ticipants responded to the extended studies follow-up questionnaire. Details on the 
design of the B-PROOF can be found elsewhere (55) and details of the follow-up study 
are provided in chapter 3.2. Exposures from B-PROOF trial studied in this thesis were 
serum vitamin B12 level, holotranscobalamin (HoloTC), methylmalonic acid (MMA), 
folic acid, vitamin D and the intervention (folic acid and vitamin B12 supplements). 
Furthermore, the outcomes assessed in this thesis were body composition (fat mass 
and fat free mass measured by DXA-scan), cancer (from national cancer registry), 
fractures (self-reported and verified by the GP’s), cardiovascular and cerebrovascular 
diseases (self-reported).
The Rotterdam Study (RS) is a population-based prospective cohort that has been go-
ing on since 1990 and includes participants aged 40 years and over. The study focuses 
on the most common diseases in this age category, such as cardiovascular, locomotor, 
endocrine, neurological and respiratory diseases. There are various examination 
cycles in the RS. For this thesis, we included the participants from RS I, RS II and 
RS III. The rationale, design and the diagram of the cycles of the study is described 
elsewhere (56). Exposures from RS studied in this thesis were diuretics use (thiazide 
and loop diuretics prescriptions) and calcium (intake by FFQ, levels and supplements). 
Outcomes assessed in this thesis were bone mineral density (BMD) and the trabecular 
bone score (TBS, measured by DXA-scan) and cancer (from national cancer registry).
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AIMS AND OUTLINE OF THIS THESIS
An important societal development of concern is the increasing use of the dietary 
supplementation due to growing interest in the role of micronutrients in optimising 
health and preventing certain diseases (14). Supplements of B-vitamins, calcium and 
vitamin D are now commonly used among older adults (11). However, there are a num-
ber of questions with regard to the effects of these vitamins on age-related changes 
in body composition, fracture risk, and the prevalence of cardiovascular disorders and 
cancer. Thus, the overall aim of this thesis is to study the role of micronutrients and 
body composition and the long-term effect of micronutrients on common negative 
health outcomes such as fractures, cancer and cardiovascular events in the older 
population (Figure 4). Further objectives of this thesis are to study the role of drug-
micronutrients interaction on bone health, specifically diuretics, and to use genetic 
variation involved in regulating calcium metabolism as a tool to understand causality 
in the association between micronutrients (e.g. calcium) and cancer (colorectal).
Chapter 2 focuses on the associations between vitamin D, B-vitamins and body com-
position using data from the B-PROOF study. In Chapter 2.1, the associations between 
vitamin D and BMI and fat mass are described. Chapter 2.2 presents the observational 
and experimental evidence from the B-PROOF study on folic acid, vitamin B-12 and 
body compositions.
Chapter 3 focuses on the long-term effect of micronutrients on disease outcomes. 
Chapter 3.1 shows the long-term effect of the folic acid and vitamin B12 intervention 
on the risk of cancer. The results concerning the long-term effect of folic acid and 
vitamin B12 intervention on the B-PROOF’s primary and secondary outcome- osteopo-
rotic fractures and cardiovascular disease- are presented in Chapter 3.2.
Figure 4. Overview of the topics of the several chapters in this thesis and their relationships
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Chapter 4 focuses on the interplay between micronutrient intake and levels, genetic 
variation and drug use in relation to colorectal cancer and bone health, respectively. 
Chapter 4.1 presents the impact of thiazide diuretics on bone mineral density and 
trabecular bone score in the Rotterdam study. Chapter 4.2 examines whether vitamin 
D level and dietary calcium intake modified the association between loop diuretics 
and bone health. Chapter 4.3 describes the associations between dietary calcium 
intake, calcium level and calcium supplementation and colorectal cancer and the 
interaction with genetic variation. In Chapter 5, the overall findings of this thesis are 
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To assess the association between obesity (measured by Body Mass Index (BMI) and fat 
percentage) and serum 25(OH)D levels in older persons.
Design
Cross-sectional analysis of data from ‘the B-PROOF study’ (B-vitamins for the Preven-
tion Of Osteoporotic Fractures).
Participants
2842 participants aged 65 years and older.
Measurements
BMI and fat percentage, measured by Dual Energy X-ray, and serum 25(OH)D levels.
Results
Mean age was 74 years (SD 6.5), with 50% women. Mean serum 25(OH)D levels were 
55.8 nmol/L (SD 25). BMI and total body fat percentage were significant inversely as-
sociated with serum 25(OH)D levels after adjustment for confounders (β-0.93; 95%CI 
[-1.15; -0.71], p<0.001 and β-0.84; 95%CI [-1.04; -0.64], p<0.001). This association 
was most prominent in individuals with a BMI in the ‘overweight’ and ‘obesity’ range 
(β -1.25 and -0.96 respectively) and fat percentage in the last two upper quartiles 
(β-1.86 and -1.37 respectively).
Conclusion
In this study, higher BMI and higher body fat percentage were significantly associated 
with lower serum 25(OH)D levels in older persons. This association was particularly 
present in individuals with overweight, and higher fat percentages, suggesting that 
these persons are at increased risk of vitamin D insufficiency.
Keywords: BMI, Fat percentage, vitamin D, elderly people
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INTRODUCTION
The percentage of individuals with overweight is growing in all age categories (1). 
This is an alarming issue (2), as overweight and obesity have been associated with 
a range of serious health consequences, including increased risk of metabolic syn-
drome, coronary heart disease, hypertension, type 2 diabetes, stroke and certain 
types of cancers (3,4). Furthermore, being overweight and obesity have been shown 
to alter the absorption, distribution, metabolism and/or excretion of micronutrients, 
which can cause several vitamin deficiencies (5-10). In particular in elderly, were 
vitamin deficiencies are more common (11,12). In this context, vitamin D deficiency 
has been associated with obesity (5-8). Because an accurate vitamin D level is impor-
tant for calcium homeostasis5-8, and osteoporosis is a serious health problem in the 
older population (13), it is important to investigate the role of obesity in vitamin D 
deficiency.
A recent meta-analysis showed a significant inverse weak association between Body 
Mass Index (BMI) and serum 25-hydroxy vitamin D (25(OH)D) levels (14). However, this 
study did not analyze the relationship between body fat mass (fat percentage) and 
serum 25(OH)D levels. it needs to be emphasized that the way to measure overweight 
by BMI amongst the population of elderly is also under debate (15). Aging is associated 
with changes in body composition (16-18), this leads to loss in muscle mass and muscle 
strength (19). Therefore, BMI could underestimate the prevalence of obesity in this 
population, and fat percentage could be a better predictor for obesity than BMI in 
elderly individuals (20). So, dependent on the above mentioned arguments, body fat 
may be a better indicator of overweight than BMI. Consequently, we will investigated 
the association between BMI and fat percentage, and serum 25(OH)D levels, in a large 
population of older persons.
MATERIALS AND METHODS
Study participants
For the present cross-sectional analyses, baseline data of the ‘B-PROOF study’ 
(B-vitamins for the Prevention Of Osteoporotic Fractures) were used. B-PROOF is 
a multi-center, randomized, placebo controlled, double-blind, intervention study, 
investigating the effect of a 2-year daily oral vitamin B12 (500 µg) and folic acid 
(400 µg) supplementation on fracture incidence. The study was conducted in three 
research centers in the Netherlands: Vu University Medical Center (Amsterdam), 
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Wageningen University (Wageningen), and Erasmus Medical Center (Rotterdam). This 
study included 2919 individuals, aged 65 years and older with an elevated homocyste-
ine levels (12 - 50 µmol/l). Participants were excluded if they had a renal insufficiency 
(creatinine level > 150 µmol/l) or presence of a malignancy in the past 5 years. A 
detailed description of the trial has been reported elsewhere (21).
All participants gave written informed consent before the start of the study. The B-
PROOF study has been registered in the Netherlands Trial Register (NTRNTR1333) and 
with ClinicalTrials.gov (NCT00696514). The WU Medical Ethics Committee approved 
the study protocol, and the Medical Ethics committees of Erasmus MC and VUmc gave 
approval for local feasibility (21).
Clinical and anthropometrics measurements
Clinical and anthropometric measurements include height, weight and blood pressure. 
Height was measured in duplicate to the nearest 0.1 cm with the participant standing 
erect and without wearing shoes, using a stadiometer (21). Weight was measured to 
the nearest 0.5 kg using a calibrated weighing device (SECA 761) with the participant 
wearing light garments, empty pockets and without wearing shoes (21). BMI was 
calculated as weight in kilograms divided by square of height in meters and expressed 
as kg/m2. Participants were categorized in underweight (BMI < 20), normal weight 
(BMI 20 - 25.0), overweight (BMI 25.0 - 30) and obesity (BMI > 30) (22). Blood pressure 
measurements were performed two times on the left arm using an Omron M1 plus 
blood pressure device (Omron Healthcare Europe). The measurement with the lowest 
diastolic blood pressure was used for further analyses. Hypertension was defined as 
systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg.
Demographic characteristics and health status variables, which included age, sex, 
self-reported medical history (cardiovascular disease and diabetes), alcohol intake, 
smoking habits, and vitamin supplement use, were determined using a structured 
questionnaire. Alcohol intake was categorised into ‘never’, ‘light’, ‘moderate’ and 
‘(very) excessive’ drinkers, based on the number of days per week alcohol was con-
sumed and the number of glasses per time, following the Dutch method of Garretsen 
et al. (23,24). Smoking habits were defined as never smoked, former smoker or cur-
rent smoker and vitamin D supplement use was defined as users or non-users.
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Physical activity
At baseline, participants were asked to complete a questionnaire about their daily 
physical activity during the past two weeks, including walking, biking, light and heavy 
household work, gardening and sports using a validated questionnaire (LAPAQ) (25) 
and was calculated in kilocalories (Kcal) per day.
Body composition
A subsample of participants underwent Dual Energy X-ray assessment (DXA) using the 
GE Lunar Prodigy device (GE Healthcare, USA, CV = 0.08%), (Erasmus MC) and the 
Hologic QDR 4500 Delphi device (Hologic Inc., USA, CV – 0.45%), (VuMC under standard 
protocols at baseline. The two devices were cross-calibrated by measuring a European 
spine phantom (ESP) five times on both devices and all results were adjusted accord-
ingly. Total body composition was calculated by summing the amount of fat-free soft 
tissue (i.e. lean mass minus bone mineral content) and fat mass. Fat percentage was 
also calculated from the DXA scan (21). For analyses, fat percentage was divided in 
quartiles.
Biological sample collection and analysis
Venous blood samples were obtained in the morning, when the participants were in a 
fasted state, or had taken a restricted breakfast. Serum 25(OH)D was released from 
the protein through a denaturized internal standard (IS: 25(OH)D3-d6). Samples were 
extracted and analyzed by XLC-MS/MS (a Symbiosis online SPE system (Spark Holland, 
Emmen, the Netherlands) coupled to a Quattro Premier XE tandem mass spectrometer 
(Waters Corp., Milford, MA). The inter-assay coefficient of variation was 9% at the 
level of 10 ng/mL and 6% at the level of 25 ng/mL. All analyses were performed in 
the Endocrine Laboratory of the VU University Medical Center. The cut-off value for 
vitamin D deficiency was defined as a serum 25(OH)D levels < 50 nmol/L7,26 which 
was based on the current recommendations by the Institute of Medicine (27) and the 
recommendations for the older adults aged >70 years by the Dutch Health Council. 
Season of blood collection was dichotomized into summer (April – September) and 
winter (October – March) for the analyses.
Statistical analyses
The total B-PROOF population was included to investigate the association between BMI 
and 25(OH)D levels (n=2842). To study the association between body fat percentage 
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and serum 25(OH)D levels, a subsample of participants that underwent a DXA scans 
(n=1197) was used. Differences between subsamples were tested using the student 
t-test or Mann-Whitney U test, based on normally distributed or skewed data. Normal 
distribution for all variables was tested by visual inspection of histograms.
Second, linear regression analysis was used to determine associations between BMI, 
body fat mass and 25(OH)D levels (model 1, crude). Subsequently, age and gender 
were added as fixed confounders (model 2a). Thereafter, other potential confounders 
were added using the forward selection method (in model 2b). Potential confounders 
were smoking, alcohol intake, hypertension (yes or no), self-reported cardiovascular 
disease, total physical activity (in kcal/day), and season of blood collection. To ad-
dress the potential mediating effect of vitamin D supplement use, this factor was 
added to the model. When the point estimate of interest changed >10%, vitamin 
D supplement use was regarded as a potential mediator and included in the final 
analysis. In addition, the interaction of age and total activity was tested in the crude 
model, and a P value < 0.1 for the interaction was considered statistically significant. If 
the interaction term was statistically significant, stratified analyses were performed. 
Stratification was performed as follow: age was dichotomized as younger or older than 
80 years; and for total activity we created quartiles; both only when the interaction 
term was significant.
Further, we tested the associations between body fat percentage and serum 25(OH)
D levels in different BMI categories (underweight, normal weight, overweight and 
obesity) and also per quartile of body fat percentage.
Statistical analysis was performed using the statistical software package of SPSS 21.0 
(SPSS Inc., Chicago, Illinois, USA). P-values of < 0.05 were considered statistically 
significant for all the analyses other than the interaction analyses (<0.1).




Population characteristics are presented in Table 1. Mean age was 74.0 years (6.5 
SD) for the total population (n=2842) and 72.8 years (5.7 SD) for the DXA population 
(n=1197). Mean BMI for the total population was 27.2 (4.0 SD), and 27.0 (3.8 SD) for 
participants who underwent a DXA measurement. The participants who underwent a 
DXA scan were significantly younger, more active, largely included during summer; 
more likely to have hypertension and different alcohol consumption patterns (more 
moderate and excessive alcohol intake and less very excessive drinkers) when com-
pared to the total B-PROOF population.
BMI and serum 25(OH)D levels
Results of the linear regression analyses of BMI and serum 25(OH)D levels are showed 
in Table 2. BMI was inversely associated with serum 25(OH)D levels after adjustments 
for covariates, indicating that for each unit increase in BMI there was a decrease in 
25(OH)D level of 0.93 nmol/L(β -0.93, p < 0.001). Age was a significant interaction-
term (p = 0.02) in this association and total physical activity was not. Stratification 
for age showed that the association between BMI and serum 25(OH)D levels was most 
pronounced in participants younger than 80 years (β -0.97 p<0.001) compared to the 
participants older than 80 years (β -0.72 p=0.006), Table 3.
When considering the categories of BMI, we observed that in overweight and obese 
individuals, BMI was significantly associated with serum 25(OH)D levels (β -1.25, 
p=0.004 and β -0.96, p=0.004 respectively, as showed in Table 4).
Fat percentage and serum 25(OH)D levels
The association between fat percentage and serum 25(OH)D levels is showed in Table 
2. Fat percentage was inversely associated with serum 25(OH)D levels, after adjust-
ments for covariates, (β -0.84, p < 0.001). No significant interaction effects were 
observed. We did observe a stronger association for the 3th and 4th quartile of body 
fat percentage (β -1.86, p=0.01 and β-1.37, p<0.001 respectively) and no association 
in the 1th and 2th quartiles (β-0.02, p= 0.92 and β-1.24, p=0.16 respectively, as 
showed in Table 5).
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participants and DXA 
scan participants 
p-value
Age (years)a 74 (6.5) 73 (5.7) <0.001*
Gender
  Female (%) 50 48 0.16
Body Mass Index (kg/m2)
  Underweight (%)
  Normal weight (%)
  Overweight (%)













  Total Fat Mass (Kg)





























Self-reported medical history of
  Cardiac disease (% yes)
  Diabetes (% yes)










25(OH)D (nmol/L)a 55.8 (25) 55.1 (24) 0.26
Vitamin D <25 nmol/L (%) 10 8 0.01*
Vitamin D <50 nmol/L (%) 47 48 0.21
Vitamin D supplement use (% yes) 20 21 0.80












Season of blood collection(%)
  Summer (April-September)






aPresented as mean (SD) *significantly differences between total population and DXA-test partici-
pants










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In our study we observed that BMI was significantly associated with serum 25(OH)D 
levels in older adults. After stratification for age, the association between BMI and 
serum 25(OH)D was only modest in the oldest group (>80 year), but stronger in the 
individuals younger than 80 years of age. This finding is consistent with the results 
of a recent meta-analysis, which showed that BMI inversely associated with 25(OH)D 
levels in a younger population14. Furthermore, we also observed that fat percentage 
was significantly associated with serum 25(OH)D levels and the association was more 
pronounced in the third and fourth quartiles of fat percentage. This finding supports 
the hypothesis that compared to BMI, body fat percentage is possibly a more accurate 
marker of obesity in our study group, to analyze the association between ‘overweight’ 
and serum 25(OH)D levels and could be used instead or next to BMI for measuring 
obesity in an older population.
A recent bi-directional genetic study, a design known to reduce the possibility of 
confounding, suggested that higher BMI leads to lower 25(OH)D levels in a younger 
population (mean age 53.4 years). Additionally, this study suggested an only modest 
relationship between lower 25(OH)D levels and BMI (28). The mechanism underly-
ing the association between obesity and serum 25(OH)D levels is not yet completely 
understood. Several factors may be responsible for the observed association in this 
population of older adults, including limited sun exposure due to impaired mobility 
or clothing habits (29). In addition, it may be speculated that older obese persons 
have a lower vitamin D dietary intake, which may also lead to decrease in serum 
25(OH)D levels (30,31). Moreover, laboratory findings indicated that adipose tissue 
is a storage site for 25(OH)D (32,33), and therefore it has been proposed that the 






pβ [95% CI] β [95% CI] β [95% CI]
Quartile 1 
N = 298
-0.06 [-0.87; 0.75] 0.88 -0.04 [-0.86; 0.78] 0.92 -0.02 [-0.80; 0.77] 0.97
Quartile 2
N = 299
-0.69 [-2.45; 1.07] 0.44 -1.29 [-3.03; 0.46] 0.15 -1.24 [-2.95; 0.48] 0.16
Quartile 3
N = 299
-1.12 [-2.66; 0.42] 0.15 -1.96 [-3.50; -0.42]* 0.01 -1.86 [-3.29; -0.43]* 0.01
Quartile 4
N = 298
-1.21 [-1.87; -0.55]* <0.001 -1.33 [-2.00; -0.66]* <0.001 -1.37 [-2.02; -0.71]* <0.001
Model 1: crude model. Model 2a: adjusted for age and sex. Model 2b: adjusted for alcohol, total 
activities (sport and non-sport) in Kcal per day, smoking, alcohol and season. *P-value <0.05.
Micronutrients & body composition 41
2
obesity-associated vitamin D deficiency may be due to the decreased bioavailability 
of vitamin D owing to its deposition in body fat compartments (34). Studies have 
also shown that weight loss and reduced body fat mass in obese persons is often 
accompanied with improvements in serum 25(OH)D levels (35).
The association between body fat and serum 25(OH)D levels may also be explained 
by metabolic pathways related to glucose intolerance. Particularly, it has been shown 
that a higher 25(OH)D levels may result in a higher insulin sensitivity, decrease in 
appetite and food intake, and thus a lower body fat percentage (36). Conversely, a 
higher body fat percentage may also result in lower serum 25(OH)D levels (36). As a 
result, vitamin D deficiency is more common in obese people (37), and this was also 
observed in our study. Based on the studies described above we can hypothesized that 
obese persons would require higher dosage of vitamin D supplementation to achieve 
accurate25(OH) vitamin D levels (38).
Limitations and future research
The main strengths of our study are its large population, and the use of both BMI and 
fat percentage measured by DXA. Limitations include, the cross-sectional approach, 
which prevents us from drawing conclusions regarding causality and the direction of 
the association. Secondly, there were some differences between the sub-samples, 
which may be explained by the fact that the younger and fitter persons were the ones 
that were able to visit the hospital to undergo the DXA scan, and this may have biased 
our results.
CONCLUSION
We observed an inverse association between BMI, body fat percentage, and serum 
25(OH)D levels in elderly people. Thus, a higher BMI and a higher body fat percentage 
were associated with lower serum 25(OH)D levels. Although it is well known that 
elderly people overall are at risk for vitamin D deficiency, the results of the current 
study indicate that vitamin D deficiency is particularly important for obese older 
adults. This study suggests furthermore that, other anthropometric measurements, 
including fat mass percentage, may be more reliable measures of obesity than BMI, 
particularly if study outcomes are fat-mass related. Thus, it can be concluded that 
further research is needed to assess the direction and potential causality of this as-
sociation in older persons and the effect of fat percentage on the dose-response 
effect of vitamin D supplementation in older persons.
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Higher folate and vitamin-B12 have been linked to lower risk of overweight. However, 
whether this is a causal effect of these B-vitamins on obesity risk remains unclear 
and evidence in older individuals is scarce. This study aimed to assess the role of 
B-vitamin supplementation and levels on body composition in older individuals.
Methods
A double-blind, randomized controlled-trial in 2919 participants aged ≥ 65 years with 
elevated homocysteine levels. The intervention comprised a 2-year supplementation 
with a combination of folic acid (400 µg)and vitamin B12 (500 µg), or with placebo. 
Serum folate, vitamin-B12, active vitamin-B12 (HoloTC), methylmalonic acid (MMA), 
and anthropometrics were measured at baseline and after 2 years of follow-up. 
Dietary intake of folate and vitamin-B12 was measured at baseline in a subsample 
(n=603) using a validated food-frequency questionnaire. Fat mass index (FMI) and fat-
free mass index (FFMI) were assessed with Dual Energy X-ray absorptiometry (DXA).
Results
Cross-sectional analyses showed that a 1 nmol/L higher serum folate was associated 
with a 0.021 kg/m2 lower BMI (95%CI -0.039; -0.004). Higher HoloTC (per pmol/L 
log-transformed) was associated with a 0.955 kg/m2 higher FMI (95%CI 0.262; 1.647), 
and higher MMA (per μgmol/L) was associated with a 1.108 kg/m2 lower FMI (95%CI 
-1.899; -0.316). However, random allocation of B-vitamins did not have a significant 
effect on changes in BMI, FMI or FFMI during 2 years of intervention.
Conclusions
Although observational data suggested that folate and vitamin B12 status are associ-
ated with body composition, random allocation of a supplement with both B-vitamins 
combined versus placebo did not confirm an effect on BMI or body composition.
Keywords
Vitamin B12 and folic acid, Body composition, BMI, Fat (Free) mass, effect of vitamin 
B12 and folic acid on obesity.
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INTRODUCTION
The prevalence of overweight is growing in all age categories (1). Among people older 
than 65 year in the European Union the prevalence of overweight, defined as a BMI of 
≥ 25, has been estimated at between 58 and 66% (2). Overweight increases the risk 
of several chronic diseases, including cardiovascular diseases, metabolic syndrome, 
and type 2 diabetes (3). For adequate prevention of these diseases, it is therefore 
important to identify factors that influence the development of overweight across 
age categories.
Several studies showed that there is an association of overweight and obesity with 
lower serum vitamin-B12 and folate levels (4-8). However, it is currently not clear 
whether deficiencies of these B vitamins are a cause or a consequence of obesity (9). 
It is suggested that being overweight or obese can alter the absorption, distribution, 
metabolism and/or excretion of micronutrients, which may cause vitamin deficien-
cies, including those of folate and vitamin-B12 (10-12). This may be particularly of im-
portance in older persons, as this group is at higher risk for deficiencies (13), including 
vitamin-B12 deficiency (14), due to inadequate dietary intake as well as malabsorption 
and higher depletion (15). Another explanation of the observed associations could be 
that B-vitamin deficiencies may contribute to adiposity, for example by the role of 
folate and vitamin-B12 in epigenetics. Vitamin-B12 and folate act as co-factors in 
one-carbon metabolism, which is important for the production of methyl donors for 
DNA methylation (16, 17). Deficiency of these nutrients could lead to dysregulation 
of DNA methylation and might generate metabolic disturbances, including disturbed 
energy and lipid metabolism, contributing to adiposity (18, 19).
To date, studies exploring the association between folate and vitamin-B12 with body 
composition in older individuals are scarce. Furthermore, BMI as a measure of over-
weight in elderly population is still under debate (20). As aging is associated with 
loss of muscle mass (21), BMI could underestimate the prevalence of obesity in this 
population. Hence, it is important to study more comprehensive measures of body 
composition in older people, e.g. by making a distinction between fat mass and fat 
free mass.
We aimed to 1) assess the cross-sectional associations of serum folate and vitamin-B12 
levels as well as dietary intake of folic acid and vitamin-B12 from both food and 
supplements with body composition in older individuals; and 2) to study the causal 
effect of these vitamins by assessing the effect of supplementation with folic acid and 
vitamin-B12 combined on body composition in a randomized controlled trial.
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METHODS
Study design and participants
For the present study, baseline data (2008-2011) and two years follow-up (2010-2013) 
data from the B-PROOF study (B-vitamins for the Prevention Of Osteoporotic Frac-
tures) were used. The B-PROOF study is a multi-center, randomized, placebo-con-
trolled, double-blind intervention study, investigating the effect of a 2-year daily oral 
vitamin-B12 (500 µg) and folic acid (400 µg) supplementation on fracture incidence. 
The study was conducted by three research centers in the Netherlands: VU Univer-
sity Medical Center (Amsterdam), Wageningen University (Wageningen), and Erasmus 
University Medical Center (Rotterdam). This study included 2919 individuals, aged 65 
years and older with elevated homocysteine levels (12 - 50 µmol/L). Participants were 
excluded if they had renal insufficiency (creatinine level > 150 µmol/L) or diagnosed 
with malignant cancer in the past 5 years. A detailed description of the trial has been 
reported elsewhere (22). All participants gave written informed consent before the 
start of the study. The B-PROOF study has been registered in the Netherlands Trial 
Register (NTRNTR1333) and with ClinicalTrials.gov (NCT00696514). The Wageningen 
University Medical Ethics Committee approved the study protocol, and the Medical 
Ethics committees of Erasmus MC and VUmc gave approval for local feasibility (22).
Anthropometrics measurements
At baseline and follow-up, height was measured in duplicate to the nearest 0.1 cm 
with the participant standing erect and without wearing shoes, using a stadiometer 
(22). Weight was measured to the nearest 0.5 kg using a calibrated weighing device 
(SECA 761) with the participant wearing light garments, empty pockets and without 
wearing shoes [22]. BMI was calculated as weight in kilograms divided by square of 
height in meters and expressed as kg/m2. Participants were categorized in under-
weight (BMI < 20 kg/m2), normal weight (BMI 20 to <25 kg/m2), overweight (BMI 25 to 
<30 kg/m2), or obese (BMI ≥ 30 kg/m2 ) (23).
Body composition measurements
At baseline and follow-up, a subsample of participants from the Amsterdam and 
Rotterdam research centers (n=424 and =803 at baseline; n=380 and n=732 at follow-
up, respectively) underwent Dual Energy X-ray assessment (DXA) using the GE Lunar 
Prodigy device (GE Healthcare, USA, CV = 0.08%), (Erasmus MC) or the Hologic QDR 
4500 Delphi device (Hologic Inc., USA, CV = 0.45%), (VuMC). The two devices were 
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cross-calibrated by measuring a European spine phantom (ESP) five times on both 
devices and all results were adjusted accordingly. Total fat mass and total fat free 
mass were estimated from the DXA scan (22). Fat Mass Index (FMI) and Fat Free Mass 
Index (FFMI) were calculated as total fat mass or total fat free mass in kilograms 
divided by square of height in meters and expressed as kg/m2. Android/gynoid fat 
ratio was calculated as fat mass android region (g)/ fat mass gynoid region (g) and was 
only available for the participants from Rotterdam (n=800).
Laboratory measurements
Venous blood samples were obtained in the morning at baseline, when the participants 
were in a fasted state, or had taken a restricted breakfast. Plasma homocysteine was 
determined at baseline, using the Architect i2000 RS analyser (VUmc, intra assay 
CV – 2%, inter assay CV = 4%), HPLC method [22] (WU, intra assay CV = 3.1%, inter 
assay CV = 5.9%) and LCMS/MS (EMC, CV = 3.1%). According to a cross-calibration, 
different methods of determined plasma homocysteine of the three centers did not 
differ significantly. Serum folate was determined by imunoelectrochemiluminescence 
on a Roche Modular E170 (Roche, Almere, The Netherlands) (CV = 5.9% at 5.7 nmol/L 
and 2.8% at 23.4 nmol/L). Serum methylmalonic acid (MMA) was measured by LC-MS/
MS (CV < 9%) and holo-transcobalamin (HoloTC), and was determined by the AxSYM 
analyser (Abbott Diagnostics, Hoofddorp, the Netherlands) (CV < 8%) (22, 25). HoloTC 
was used as measure of vitamin-B12 status, because it has been shown to better 
reflect vitamin-B12 status than serum total vitamin-B12 (26). To isolate DNA, buffy 
coats were used. The MTHFR genotypes, 677CC, 677CT or 677 TT, were determined 
using the Illumina Omni-express array (Illumina Inc., San Diego, CA, USA).
Food intake measurements
Dietary intake was estimated at baseline in a subsample, i.e. all participants of the 
Wageningen region (n=603), by a 190 item Food Frequency Questionnaire (FFQ), 
originally designed to assess intake of energy, total fat, fatty acids and cholesterol. 
This FFQ was updated using the Dutch National Food Consumption Survey of 1998 
and extended with questions to estimate other macronutrients, vitamin-B12, folate, 
vitamin D, and calcium intake by the dietetics group of Wageningen University (27, 
28). When one item contributed to more than 0.1% of the intake of macronutrients, 
vitamin B12, folate, vitamin D or calcium in this national survey, this item was added 
to the FFQ. In the end, all items in the FFQ accounted for 90% of the total folate and 
vitamin-B12 intake according to Dutch National Food Consumption Survey data of 
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1998. The Dutch Food Composition database (NEVO) was used to calculate daily folate 
and vitamin-B12 intake (29).
All dietary nutrient intake were adjusted for total energy intake using the residual 
method (30). The participants were also asked to write down the brand names of each 
supplement they used in the questionnaire at the baseline. Current use of folic acid 
and/or vitamin-B12 supplement was defined as users or non-users (22). Total amount 
of folic acid and vitamin-B12 supplement was also measured from the FFQ.
Covariates
Demographic characteristics and health status, which included age, sex, self-reported 
medical history (cardiometabolic diseases i.e. cardiovascular disease, diabetes, 
hypertension and hypercholesterolemia), alcohol intake, smoking habits, physical 
activity (PA, from the LASA Physical Activity Questionnaire, total activity expressed 
in kcal/day), education, were determined using a structured questionnaire. Alcohol 
intake was categorized into ‘never’, ‘light’, ‘moderate’ and ‘excessive’ , based on the 
number of days per week alcohol was consumed and the number of glasses per time, 
following the Dutch method of Garretsen et al. (31, 32) smoking habits were defined 
as never smoked; former smoker, or current smoker.
Statistical analyses
Normal distribution for all variables was examined by visual inspection of histograms. 
When necessary, data were log-transformed. For the cross sectional analyses at base-
line, linear regression analysis was used to determine associations of serum folate, 
vitamin-B12, HoloTC, MMA, folic acid intake, vitamin-B12 intake, folic acid supple-
ment use, and vitamin-B12 supplement use, and total folic acid and vitamin B-12 
(from food and supplement) with BMI, FMI and FFMI. All analyses were adjusted for 
age and sex, and for energy intake for the associations for folic acid and vitamin-B12 
intake (from food and supplements) (model 1). Subsequently, based on literature, 
smoking, alcohol, PA, education, hypertension, and hypercholesterolemia were 
added as confounders (33, 34). In addition, the associations and correlations between 
energy-adjusted folate and vitamin-B12 intake and status were calculated using linear 
regression and Spearman’s correlation coefficient. Furthermore, low serum vitamin-
B12 and folate levels are characteristics of overweight and obese subjects, therefore 
we stratified the population into three different groups, normal weight (BMI <25 kg/
m2), overweight (BMI 25-30 kg/m2) and obesity (BMI>30 kg/m2).
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For the analyses on the effect of the intervention, the primary analyses were per-
formed according to the intention-to-treat (ITT) principle. To study the effect of the 
treatment on BMI, FMI and FFMI, linear regression analyses were performed for the 
subjects with at least one observation of height and weight (baseline and/or follow-
up). The independent variable as randomization group (intervention vs. placebo) and 
the dependent variables were measures of body composition at follow-up as well as 
the difference between baseline and follow-up measurement (delta BMI, delta FMI 
and delta FFMI).The effect of the treatment on delta body composition was adjusted 
for baseline measurement of body composition and HoloTC (because significant differ-
ences in HoloTC was present between the treatment and control group).
In addition, for the experimental analyses, we assessed whether our findings were 
different by age, gender, homocysteine concentrations, presence of cardiometabolic 
disease, and genetic vulnerability, by testing the interaction of these potential effect 
modifiers with the intervention. If the P value for interaction was < 0.1, stratified 
analyses were performed. Statistical analyses were performed using the statistical 
software package of SPSS 24.0 (SPSS Inc., Chicago, Illinois, USA). P-values of < 0.05 




Population baseline characteristics are presented in Table 1. Mean age was 74.0 years 
(SD 6.5) for the total population (n=2919), 72.9 years (SD 5.7) for the DXA population 
(n=1227) and 72.8 years (5.7 SD) for the population with dietary intake data (n=603). 
In the total population, mean BMI at baseline was 27.1 kg/m2 for the intervention 
group and 27.2 kg/m2 and control group. In the DXA population, mean FMI and FFMI 
were 8.9 and 18.0 kg/m2 respectively, for the intervention group and 8.9 and 18.1 kg/
m2 respectively, for the control group at baseline. Mean baseline folic acid level of 
total population was 21.0 nmol/L (11.62 SD) and mean baseline vitamin B12 level was 
285.5 pmol/L (116.0 SD). Follow-up measurements were conducted 2 years after in 
2636 participants. The characteristics of these participants are shown in Supplemen-
tal Table 1. Mean folic acid level of total population raised to 40.5 nmol/L and for 
vitamin B12 level the mean raised to 472.6 pmol/L (378.2 SD) after the intervention.
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Age (years)a 74 (6.5) 72.9 (5.7) 72.8 (5.7)
Sex
  Female (%) 50 48.3 42.1
Body Mass Index (kg/m2)a
  Underweight (%)
  Normal weight (%)
  Overweight (%)

















  Total Fat Mass (kg)
  Total Fat Percentage (%)
  FMI (kg/m2)





































Self-reported medical history of
  Cardiac disease (% yes)
  Diabetes (% yes)














Homocysteine (mmol/L)b 14.4 [3.4] 14.3 [3.2] 14.0 [3.2]
Serum Folate (nmol/L)a 21.0 (11.62) 21.3 (9.3) 20.1 (17.2)
Serum Vitamin-B12 (pmol/L)a 285.5 (116.0) 287.5 (115.2) 281.2 (107.9)
Holotranscobalamin (pmol/L)b 64.0 [251.0] 67.0 [41.0] 60.0 [34.0]














Folic Acid supplement use (%) 16.0 16.3 11.1
Vitamin-B12 supplement use (%) 16.2 16.8 11.1
Folate intake from food (mcg/day)a NA NA 191.5 (53.9)
Vitamin-B12 intake from food (mcg/day)a NA NA 4.1 (2.0)
Total activity (Kcal/day)b 560 [489] 595 [504] 593 [506]
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Baseline associations of vitamin B12 and folic acid with body 
composition
Results of the cross-sectional linear regression analyses of serum folate, serum 
vitamin-B12, HoloTC, MMA, folic acid supplement use, and vitamin-B12 supplement 
use with BMI for the total population, are shown in Table 2. Higher serum folate (per 
nmol/L) was associated with a 0.021 kg/m2 lower BMI (95% CI -0.039; -0.004) after 
adjustments for covariates. Serum vitamin-B12, HoloTC, MMA, folic acid supplements 
and vitamin-B12 supplements were not associated with BMI after adjustment for 
covariates (Table 2). We found also no significant associations between intake of folic 
acid and vitamin-B12 (total and from food only) and BMI (Table 2).
Results in a subgroup (n=1227) with DXA measurements showed that there was an as-
sociation between HoloTC and FMI (β 0.955 kg/m2 per pmol/L; 95% CI 0.262; 1.647) in 
the adjusted model, indicating that for each pmol/L higher log-transformed HoloTC, 
there was a 0.955 kg/m2 higher FMI. MMA was significantly inversely associated with 
FMI, indicating that for each μgmol/L higher MMA, there was a 1.108 kg/m2 lower FMI 
(95% CI -1.899; -0.316). None of the examined exposures were associated with FFMI 
(Table 3) or with android/gynoid fat ratio (data not shown).
Stratified analysis of different groups of BMI showed that higher serum folate level was 
associated with a lower BMI in the population with overweight and obesity, however 
the associations were not statistically significant (Supplemental Table 2).





































aPresented as mean (SD)b median [IQR]
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The effect of the intervention
After 2 years follow-up, mean BMI was 27.2 kg/m2 for both groups, mean FMI and FFMI 
were 9.1 and 18.0 kg/m2 respectively, for the intervention group, and 9.0 and 18.0 
kg/m2 respectively, for the control group. Linear regression analyses showed that the 
combined vitamin B12 and folic acid intervention did not affect changes in BMI (β= 
-0.051; 95%CI: -0.368; 0.265 for the effect on FU BMI and β= -0.031; 95%CI: -0.156; 
0.093 for the effect on delta BMI in the total population) (Table 4). Also, no significant 
effect of the intervention on changes in FMI or FFMI were observed (Table 4).
Additional analyses on the intervention
For the experimental analyses, we observed a significant interaction between treat-
ment and gender with BMI (p for interaction 0.001), cardiometabolic diseases with 
FMI and FFMI at the end of follow-up (p for interaction 0.06 and 0.02 resp.), and 
MTHFR with change in FFMI (p for interaction 0.05). Stratified analyses showed only a 
significant effect of the intervention for people with MTHFR genotype TT, compared to 
Table 2. Baseline associations of serum folate, vitamin-B12, HoloTC, MMA, folic acid supple-






Serum Folate (nmol/L) (n=2919) -0.018 [-0.030; -0.005]* -0.021 [-0.039; -0.004]*
Serum Vitamin-B12 (pmol/L) (n=2919) -0.001 [-0.003; -0.00001]* -0.001 [-0.002; 0.001]
HoloTC_loga (pmol/L) (n=2919)  0.533 [-0.085; 1.151]  0.612 [-0.099; 1.323]
MMA (μgmol/L) (n=2919) -0.258 [-0.742; 0.225] -0.675 [-1.470; 0.120]
Folic acid supplement use (n=2919) -0.271 [-0.666; 0.124] -0.104 [-0.543; 0.335]
Vitamin-B12 supplement use (n=2919) -0.366 [-0.758; 0.026] -0.268 [-0.705; 0.169]
Folic acid total intake (FFQ) (n=1227) -0.0002 [-0.002; 0.001] 0.0005 [-0.003; 0.002]
Vitamin-B12 total intake (FFQ)a (n=1227) -0.795 [-2.086; 0.496] -1.045 [-2.735; 0.646]
Folic acid intake from food (FFQ) (n=1227) 0.005 [-0.002; 0.011] 0.007 [-0.001; 0.015]
Vitamin-B12 total intake from food (FFQ) 
(n=1227)
0.033 [-0.013; 0.080] 0.069 [-0.006; 0.143]
Values are regression coefficients and 95% CIs based on linear regression models and reflect dif-
ferences in BMI per 1 unit increase of serum folate, serum vitamin-B12, HoloTC, MMA, folic acid 
supplements, vitamin-B12 supplements; Model 1 is adjusted for age and sex. Model 2 is additionally 
adjusted for smoking, alcohol consumption, physical activity, education, hypertension and hyper-
cholesterolemia. alog transformed *P-value <0.05.
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CT and CC (β 0.46, 95%CI 0.13; 0.79 and β-0.05, 95%CI -0.26; 0.16 and β-0.04, 95%CI 
-0.25; 0.18 resp.) (Supplemental Table 3).
DISCUSSION
In the current study, we integrated observational and experimental data on B-vitamins 
and body composition in a large elderly population. Although we found that higher 
serum folate was associated with a lower BMI and, that indices of a higher vitamin B12 
status were associated with a higher FMI, we did not observe any effect of random 
allocation with both B-vitamins combined on BMI or body composition after 2 years 
of intervention.
Hypotheses of the observed associations between B-vitamins and body composition 
have been proposed for both directions: folate and vitamin-B12 deficiency may be 
a consequence of obesity due to inadequate dietary intake, altered absorption and 
(urinary) excretion of folate and vitamin-B12 (35), but may also cause obesity via 
epigenetic mechanisms, such as DNA methylation and miRNA expression involved 
in lipid homeostasis and inflammatory pathways (18, 19, 36). In our observational 
data, we confirmed results from previous studies showing associations between 
B-vitamin status and body composition. However, we did not find any differences 
in body composition after supplementation with folic acid and vitamin B12 after 2 
years of follow-up, suggesting that B-vitamins may not have a role in the etiology 
of obesity or changes in body composition in the older individuals. In addition, to 
evaluate whether insufficient dietary intake explained the results, we examined the 
associations between dietary intake of folate and vitamin-B12 with body composition 
which also did not show that (dietary intake) vitamin-B12 and folate were related to 
differences in body composition. Thus, on the basis of our findings, it may be argued 
that obesity or increased fat mass may lower B-vitamins status (37), but not the other 
way around. This is in line with a previous study in which the causality of the relation 
between vitamin-B12 and BMI was studied with use of a Mendelian randomization 
approach. The authors reported that vitamin-B12 levels were associated with BMI, 
however, there was no evidence that lower vitamin-B12 levels caused a higher BMI 
(38). In our observational data, we found a non-significant association of a lower BMI 
with higher intake of vitamin-B12. In contrast to our hypothesis, we observed that 
several biomarkers of higher vitamin-B12 status, including higher levels of HoloTC and 
lower levels of MMA, were associated with a higher FMI. In contrast, in another study 
among adults from a primary care-based setting vitamin-B12 level was negatively 
correlated with BMI [6]. With regard to folate, Kimmons et al. showed that, compared 
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with normal-weight adults, overweight and obese adults were more likely to have 
low folate levels [4]. Similarly, a study by Mahabir et al. showed that adiposity was 
associated with lower serum folate levels in postmenopausal women [5], suggesting 
that obese individuals are at increased risk of folate deficiency.
We found an indication that the B-vitamin intervention had an effect on changes in 
FFMI in participants with the MTHFR TT variant, and not in the those with the CT and 
CC variant. It is known that the TT variant is associated with higher risk of folate 
deficiency and increased homocysteine concentrations, which may suggest that a 
potential effect of B-vitamins on change in fat free mass may be restricted to elderly 
population at risk for folate deficiency or disturbances in one-carbon metabolism, but 
this needs further replication in larger intervention studies.
Strengths and limitations
The current study has several strengths and limitations. An important strength is 
the size of the population included and the combination of both observational and 
experimental data. Another strength of this study was that detailed body composition 
measurements were available using DXA. Although BMI may be practical to measure, 
it is limited regarding prediction of several health outcomes, especially in older 
individuals, because it does not take into account body composition (39, 40). We had 
also several methods to measure vitamin-B12 levels which provided better insight into 
potential deficiencies. For instance, HoloTC has been shown to be a more accurate 
to detect vitamin-B12 deficiency compared to other methods (41). Also serum con-
centrations of MMA are considered to be metabolic indicators of vitamin-B12 status 
through the L-Methylmalonyl-CoA mutase (42).
To appreciate our findings also some limitations should be taken into account. We 
used the intervention data to show that folic and vitamin B12 supplementation did 
not affect body composition. Thus, our findings suggest that obesity or increased fat 
mass may lower B-vitamin status, but not vice versa. However, due to potential re-
sidual confounding we cannot conclude that the cross-sectional association between 
biomarkers of vitamin-B12 with FMI is explained by an effect of adiposity on B12 
levels. Associations may also be due to e.g. other dietary and lifestyle factors, which 
unfortunately we could not explore in this population. Furthermore, due to the low 
variation of B-vitamin status in our study population, we may not have been able to 
detect any possible effect of the intervention on body composition and the results are 
less generalizable in other populations. The combination of vitamin B12 and folic acid 
in the intervention may have limited our ability to detect an individual effect of these 
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vitamins on body composition. In cross sectional analyses, we observed associations 
in different directions for folate levels and biomarkers of vitamin B12. Therefore, 
a potential effect of either of these vitamins on body composition could not be de-
tected in our experimental data, as these may have canceled each other. Replication 
of findings forthcoming this study are thus required to examine whether results are 
true associations and should be examined for vitamin B12 and folic acid separately.
CONCLUSION
In this large population of older individuals, although observational evidence sug-
gested that folate and vitamin B12 are associated with body composition, random 
allocation of a supplement with both B-vitamins versus placebo did not confirm an 
effect on body composition. Future studies should further investigate mechanisms 
underlying potential effects of body composition on B-vitamin status and how these 
effects may differ for certain subgroups.
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Supplemental Table 1. Population follow up characteristics
B-PROOF Participants (N =2636)
Age (years)a 75.6 (6.2)
Sex
  Female (%) 50
Body Mass Index (kg/m2)a
  Underweight (%)
  Normal weight (%)
  Overweight (%)







  Total Fat Mass (kg)
  Total Fat Percentage (%)
  FMI (kg/m2)
  FFMI (kg/m2)
NA
Smoking (%)
  Smoking not changed
  Stopped smoking













Self-reported medical history of
  Cardiac disease (% yes)
  Diabetes (% yes)






Homocysteine (mmol/L)b 12.2 [5.0]
Serum Folate (nmol/L)a 40.5 (22.6)
Serum Vitamin-B12 (pmol/L)a 472.6 (378.2)
Holotranscobalamin (pmol/L)b 87.0 [70.0]








Folic Acid supplement use (%) 12.0
Vitamin-B12 supplement use (%) 12.1
Folate intake from food (mcg/day)a NA
Vitamin-B12 intake from food (mcg/day)a NA
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Supplemental Table 1. Population follow up characteristics (continued)















aPresented as mean (SD)b median [IQR]
Supplemental Table 2. Associations between vitamin B12 and folate intake and serum and BMI 
- stratified for BMI (normal weight, overweight and obesity).
BMI
Model 1 β 95% CI Model 2 β 95% CI
Normal weight (BMI <25)       
Serum folate 0.002 -0.008 0.013 0.003 -0.010 0.015
Serum vitB12 -0.0002 -0.001 0.001 -0.0003 -0.001 0.001
Overweight (BMI 25-30)
Serum folate -0.002 -0.007 0.003 -0.0003 -0.009 0.008
Serum vitB12 0.0001 -0.001 0.001 0.0002 -0.001 0.001
Obesity (BMI >30)
Serum folate -0.024 -0.057 0.009 -0.013 -0.053 0.026
Serum vitB12 -0.0005 -0.003 0.002 -0.001 -0.004 0.002
Model 1 is adjusted for age and sex; Model 2 is additionally adjusted for smoking, alcohol consump-
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Folic acid and vitamin-B12 play key roles in one-carbon metabolism. Disruption of 
one-carbon metabolism may be involved in the risk of cancer. Our aim was to assess 
the long-term effect of supplementation with both folic acid and vitamin-B12 on the 
incidence of overall cancer and on colorectal cancer in the B-PROOF trial.
Methods
Long-term follow-up of B-PROOF trial participants (N=2,524), a multi-center, double-
blind randomized placebo-controlled trial designed to assess the effect of 2-3 years 
daily supplementation with folic acid (400 µg) and vitamin-B12 (500 µg) versus placebo 
on fracture incidence. Information on cancer incidence was obtained from the Neth-
erlands cancer registry (Integraal Kankercentrum Nederland), using the International 
Statistical Classification of Disease (ICD-10) codes C00-C97 for all cancers (except C44 
for skin cancer), and C18-C20 for CRC.
Results
Allocation to B-vitamins was associated with a higher risk of overall cancer (171 
[13.6%] vs. 143 [11.3%]), HR 1.25; 95%CI 1.00-1.53, p=0.05). B-vitamins were signifi-
cantly associated with a higher risk of colorectal cancer (43[3.4%] vs. 25[2.0%]), HR 
1.77; 95%CI 1.08-2.90, p=0.02).
Conclusion
Folic acid and vitamin-B12 supplementation was associated with an increased risk of 
colorectal cancer.
Impact
Our findings suggest that folic acid and vitamin-B12 supplementation may increase the 
risk of colorectal cancer. Further confirmation in larger studies and in meta-analyses 
combining both folic acid and vitamin-B12 are needed to evaluate whether folic acid 
and vitamin B12 supplementation should be limited to patients with a known indica-
tion such as a proven deficiency.
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INTRODUCTION
A large proportion of the population globally, especially older people, use dietary 
supplements to promote good health (1). Studies of National and International Food 
Consumption Surveys, reported for example in the USA, UK and The Netherlands that 
56%, 39% and 27% of older adults respectively use dietary supplements (2-5). However, 
supplements may not always be favorable, and in certain cases or doses they may 
even have adverse health effects (6). In addition, potential effects need to be put into 
perspective according to different fortification policies in countries (e.g. mandated 
vs. voluntary folic acid fortification). Together with vitamin-B12, folic acid plays a key 
role in one-carbon metabolism being involved in DNA methylation and DNA synthesis 
(7, 8). Several studies have suggested that altered DNA methylation is associated 
with a higher risk of certain cancers, including breast, prostate and colorectal cancer 
(CRC). Until recently, it was believed that folate and folic acid supplementation may 
have a protective effect on the risk of malignancies (9, 10). However, over the past 
decade, there have been some concerns that folic acid supplementation may actually 
increase the risk of cancer (11-15), possibly by promoting the progression of pre-neo-
plastic and undiagnosed neoplastic lesions (8, 16). Although some countries, including 
The United States, South Africa and Australia, have introduced population-wide folic 
acid fortification to prevent neural tube defects in the fetus (17-21), mandatory folic 
acid fortification has not been implemented in New Zealand or in several Western 
European countries partly because of these concerns about potential adverse effects 
on cancer incidence or progression (21, 22).
A recent meta-analysis of 10 studies (n=19,106; age range 26-69 years), reported no 
significant excess risk of folic acid (0.4 to 1 mg) supplementation on overall cancer 
incidence (23). However, previous results from the B-PROOF study, a randomized con-
trolled trial on vitamin-B12 and folic acid supplementation on fracture risk in older 
persons, reported a higher incidence of self-reported cancer in the intervention group 
relative to the control group after a follow-up of 2-3 years (HR 1.56; 95% CI 1.04-
2.31). Additional subgroup analysis revealed that the excess risk was predominantly 
explained by a higher CRC incidence, and that the effect appeared to be strongest in 
people aged older than 80 years (24).
Since the adverse effect of folic acid and vitamin-B12 supplementation on self-report-
ed (colorectal) cancer was previously observed within 2-3 years in the B-PROOF study 
(24), the objective of this study was to validate these findings with data on confirmed 
cancer diagnosis and assess the long-term effects of folic acid and vitamin-B12 co-
supplementation on the risk of overall cancer incidence and on CRC using prolonged 
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follow-up of trial participants. As such this secondary analysis of the B-proof study will 
contribute to current understanding of the biological plausibility of the effect of folic 
acid and vitamin- B12 co-supplementation on cancer (CRC) risk which will contribute 
to the ongoing fortification debate ongoing in several countries.
MATERIALS AND METHODS
The B-PROOF study (B-vitamins for the Prevention Of Osteoporotic Fractures) is a 
large multi-center (Erasmus MC Rotterdam, VU University Medical Center Amsterdam 
(VUmc) and Wageningen University (WUR), the Netherlands), randomized, placebo-
controlled, double blind study, investigating the effect of daily oral vitamin-B12 and 
folic acid supplementation over a period of 2 to 3 years on fracture incidence.
Recruitment of participants took place between September 2008 and March 2011. A 
detailed description and study protocol of the trial has been reported elsewhere (25). 
Participants (n=2919) aged 65 years and over with an elevated homocysteine level 
(Hcy 12-50 µmol/l) were included. Participants were excluded if they had a renal 
insufficiency (creatinine level > 150 µmol/l) or history of a malignancy (excluding non-
melanoma skin cancer) in the past 5 years or if they used high dosages of B-vitamins 
(intramuscular injections of vitamin-B12 and/or folic acid intake >300 µg/day, this 
was reported at the time of recruitment and was asked again by the questionnaire at 
the baseline).
Written informed consent was obtained before allocated treatment for all partici-
pants. For the present analysis, we used only the information of participants who gave 
permission to contact health institutes and medical doctors for their health details 
and medical history (n=2,524).
The B-PROOF study was registered in the Netherlands Trial Register (NTRNTR1333) 
and ClinicalTrials.gov (NCT00696514). The Ethics Committee approval for the study 
protocol was obtained from the Medical Ethics committees of Erasmus MC, VUmc and 
WU universities, according to declaration of Helsinki (25).
The intervention group received a daily tablet with 500 µg vitamin-B12 and 400 µg 
folic acid. In addition, both the control and intervention groups received 15 µg (600 
IU) of vitamin D3 daily to ensure a normal vitamin D status. The intervention and 
placebo tablets, produced by Orthica, Almere, the Netherlands, are indistinguishable 
in taste, smell and appearance. The duration of intervention was 2 years, and to 
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increase power, individuals who finished their participation extended their participa-
tion for 1 more year (n=339 had 3 years intervention)(25).
The primary outcome of this study was the incidence of any cancer defined based 
on the International Statistical Classification of Disease (ICD-10) codes C00-C97. 
Individual data were obtained by linkage to the Netherlands cancer registry (Integraal 
Kankercentrum Nederland IKNL) from baseline until May, 2017. The Netherlands 
Cancer Registry is linked to the International Agency for Research on Cancer (IARC) 
and delivers pseudonymous data to the European database of the European Network 
of Cancer Registries (ENCR). Hence, employees of the cancer registry were unaware 
of treatment allocation of the participants. We used C00-C97 ICD codes for overall 
cancer (except C44 for skin cancer), and C18-C20 for CRC (26).
At baseline, height was measured using a stadiometer in duplicate to the nearest 0.1 
cm and weight by using a calibrated weighing device (SECA 761) to the nearest 0.5 
kg, both without wearing shoes (25). Body mass index (BMI) was calculated as weight 
in kg/height in m2. A structured questionnaire was used to assess self-reported medi-
cal history (cardiovascular disease and diabetes mellitus), current use of medication 
and supplements, alcohol intake and smoking habits. Blood was collected, plasma 
homocysteine (Hcy), serum folate, vitamin-B12, holotranscobalamin (HoloTC), 25(OH)
D and methylenetetrahydrofolate reductase (MTHFR)-genotype were determined; 
details of the methods used have been described previously (25).
Statistical analyses
We extended the follow-up of the original B-proof study to study the incidence of 
pathology-proven solid cancers. For all variables, mean with standard deviations 
(SD) or percentages were reported for each group. Differences between groups were 
tested with the t-test for continuous variables, Mann-Whitney U for normally skewed 
variables, and Chi-squared test for categorical variables. The cumulative event-free 
survival for cancer was analyzed by a Kaplan-Meier event curve. We calculated 
follow-up time as the number of months from the baseline measurement until the 
first diagnosis of incident cancer, death, loss-to-follow-up, or end of the study period, 
whichever occurred first. The incidence rate ratio was calculated on the incidence-
rate of cancer for both treatment groups, which is defined as the number of cancer 
cases divided by the total sum of the follow-up in each group (cases/persons years). To 
avoid bias, primary analysis was based on the intention to treat (ITT) principle, where 
participants were analyzed based on the initial treatment allocation. Unadjusted 
Cox proportional hazard analyses were conducted with treatment (intervention vs. 
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control group) as the independent variable and the cancer diagnosis as the dependent 
outcome variable. Multivariable Cox proportional hazard regression analyses were ap-
plied adjusted for serum HoloTC, because this variable differed significantly between 
the intervention and the control group despite randomization. All other potential 
confounders were equally distributed between both groups. Additionally, subgroup 
analyses were performed to assess whether the treatment effect was different in 
strata of sex, age, plasma Hcy and MTHFR polymorphism, interaction with these 
variables were evaluated in the multivariable model for both overall cancer and CRC. 
When p for interaction was <0.1, subgroup analyses were performed. Second, per 
protocol (PP) analyses were performed that included data only from subjects who 
were compliant (>80% of pills consumed) to the study protocol, details have been 
described previously (25) and also a sensitivity analysis was performed in participants 
who were not using folic acid and vitamin- B12 supplements. Exploratory analysis has 
been done by duration of treatment (2 years vs. 3 years). Furthermore, for compari-
son purposes, we also calculated the risk ratio (RR) and log-rank observed – expected 
statistic. p-values <0.05 were considered to be statistically significant. Analyses were 
performed using IBM SPSS 21.
Figure 1 Flow-chart of the B-PROOF Trial based on the CONSORT 2010 Statement. A total of 
2,524 participants were included in the intention to treat analyses.
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BMIa 27.2 (4.0) 8 27.1 (4.0) 10 0.67













Folic acid use supplements (%)
  Yes
  No









Vitamin-B12 use supplements (%)
  Yes
  No









Vitamin D use supplements (%)
  Yes
  No









Serum 25(OH)D (nmol/L)a 55.8 (23.9) 30 56.0 (25.9) 26 0.82
Serum Folate (nmol/L)a 20.1 (7.3) 44 20.3 (7.4) 45 0.47
Serum Vitamin-B12 (pmol/L)a 283.6 (115.0) 17 289.7 (116.2) 11 0.19
Serum Holotranscobalamin (pmol/L)a 70.9 (42.5) 11 74.3 (44.5) 7 0.05*
amean (SD)bmedian (IQR) *p<0.05
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RESULTS
A flow chart of 2,524 participants (86.5% of the initial 2,919 participants) is shown in 
Figure 1. Baseline characteristics were similar for the participants with and without 
informed consent for medical follow-up (n=2,524 vs. n=395).
Table 1 presents the selected baseline characteristics of the B-PROOF population, by 
allocated treatment. Mean (SD) age was 74 years (6.2) in both treatment and control 
groups and mean values for all other baseline characteristics were similar for treat-
ment (n=1,257) and control groups (n=1,267), except for serum HoloTC concentration 
which was slightly higher in the treatment group (mean 74.3 (44.5 SD) vs. 70.9 (42.5 
SD); p<0.05).
Intention To Treat (ITT) analyses showed that 314 persons were diagnosed with any 
cancer (171 cases [13.6%] in the intervention group vs 143 cases [11.3%] in the control 
group) and 68 persons were diagnosed with CRC (43 cases [3.4%] in the intervention 
group vs 25 cases [2.0%] in the control group) during a median follow up of 78 months; 
IQR: 74-83. Crude Cox proportional hazards models showed that persons in the inter-
vention group did not have a significantly higher risk of any cancer than persons in 
the control group (HR 1.23; 95%CI 0.98-1.53; Table 2). However, the risk of CRC was 
significantly higher in the intervention group than persons in the control group (HR 
1.76; 95% CI 1.07-2.88; Table 2) (Figures 2 and 3). After additional adjustment for 
baseline HoloTC, the risk of any cancer tended to be higher in the intervention group 
than in the control group (HR 1.25; 95%CI 1.00-1.57) and a significant increased risk 
remained for CRC (HR 1.77; 95%CI 1.08-2.90; Table 2).
Table 2. Effect of folic acid and vitamin-B12 on overall cancer, and on CRC incidence. Cox 
proportional hazard analysis of risk of cancers (ITT) in total group
Type of cancer (cases 








HR [95%CI]a p-value HR [95% CI]b p-value
Any cancers (171 vs. 143) 2.3 vs. 1.9 1.23 [0.98; 1.53] 0.07 1.25 [1.00; 1.57] 0.05
CRC (43 vs. 25) 0.6 vs. 0.3 1.76 [ 1.07; 2.88]* 0.03 1.77 [1.08; 2.90]* 0.02
a Crude model b adjusted for HoloTC (significant difference between intervention and control 
group) *p<0.05 CRC=colorectal cancer; HR: Hazard Ratio; ITT: Intention To Treat; PY= person years.
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Interaction analyses revealed that the effect of the intervention did not significantly 
differ by age (<80 vs. >80 years), sex, plasma Hcy and MTHFR polymorphism (p-inter-
action > 0.10) for overall cancer and CRC.
Per Protocol (PP) analysis was conducted in compliant participants (n=2,330). After 
PP analyses, the HR on any cancer weakened but the HR on CRC became stronger 
relative to the ITT analyses (HR 1.00; 95%CI 0.99-1.00 and HR 2.17; 95%CI 1.26-3.75 
respectively in the adjusted model; Table 3). Sensitivity analysis in participants who 
were not using folic acid and/or vitamin-B12 supplements, showed that the HR for 
Figure 2. Kaplan-Meier curve of survival analysis of any cancers for the intervention (dashed 
line) and the control group (continuous line) and the follow-up time in months.
Table 3. Effect of folic acid and vitamin-B12 on overall cancer, and on CRC incidence. Cox pro-
portional hazard analysis of risk of cancers (PP) in compliance participants >80%
Type of cancer (cases 







HR [95%CI]a p-value HR [95% CI]b p-value
Any cancers (160 vs. 124) 2.3 vs. 1.7 1.32 [1.05; 1.67]* 0.02 1.00 [0.99; 1.00] 0.10
CRC (40 vs. 19) 0.6 vs. 0.3 2.15 [1.25; 3.72]* 0.01 2.17 [1.26; 3.75]* 0.01
a Crude model b adjusted for HoloTC (significant difference between intervention and control 
group) *p<0.05 CRC=colorectal cancer; HR: Hazard Ratio; ITT: Intention To Treat; PY= person years.
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any cancer and CRC became stronger relative to the ITT analyses (HR 1.30; 95%CI 
1.01-1.66 and HR 2.10; 95%CI 1.21-3.63 respectively in the adjusted model).
Exploratory analysis stratified by duration of the treatment (2 years vs. 3 years) 
showed that the HR on CRC were slightly weaker for participants with 2 years of 
intervention relative to the ITT analyses, but was still significant (HR= 1.72; 95%CI: 
1.03-2.88 in the adjusted model ).
We compared the results from the Cox proportional hazard model with the risk ratio 
(RR) and log-rank statistics and found similar results.
DISCUSSION
The findings of this study showed that allocating older persons with mildly elevated 
homocysteine levels to receive combined folic acid and vitamin-B12 supplementation 
was associated with a slight excess risk of overall cancer but a statistically significant 
increased risk for CRC when compared to placebo. The effect on CRC risk was even 
Figure 3. Kaplan-Meier curve of survival analysis of colorectal cancer (CRC) for the interven-
tion (dashed line) and the control group (continuous line) and the follow-up time in months.
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more extreme in compliant participants (>80%). As difference in cancer risk was 
already apparent within the first years of follow-up, these findings are consistent 
with evidence that folic acid (combined with vitamin-B12) may promote the growth 
of early precursor mucosal lesions (8, 16). However, on the basis of the previous 
observations and the results of the B-PROOF study, we cannot yet ascertain whether 
this is due to an individual effect of folic acid or vitamin-B12, or an interactive effect 
of both folic acid and vitamin-B12 combined. The current findings confirm previous 
observations from the primary analyses of the B-PROOF trial (using self-reported 
cancer data), which showed an increased cancer risk in participants using folic acid 
and vitamin-B12 supplementation(24). A major strength of the current study is the 
extended follow-up of the B-PROOF study combined with the use of pathology-proven 
malignancies as an outcome measure. This is particularly important because of the 
long latency period between dietary risk-factors and cancer as well as the timeframe 
from premalignant lesions to cancer diagnosis in elderly. However, the findings differ 
from three recent meta-analyses, with mostly overlapping trials, which studied the 
effects of folic acid on cancer risk. Qin et al. found no significant overall effect of 
folic acid supplementation (mean dosage 1.64 mg) on cancer and CRC during a mean 
follow-up time of 5.3 years (mean age: 62.5 yrs.) (27). Vollset et al demonstrated 
no significant effect on cancer incidence including colon cancer in a time-frame of 
1.8 to 7.4 years with a mean dosage of 4.7 mg (mean age: 64 yrs.) (28). In contrast, 
Baggott et al. (2012) reported a higher cancer risk in participants receiving folic 
acid supplementation during 3-8 years (mean dosage 1.3 mg), in a meta-analysis of 
a subset of these trials (mean age: 62.0)(29). The results of the present study differ 
from the three meta-analyses, probably because these studies addressed a younger 
population, as well as different dosages of supplementation and different outcome 
measures. It should also be noted that most studies included individual folic acid 
supplementation without vitamin-B12. Besides B-PROOF, only two other RCT’s studied 
the effect of both folic acid and vitamin-B12. Although these trials included a selected 
population of people with ischemic heart disease, they also observed a significantly 
higher overall cancer risk (HR 1.21; 95% CI 1.03-1.41; p=0.02)(11), which is consistent 
with our findings. Most of the previous trials had a shorter follow-up, albeit they had a 
longer duration of treatment than B-PROOF. Whether folic acid, vitamin B-12, or both 
explain the results, cannot yet be confirmed. Especially because the studies of the 
effect of dietary, supplements, and plasma levels of folate and vitamin-B12 on cancer 
risk showed opposing results and none of these were randomized controlled trials (30-
33). For example, Matejcic et al. (2017) found that overall, folate and vitamin-B12 
status was not clearly associated with breast cancer risk in their prospective cohort 
study. They did, however, find potential interactions between vitamin-B12 and folate 
on the risk of breast cancer and suggested that low plasma folate concentrations 
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(mainly 5-methyl THF), as a consequence of high vitamin-B12 status, may impair DNA 
methylation (32). Price et al. (2016) reported a small increased risk of prostate cancer 
with higher folate and vitamin-B12 concentrations, in data from six cohorts (33). 
Another recent study, reported a 30-40% increase in lung cancer risk in men using 
vitamin-B12 supplements (not from multivitamins). They found no association of use 
of folic acid supplements in men and women in risk of lung cancer (31).
The previous analysis of the B-PROOF study showed that curves for cancer incidence 
separated shortly after the start of the intervention, which may imply that the effect 
of the treatment was on cancer progression rather that cancer induction. Since our 
previous analysis of the B-PROOF study showed a higher risk in persons aged >80y 
(24), and given that the results of the current study showed that 18 of the 28 excess 
cancers were CRC, it may be argued that the older age group has a higher prevalence 
of latent colorectal neoplastic cells (8) since the risk of CRC increases with advanced 
age (34) and older individuals may therefore be more prone to the effects of folic acid 
and vitamin-B12 supplementation. However, we did not have data on the presence of 
early neoplastic lesions in the colorectal mucosa to confirm this hypothesis.
The intervention dosage was 500µg vitamin-B12 and 400 µg folic acid per day. Al-
though the dosage of folic acid was close to the recommended daily intake and well 
below the Tolerable Upper Intake Level for folic acid of 1 mg/d in Europe (35), the 
dosage of vitamin-B12 was almost 200 times higher than the recommended intake. For 
vitamin-B12, no systematic toxicological effects have been reported so far, (35), but 
we cannot rule out that the high dosage of vitamin-B12 supplementation influenced 
the risk of CRC in our study.
There may be several plausible mechanisms by which folic acid and vitamin-B12 
supplementation increase the risk of CRC in particular. First, the epithelial cells of 
the colorectal mucosa have the most rapid turnover rate of any tissue in the body. 
Hence, it may be speculated that this tissue may be particularly sensitive to nutrients 
involved in cell growth such as B-vitamins. Folic acid and vitamin-B12 play a key role 
in one-carbon metabolism and cells require one-carbon units for DNA synthesis and 
methylation (36). Thus, these nutrients may influence pathways enhancing prolif-
eration of cancer cells and modulate DNA and therefore the chance of developing 
a neoplastic cell (36). Folate has been demonstrated to affect neoplastic cells by 
enhancing growth in both animal and in-vitro models in DNA synthesis (36). Both folic 
acid and vitamin-B12 are essential for the synthesis of methionine and S-adenosyl 
methionine (SAM), which are required as the common methyl donor for the regula-
tion of DNA methylation patterns in DNA influencing gene expression (36-38). DNA 
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methylation occurs mainly in CpG dinucleotides, concentrated in short CpG-rich 
DNA fragments so-called ÇpG islands’ (39, 40). In normal cells, CpG island in active 
promoters can be methylated, which lead to long-term silencing of transcription. 
However, gene expression may be inactivated in genes that are hypermethylated at 
their CpG island-containing promotors, through which a neoplastic cell can develop 
(41). Currently little is known about the possible relation between vitamin-B12 and 
cancer risk. However, since vitamin-B12 has a key role in one-carbon metabolism and 
cells require one-carbon units for DNA synthesis, methylation as well as redox and 
reductive metabolism, vitamin-B12 may influence pathways enhancing the prolifera-
tion of cancer cells (42).
A second potentially relevant mechanism for CRC specifically may be via the gut 
microbiome. Several studies have shown that microbial imbalance of Fusobacterium 
spp., Streptococcus gallolyticus susp. gallolyticus may play a role in CRC etiology (43-
45). Vitamin-B12 and folate can be synthesized by human gut microbes as a valuable 
resource in the gut (46). It has been suggested by others that competition and ex-
change of vitamin-B12 and cofactors from both dietary intake and gut microbes affect 
the gut microbial community (46). Thus, there may be an interaction between the 
gut microbiome and B-vitamins but further exploration of this hypothesis is needed.
The present study has several strengths as well as potential limitations. The main 
strengths of the present study were the randomized controlled study design, the 
pathology-proven cancer, the large sample size of elderly subjects, and the prolonged 
follow-up relative to other trials. A limitation of the present study is that it presents 
secondary analyses of a randomized controlled trial primarily designed to study the 
effect on fracture risk. As a result, a significant results of such analysis have to be 
interpreted in the context of other evidence in the literature. However, with a sample 
size of 2,524, an alpha of 5% and a power of 80% our study was able to detect a HR 
of 0.85/1.18 on overall cancer (47). In addition, the decision to study CRC in the 
B-PROOF study and other (non-site specific) was made on the basis of prior results on 
self-reported cancer as adverse event of the trial. We did not include other GI can-
cers, due to the limited power. It can be argued that this approach may increase the 
probability of type I errors because we did not adjust for multiple comparisons. For 
possible type I errors, stringent interpretation of p-values, especially for the results 
on all (non-site specific) cancers (p=0.05) should be made with caution. The initial 
B-PROOF study included 2,919 participants, but for the current extended follow-up 
analyses we collected data from a subgroup of 2,524 participants which could intro-
duce a source of bias. However, there was no difference between the intervention and 
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control group in baseline characteristics between the participants with and without 
informed consent for medical follow-up.
Another source of potential bias was that the allocation to the intervention and 
control group was no longer blinded to the researchers. However, since the data 
collection of cancer was derived from the independent national cancer registry, and 
the physicians involved in the cancer diagnosis were blinded to the allocation of the 
intervention, observer bias is unlikely. Another possible limitation is that we only 
included Caucasian participants aged 65 years and over with elevated homocysteine 
levels in a country where no mandated folic acid fortification has been implemented. 
Therefore, the results may not be generalizable to other populations. Nonetheless, 
this trial is one of the few that were done in a population without mandated folic acid 
fortification and relatively low supplement use. As a result we were able to clearly 
discern the effect of supplementation in a population with limited intake of folic acid 
above the tolerable upper intake level.
CONCLUSION
The present study reported a higher risk of CRC among those allocated to folic acid 
and vitamin-B12 compared with placebo, which persisted over time (6-9 years). This 
was observed in older ambulant persons with mildly elevated homocysteine concen-
trations. The primary analyses of the B-PROOF trial did not show any protective effect 
of folic acid and vitamin-B12 supplementation on fracture, falls, and cardiovascular 
disease (with the exception of CVA). However, since secondary analyses of this 
trial, showed potential adverse effects on cancer, careful monitoring of long-term 
hazards of B-vitamins is required before making any recommendations for public 
health related to the implementation of fortification policies. To clarify the role of 
combined supplementation with B-vitamins on CRC, further confirmation for example 
by individual meta-analyses of existing, large RCT of folic acid and vitamin-B12, with 
additional information on the presence of early neoplastic lesions in the colorectal 
mucosa is needed.
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In the initial B-proof we found inconsistent results of B vitamin supplementation. 
However the debate regarding the effects of B vitamins on age-related diseases 
continues. Therefore, our aim was to investigate the long-term effects (5-7 years 
follow-up) of an intervention with folic acid and vitamin-B12 supplementation on 
fracture and cardiovascular disease risk.
Methods
Extended follow-up of the B-PROOF trial, a multi-center, double-blind randomized 
placebo-controlled trial designed to assess the effect of 2-3 years daily supplemen-
tation with folic acid (400 µg) and vitamin-B12 (500 µg) versus placebo (n=2,919). 
Primary outcome was verified self-reported fracture incidence and secondary out-
comes were self-reported cardiovascular endpoints, which were collected through 
a follow-up questionnaires Proportional hazard analyses was used for the effect of 
the intervention on risk of fracture(s) and logistic regression for the effect of the 
intervention on risk of cardiovascular disease.
Results
A total of 1,298 individuals (44.5%) participated in the second follow-up round with 
median of 54 months [51-58], (n=662 and n=636, treatment versus placebo group). 
Median age at baseline was 71.0 years [68.0-76.0] for both groups. No effect was 
observed of the intervention on osteoporotic fracture or any fracture risk after a 
follow-up (HR: 0.99, 95% CI: 0.62-1.59 and HR: 0.77; 95% CI: 0.50-1.19, respectively), 
nor on cardiovascular or cerebrovascular disease risk (OR: 1.05; 95%CI: 0.80-1.44 and 
OR: 0.85; 95%CI: 0.50-1.45, respectively). Potential interaction by baseline homo-
cysteine concentration was observed for osteoporotic- and any fracture (p= 0.10 and 
0.06 respectively), which indicated a significantly lower risk of any fracture in the 
treatment group with higher total homocysteine concentrations (>15.1 µmol/l). No 
age-dependent effects were present.
Conclusions
This study supports and extends previous null-findings of the B-PROOF trial and shows 
that supplementation of folic acid and vitamin-B12 has no effect on fracture risk, nor 
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on cardiovascular disease in older individuals over a longer follow-up period. How-
ever, B-vitamin supplementation may be beneficial in reducing fractures in individuals 
with high total homocysteine concentrations, a finding which needs to be replicated.
Keywords
B-vitamins, fracture, cardiovascular disease, long-term follow-up.
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INTRODUCTION
Previously, homocysteine-lowering therapy has been suggested as a potential treat-
ment option for common diseases such as osteoporosis and cardiovascular disease (1). 
An effective method of normalizing homocysteine concentration is treatment with 
B-vitamins, which play a central role in homocysteine metabolism (2). Over the years, 
several intervention trials have been performed, but conflicting effects of treatment 
with B-vitamins and homocysteine were observed for both fracture and cardiovascular 
outcomes (3, 4).
An association between increased homocysteine concentration and risk of cardiovas-
cular disease and fracture has been observed in particular in older individuals (5). 
Recently within the older B-PROOF population, we observed no effect of B-vitamin 
intervention on the overall incidence of coronary heart disease, but a significantly but 
slightly lower risk of cerebrovascular events was observed among females. This was 
further confirmed by a recent meta-analysis that also showed a reduced risk of stroke 
with folic acid alone and B-complex supplementation (5). Yet, this meta-analysis 
included, beside our initial B-PROOF study, studies with mostly younger individuals 
which makes it difficult to extrapolate these findings to older populations. With re-
gard to fractures, the B-PROOF trial did show lower osteoporotic fracture incidence 
but only in a subgroup of compliant persons aged 80 years and over (6).
The mechanism of B-vitamins in bone health is not yet completely understood, but 
B-vitamins appear to influence the development of collagen and alter the metabolism 
of osteoblasts in a dose-dependent manner (7, 8). Moreover, low levels of B-vitamins 
have been associated with low bone mineral density (BMD) and increased fracture 
risk (9). The recent meta-analysis by Gracia Lopez et al., however, did not show 
a significant reduction of fractures after B-vitamin supplementation (10). From all 
included RCT’s in this meta-analysis with different dosages of B-vitamins, only our 
initial B-PROOF trial had fractures as main outcome and included older participants 
(6). Other trials which included selected patients with cardiovascular disease or 
colorectal adenomas, found no significant differences in fracture risk (as secondary 
outcome) between the groups (4, 11-13).
Another potential explanation for previous inconsistent and null-findings may be the 
relatively short follow-up time of the trials. Besides increasing power, prolonged fol-
low-up could account for the potential latency period between exposure (B-vitamins) 
till event. As known, the latency period of coronary heart disease (from exposure to 
mortality) may be 10 years or more (14). Thus, additional post-trial follow-up on risk 
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of fractures and cardiovascular diseases could provide valuable scientific informa-
tion on potential long-term effects of supplementation (15). For that reason, this 
study aimed to examine the primary and secondary endpoints of the B-PROOF study 
(fracture and cardiovascular disease) with a longer follow-up time to validate our 
previous findings (16).
MATERIALS AND METHODS
The initial B-vitamins for the Prevention Of Osteoporotic Fractures (B-PROOF) trial 
was a multi-center (Erasmus MC Rotterdam, VU University Medical Center Amsterdam 
(VUmc) and Wageningen University (WUR), the Netherlands), double blinded, random-
ized placebo-controlled study. This trial was designed to investigate the effect of daily 
oral folic acid (400 µg) and vitamin-B12 (500 µg ) supplementation (treatment group) 
on fracture incidence as a primary outcome. Secondary outcomes included amongst 
others cardiovascular events. Placebo- and treatment group received daily 15 µg (600 
IU) vitamin D3 to ensure a normal vitamin D status. The duration of the intervention 
was 2 years, and this was extended in a subgroup for 1 more year with the aim to 
increase power (n=339 out of 2,919 participants had 3 years intervention) (17).
The recruitment period was between September 2008 and March 2011. A total of 2,919 
participants aged 65 years and over with an elevated homocysteine concentration 
(12-50 µmol/l) were included in the study. Exclusion criteria were renal insufficiency 
(creatinine level > 150 µmol/l), history of malignancy (except non-melanoma skin 
cancer) in the past 5 years before the recruitment and use of high dosage of B-vita-
mins (folic acid intake >300 µg/day and/or intramuscular injections of vitamin-B12 at 
recruitment and baseline). The study protocol of the trial and a detailed description 
of the study have been reported elsewhere (17). The B-PROOF study was registered 
in the Netherlands Trial Register (NTRNTR1333) and ClinicalTrials.gov (NCT00696514). 
The study protocol was approved by The Medical Ethics committees of Erasmus MC, 
VUmc and WU universities (17). In 2015, we extended the follow-up of the original 
B-PROOF study by sending the participants who gave permission to contact them 
additional questionnaires to investigate the long-term effect of the intervention on 
risk of cancer, fracture and cardiovascular diseases (n=1,298). The long-term effect 
on cancer has been described in a separate paper (18). The current paper describes 
the outcomes of the extended follow-up on fracture and cardiovascular diseases. End 
of follow-up for this study was December of 2017.
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Covariates and outcomes
A wide set of measurements (e.g. BMI, medical history, plasma homocysteine (Hcy), 
serum folate, vitamin-B12, holotranscobalamin (HoloTC), methylmalonacid (MMA) and 
25(OH)D) was performed at baseline and at 2-y follow-up (17). The extended (5-7y) 
follow-up structured questionnaire was used to assess self-reported medical history 
(fractures and cardiovascular disease (CVD)), alcohol intake and smoking habits. All 
reported fractures were verified with the general practitioner of the participants and 
were categorized as osteoporotic (all fractures excluding head, hand, finger, foot or 
toe fractures, fractures caused by traffic accidents or by cancer) or any fracture. 
CVD was assessed, in concordance with the original B-PROOF trial outcomes, as self-
reported and without date of event. Self-reported CVD events were also verified by 
the GP in order to obtain information on the validity of these events. Cohen’s kappa 
coefficient was calculated for the agreement between the self-reported and verified 
CVD events. For CVD the coefficient was 0.89 (excellent agreement between self-
reported and verified events) and for Cerebrovascular accident (CVA) 0.72 (fair to 
good agreement between self-reported and verified events). CVD was classified as any 
type of CVD, and subgroups of myocardial infarction (MI), angina pectoris (AP), hearth 
failure and cardiac valve disease were assessed. CVA and Transient Ischemic Attack 
(TIA) were included as cerebrovascular disease.
Statistical analysis
Mean with standard deviations (SD), or median with interquartile range (IQR) or 
percentages were reported. Differences between groups at baseline were tested with 
t-test for continuous variables and Mann-Whitney U for not normally distributed data. 
Chi-squared tests were used for categorical variables. Kaplan-Meier event curve was 
used for the cumulative event-free survival on the basis of fracture incidence. The 
follow-up time was calculated as the number of months from the baseline measure-
ment until the first diagnosis of incident fracture, death (derived from the national 
institute ‘Centrum voor familiegeschiedenis’, CBG), loss-to-follow-up, or end of the 
study period, whichever occurred first for the participants with complete follow-up. 
The incidence rate ratio was calculated on the incidence-rate of fracture for both 
treatment groups, which is defined as the number of events divided by the total 
sum of the follow-up in each group (cases/persons years). Participants were analysed 
based on the initial treatment allocation (intention to treat principle (ITT)). Unad-
justed Cox proportional hazard analyses were conducted with treatment (treatment 
vs. placebo group) as the independent variable and the fracture diagnosis as the de-
pendent outcome variable. Subsequently, per protocol (PP) analyses were performed 
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that included data only from participants who were compliant during the intervention 
(>80% of pills consumed) (17). Then, cluster proportional hazard model was used to 
analyse the effect of the intervention on the multiple osteoporotic fracture risk (19). 
Multiple osteoporotic fracture was defined as total osteoporotic fractures during the 
intervention in the total population.
For the analyses with cardiovascular and cerebrovascular disease as outcome, binary 
logistic regression analysis was used for the population with complete follow-up, due 
to the absence of a precise time of onset, a Cox regression analysis was not possible. 
Self-reported events were used as the dependent factor and the treatment group as 
the independent factor. Multivariable Cox proportional hazard regression analyses 
and binary logistic regression analysis were adjusted for serum HoloTC since this vari-
able differed significantly between the treatment and the placebo group regardless 
of randomization. All other potential confounders were equally distributed between 
both groups. Furthermore, as in the original B-PROOF trial, multivariable analyses 
were performed to test the interaction between sex, age (continuous) study center, 
homocysteine concentration, MTHFR polymorphism, vitamin-B12 and folate level and 
baseline CVD. Appropriate subgroup analyses were performed when p for interaction 
was <0.10.
P-values <0.05 were considered to be statistically significant (except the interaction 
analysis). Analyses were performed using IBM SPSS 24, the library survival R statistical 
packages(20).
RESULTS
The baseline characteristics of the total population (initial B-PROOF trial with 2-3 
years follow-up, n=2,919) and population with (n= 1,298) and without 5-7 years 
follow-up (n=1,621) are shown in table 1. The median or mean values for all variables 
were similar for treatment (n=1,485) and placebo (n=1,461) group at baseline, except 
for serum HoloTC levels, with higher levels in the treatment group compared to pla-
cebo group (65.0 [48.0-86.0] vs. 63.0 [45.0-84]). A total of 1,298 participants (n=662 
in the treatment group and n=636 in the placebo group) sent the second follow-up 
questionnaire back, with the median age at baseline of 71.0 years [68.0-76.0] for 
both groups. The median follow-up time was 54 months [IQR 51-58]. There were some 
differences in the baseline characteristics of the participants who did not return the 
second questionnaire compared to the participants with 5-7 y follow-up. For example, 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































at baseline of 75.0 years [70.0-80.0] for the treatment group (n=799) and 74.0 years 
[70.0-80.0] for the placebo group (n=822) (Table 1).Furthermore, the baseline char-
acteristic of the participants with 5-7 y follow-up was different for vitamin B12 level 
between placebo and the treatment group (15.7% vs. 15.0%, respectively).
Fracture incidence
Table 2 shows the incidence of osteoporotic fractures, any fractures, and the ef-
fect of the intervention on these outcomes. The incidence of osteoporotic fractures 
was not different between the treatment and placebo group for participants with 
complete follow-up (n=1,298, 35 vs. 35). However, the incidence of any fractures 
tended to be lower in the treatment group compared to the placebo group (37 vs. 
47, p=0.19). The results of ITT analyses of the effect of folic acid and vitamin B-12 on 
verified first osteoporotic fractures in participants with complete follow-up showed 
no effect of treatment of folic acid and vitamin-B12 on first osteoporotic fracture and 
any fracture risk after a follow-up of 5-7 years in the adjusted model (HR: 0.99, 95% 
CI: 0.62; 1.59 and HR: 0.77, 95% CI: 0.50; 1.19 respectively, table 2 and figure 2). PP 
analyses showed also no effect of the treatment of folic acid and vitamin-B12 on both 
osteoporotic fractures and any fractures in the final model (HR: 1.09, 95% CI: 0.66; 
1.79 and HR: 0.81, 95% CI: 0.52; 1.28 respectively, table 2).
Total fractures and first osteoporotic fractures from baseline to the end of follow-up 
periods for the total population (participants with only FU1) and participants with 
complete follow-up (participants with FU1 and FU2), are shown in supplemental 
table S1. Supplemental table S3 shows the number of osteoporotic fractures in the 
treatment and placebo group at FU1 and FU2 in detail. In table 2, the effect of the 
intervention on the multiple osteoporotic fracture risk is shown. In the total popula-
tion, the number of osteoporotic fractures was lower in the treatment group than in 
the placebo group (81 vs. 86). The intervention had no effect on multiple osteoporotic 
fracture incidence in the total population (HR=0.93; 95% CI: 0.65; 1.33, table 2).
In the interaction analysis, we found only a significant interaction term for homocys-
teine concentration for the effect of the intervention on first verified osteoporotic and 
any fracture (p=0.10 and p=0.06 respectively). After stratification for homocysteine 
in tertiles, the risk of osteoporotic fracture did not significantly differ between the 
groups. However, we found a lower risk of any fractures for those with homocysteine 
concentration above 15.1 mmol/l for the treatment group compared to the placebo 
group (HR: 0.42, 95%CI: 0.19; 0.92, figure 1). Baseline characteristics of population 
with homocysteine concentration < and ≥ 15.1 mmol/l are shown in supplemental 
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table S2. Besides, we found differences in baseline characteristics between placebo 
and intervention group within each category by homocysteine level. For the par-
ticipants with homocysteine concentration <15.1 mmol/l (lower two tertiles), weight 
(p=0.04), vitamin B12 level (p=0.01), smoking (p=0.03) and kidney problems (p=0.04) 
were different between placebo and intervention group. For the participants with 
homocysteine ≥ 15.1 (higher tertile), there were no differences between placebo and 
intervention group in baseline characteristics.
Median homocysteine concentration for the participants with the extended follow-up 
changed more after the intervention in the treatment group in the highest tertile 
compared to the first two tertiles (-3.1 for the first tertile and -4.1 mmol/l for the 
second tertile, -6.0 for the last tertile, data not shown).
Table 2. Effect of folic acid and vitamin-B12 intervention on verified first osteoporotic fracture 










HR [95%CI]a HR [95%CI]b
ITT analysis (n=1,298: 
636 in placebo and 662 in 
control group)c
  Osteoporotic Fractures 35 1.3 35 1.2 0.96 [0.60; 1.53] 0.99 [0.62; 1.59]
  Any Fractures 47 1.7 37 1.3 0.75 [0.49; 1.16] 0.77 [0.50; 1.19]
PP analysis (n=1,245 1,325 
in placebo and 1,336 in 
control group)c
  Osteoporotic Fractures 30 1.1 33 1.2 1.04 [0.64; 1.71] 1.09 [0.66; 1.79]
  Any Fractures 42 1.6 35 1.2 0.79 [0.51; 1.24] 0.81 [0.52; 1.28]
Multiple fracture 
incidence analysis 
(n=2,919 1,458 in placebo 
and 1,461 in control 
group)d
Osteoporotic fractures 86 NA 81 NA 0.92 [0.65; 1.31] 0.93 [0.65; 1.33]
a unadjusted model; b adjusted model for HoloTC (significant difference between treatment and 
placebo group); c Values were derived from Cox proportional hazards, ITT, and PP analyses; d Val-
ues were derived from Cluster proportional hazards *p<0.05. HR= Hazard Ratio; ITT= Intention To 
Treat; PP= Per Protocol; PY= person years, FU= Follow-up.
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Figure 1. the effect of folic acid and vitamin-B12 on verified first osteoporotic fracture and 
any fracture in participants with complete follow-up (n=1,298) stratified by homocysteine 
tertiles (≤ 13.2, 13.2-15.1 and ≥15.1 mmol/l) in the adjusted model (p- for interaction=0.10 
and p=0.06 respectively).
Hcy= Homocysteine, HR= Hazard Ratio.
Figure 2. Kaplan-Meier curve of survival analysis of any type of fractures for the treatment 
(continue line) and the placebo (dotted line) group.
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The interaction analysis of the effect of the intervention on multiple fracture inci-
dence showed no significant interaction terms for age, gender, study center and total 
homocysteine and MTHFR (data not shown).
Cardiovascular disease and cerebrovascular disease
The incidence of any type CVD, MI, AP, heart failure and/or cardiac valve disease 
during the follow-up period for the participants with complete follow-up was higher 
in the treatment group compared to the placebo group (130 vs. 120, 20 vs. 18, 43 
vs. 42 and 41 vs. 35 respectively), except for cerebrovascular disease (27 vs. 30). 
However, the differences were not statistically significant (logistic regression analysis, 
table 3). Sex and study center were significant modifiers in the intervention effect 
on any type of CVD (P-for interaction=0.03 and 0.09, respectively). In addition, sex 
had a potential interaction with the intervention effect on heart failure/cardiac valve 
disease (P-for interaction=0.10). After stratification for sex, the intervention showed 
a higher risk of any type of CVD, heart failure and/or cardiac valve disease for women 
compared to men, but these differences were non-significant (for women: OR=1.53; 
95% CI: 0.99-2.35 for any type of CVD and OR=1.52; 95% CI: 0.78-2.97 for heart failure 
and/or cardiac valve disease, for men: OR=0.81; 95% CI: 0.56-1.17 for any type of CVD 
and OR=0.71; 95% CI: 0.39-1.31 for heart failure and/or cardiac valve disease). After 
stratification for study center, the intervention showed a higher risk (not significant) 
of any type of CVD for the participants from Rotterdam than participants from Am-
sterdam or Wageningen (OR=1.36; 95%CI: 0.93-2.00, OR=0.80; 95%CI: 0.45-1.42 and 
OR=0.78; 95%CI: 0.44-1.40 respectively).
DISCUSSION
The extended follow-up of 5-7 years of a 2-year supplementation with folic acid and 
vitamin-B12 within a multi-center, randomized, double-blind, placebo-controlled 
trial in older adults, showed no effect on incidence of first osteoporotic or any type 
of fractures and multiple osteoporotic fractures. However, after stratification, the 
intervention led to a significantly lower incidence of any fractures in the participants 
with the highest total baseline homocysteine. Furthermore, the intervention had no 
effect on the incidence of CVD or cerebrovascular disease.
No overall long-term effect of 2 years of supplementation of folic acid and vitamin-
B12 on fracture risk was found in our extended follow-up study. This is in line with the 
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treatment with these B-vitamins and the risk of fracture was shown including long 
term follow-up studies (10). However, only 2 of the 6 included trials had a longer 
(extended) follow-up (7 years and 11.1 years) (3, 21). Although the initial B-PROOF 
trial was also included in this meta-analysis, differences in study design and popula-
tion with B-PROOF should be noted. The study population of other included trials 
was younger compared to B-PROOF (62.5-68.8 years). Nevertheless, there was no 
indication of an age-dependent effect in our current extended follow-up analyses. 
The baseline total homocysteine concentration of the included participants was also 
different compared to our study (9.8-13.4 mmol/l versus 14.4 mmol/l). Interestingly, 
we found a lower fracture incidence for the group with higher total homocysteine 
concentration at baseline (>15.1 µmol/l). The findings were supported by the ten-
dency toward fracture reduction in the total group, but not by the findings on osteo-
porotic fractures. Yet the numbers of cases were low in the stratified analysis and for 
this reason, these explorative findings should be interpreted with caution. Also, the 
participants in the treatment group with higher baseline homocysteine concentration 
had a steeper decline of total homocysteine concentration after the supplementation 
of folic acid and vitamin-B12 than the participants with lower baseline homocysteine 
concentration suggesting that the effect of the intervention was more pronounced 
in participants with higher total homocysteine concentration. This is in line with 
treatment of vitamin D deficiency, where the effect on serum parathyroid hormone 
concentration is greater when the baseline serum 25-hydroxyvitamin D is lower (22). 
In general, vitamin supplementation may show a threshold effect, working only in 
deficient people (23). In a similar way of reasoning, the effects may soon disappear 
after discontinuation of supplementation. This follow-up study reports outcomes 
after a follow-up of 5 to 7 years, including treatment for 2 to 3 years only, thus, the 
effect of supplementation may be disappeared. Besides, from our previous findings 
of an increased risk of colorectal cancer with B-vitamins supplementation, we do not 
recommend supplementation of these vitamins in not-deficient general population 
(18).
It may be speculated that the latter indicates a (intracellular) B-vitamin deficiency 
(24). As known, B-vitamins lower total homocysteine concentration and play an im-
portant role in the homocysteine metabolism (1). However, the studies of the relation 
between high homocysteine concentration and bone show conflicting results (25). 
From the previous studies which reported an association between elevated total 
homocysteine concentration and fracture risk, it remains unclear whether this could 
be explained by disrupted one-carbon metabolism or whether residual confounding 
by other physiological and lifestyle factors that associate with hyperhomocysteinemia 
may play a role (25). The one-carbon metabolism can be disrupted by vitamin-B12 and 
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folate deficiencies. However, other causes of hyperhomocysteinemia are high intake 
of methionine, certain diseases (chronic renal failure, hypothyroidism and malignant 
tumors in the breast, ovary or pancreas) and ingestion of certain drugs (26-29). How-
ever, in our study, vitamin-B12 and folate level was not an effect modifier in the effect 
of the intervention on fracture risk, suggesting that different levels of vitamin-B12 
and folate would not make a difference in the risk of fracture. Our population was 
also not deficient in B-vitamin measured by different methods (active vitamin-B12, 
HoloTC and MMA). Since the methods to detect vitamin-B12 and folate deficiency are 
under debate, (30) due to its low biased value of B-vitamin level, the effectiveness of 
the intervention in the high homocysteine group might be explained by a subclinical 
deficiency of B-vitamins, that warrants further study.
With regard to the cardiovascular diseases, we found no effect of the intervention 
with B-vitamins and risk of cardiovascular diseases in this extended follow-up. How-
ever, like the initial B-PROOF study we found a lower incidence of cerebrovascular 
events in the treatment group, but this was not significant. In line with our results, an 
update of a Cochrane review showed no effect of homocysteine-lowering B-vitamins 
supplementation compared to placebo on MI, but they did show a small reduced 
risk of stroke with B-vitamin interventions (vitamin B6, B9 or B12 given alone or in 
combination compared to placebo RR=0.90; 95% CI: 0.82-0.99) (5). Also, the recent 
meta-analysis of Jenkins et. al. showed reduced risk of stoke with folic acid alone 
and B-vitamins with folic acid, B6 and B12 (RR= 0.83; 95%CI: 0.69-0.93 for folic acid 
treatment and RR=0.90; 95%CI: 0.81-1.00 for B-complex treatment) (31). However, 
these latter results were driven by one large Chinese trial of 20,000 participants.
For the effect of the intervention on CVD and heart failure/cardiac valve disease, 
the risks were higher in women compared to men, however, the differences were not 
significant. A possible greater vulnerability of women to folic acid and vitamin B12 
supplementation could be explained by the influences of sex hormones in one-carbon 
metabolism and the differences between men and women in the expression level of 
enzymes in this metabolism (32).There is a gap in the knowledge of CVD in different 
sex and age groups, due to under-representation of women and the older population 
(because of higher comorbidities) (33). It has been suggested that there is more vari-
ability of the increased risk factors by ageing, related to sex differences that could 
change between middle-aged and elderly adults (33). In addition, heart failure, occurs 
mostly in (postmenopausal) women (34). Thus, probably, the differences in incidence 
of CVD are due to sex-differences in baseline risk, regardless of the intervention.
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Strengths and limitations
A strength of our study is that the B-PROOF trial was initially designed to study frac-
ture risk as primary outcome in an older population. The extended follow-up period 
allowed us to study long-term effects as well as increase power, and it allowed us to 
analyse the risk of multiple fractures.
A limitation of our study was that some of the baseline characteristics of the re-
sponders were different compared to the total populations and non-responders of 
the second follow-up questionnaire. The participants who did not return the second 
questionnaire, were older, and the high mortality and morbidity rate within this age 
group, may have influenced our results through competing risk bias. Also, the differed 
in HoloTC and vitamin-B12 levels. So, the results are less powered and need to be 
interpreted with caution. However, the variables were not different between the 
treatment and placebo group in responders and non-responders, respectively, which 
indicate that the randomisation and internal validity was still intact.
A second limitation is the self-reported cardiovascular events used both in the initial 
and the extended B-PROOF study. However, the agreement between self-reported and 
verified events for CVD and cerebrovascular events were more than adequate, respec-
tively 0.89-0.72 (excellent and fair to good agreement). Due to missing of completely 
verified data, we were not able to do time to event analysis for these outcomes. 
Additionally, events in the subgroups of CVD (MI, AP, heart failure and cardiac valve 
disease) as well as cerebrovascular disease group were too small to conduct in depth 
analysis.
Moreover, there were more participants recruited from Rotterdam than other regions 
(1,285 participants from Rotterdam and, 857 from Wageningen and 777 from Am-
sterdam). Other differences in characteristics were found between study centers: 
participants from Rotterdam had lower 25(OH)D level, lower SES, higher use of 
vitamin D, folic acid and vitamin-B12 supplements, compared to other regions. Also 
the incidence of CVD was already higher at the baseline for the participants from Rot-
terdam with an extended follow-up. Nonetheless, after stratification by study center, 
the intervention showed a higher risk of any type of CVD for participants who were 
recruited from Rotterdam, however not significant.
Finally, the population with extended follow-up reported a lower use of over the 
counter vitamin B supplements at FU1 and FU2 compared to the total population 
at FU1, but the treatment group reported a higher intake of folic acid and vitamin-
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B12 supplements compared to the placebo group at FU2. Other differences between 
groups might have arisen after the baseline visit and FU1 (for example drug use and 
other diseases), which we were unfortunately not able to measure. Furthermore, we 
have no information about the B-vitamin level and total homocysteine concentration 
at FU2 to evaluate the effect of the intervention on actual blood biomarkers.
In conclusion, in the extended follow-up of B-PROOF, an overall effect of supple-
mentation of folic acid and vitamin-B12 on fracture risk, CVD and cerebrovascular 
risk in older individuals with elevated homocysteine concentration was not observed. 
However, the results of the stratified analyses suggest a reduced fracture risk in 
individuals with higher total homocysteine concentration. This needs further replica-
tion. Currently, we do not recommend supplementation of these B-vitamins in healthy 
(non-deficient) general population for fracture prevention.
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Table S3: Number of osteoporotic fractures in the placebo and treatment group at FU1 and FU2














FU1 0 596 646 0 611 647
1 32 12 1 22 12
2 5 3 2 2 2
3 2 1 3 1 21
4 1 0 4 0 0
Missing 0 0 Missing 0 0
FU2 0 608 627 0 625 642
1 14 20 1 11 17
2 1 2 2 0 3
3 1 1 3 0 0
4 0 0 4 0 0
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ABSTRACT
The decreased risk of osteoporotic fractures in thiazide diuretics (TD) users is possibly 
not only caused by an increase in bone mineral density (BMD), but by an increase in 
other determinants of bone strength as well, such as the trabecular bone score (TBS). 
To test this hypothesis, we studied the association between TD use and both lumbar 
spine BMD (LS-BMD) and lumbar spine TBS (LS-TBS) cross-sectionally in 6,096 partici-
pants from the Rotterdam Study, as well as the association between TD use and bone 
turnover estimated by serum osteocalcin levels. We found that past and current use of 
TD were associated with an increase of LS-BMD (β = 0.021 g/cm2 (95% CI: 0.006;0.036) 
and β = 0.016 g/cm2 (95% CI: 0.002;0.031), respectively). Use of ≥1 defined daily dose 
(DDD) (β = 0.028, 95% CI: 0.010;0.046; p for trend within DDD of use <0.001) and 
use of >365 days (β = 0.033, 95% CI: 0.014;0.052; p for trend within duration of use 
< 0.001) were positively associated with LS-BMD. No significant association between 
TD use and LS-TBS was observed. Mean serum osteocalcin levels were significantly 
different between users and non-users of TD (20.2 ng/ml (SD 8.3) and 22.5 ng/ml (SD 
17.0), respectively, p<0.001). Furthermore, linear regression analysis showed that the 
use of TD was associated with a 3.2 ng/l (95% CI: -4.4.;-2.0) lower serum osteocalcin 
level compared to non-use of TD, when adjusted for Rotterdam Study cohort, age and 
sex. Our results suggest that the decreased fracture risk in TD users is explained by 
increased bone mass rather than by improved bone microarchitecture. Alternatively, 
changes in bone microarchitecture might not be detected through TBS and more so-
phisticated techniques are possibly needed to study a potential effect of TD on bone 
microarchitecture.
The Impact of Thiazide Diuretics on Bone Mineral Density and the Trabecular Bone Score 123
4
INTRODUCTION
Thiazide diuretics are known to have a small but positive effect on bone mineral 
density (BMD) 1-8. Furthermore, our research group demonstrated in 2003 that the use 
of thiazide diuretics was associated with a significantly reduced risk of hip fracture, 
which disappeared after four months of discontinuation of use 9. Similarly, several 
other studies have shown a reduced risk of hip fractures as well as of other osteopo-
rotic fractures when using thiazide diuretics 10-13.
Thiazide diuretics can affect bone through different mechanisms. These drugs were 
shown to directly stimulate osteoblast differentiation and bone formation 14. This 
could result in an increase in serum osteocalcin, which is considered as a marker of 
osteoblast activity, bone formation, and bone turnover in general 15-17. However, bone 
histomorphometric studies have presented evidence for a reduced bone resorption, 
and markers of bone resorption such as N-telopeptide and of bone formation such as 
osteocalcin have been shown to be reduced especially during the first six months of 
therapy with thiazide diuretics 6,18. Furthermore, use of thiazide diuretics directly 
stimulates calcium uptake by the bones 19 and indirectly increases the calcium con-
centrations in the human body via calcium retention through the kidneys 20-22. In 
addition, thiazide diuretics use has been associated with lower parathyroid hormone 
(PTH) levels, independently of serumcalcium levels 23. PTH plays an important role in 
skeletal home-ostasis and lower levels of this hormone can lead to a decrease in bone 
remodeling 24.
BMD is an important determinant of bone strength 25 and fracture risk 26. However, 
previous studies have shown that use of thiazide diuretics is associated with only a 
small increase in BMD and a much larger decrease in the risk of osteoporotic fractures, 
suggesting that this decrease is not only caused by an increase in BMD, but by an in-
crease in other determinants of bone strength as well. This highlights the importance 
of measuring and studying determinants of bone strength other than BMD. Recently, 
the trabecular bone score (TBS), estimated from dual-energy X-ray absorptiometry 
(DXA) scan images, has been approved by the Food and Drug Administration (FDA) as a 
non-invasive technique for producing a metric that correlates with the trabecular mi-
croarchitecture of bones 27. BMD and TBS are independent measures of bone strength 
25. In addition, TBS has been shown to be a predictor of fracture risk independently of 
both BMD and the Fracture Risk Assessment Tool (FRAX) and adjusting the FRAX score 
for TBS could also improve the assessment of fracture risk 28–30. Thus, investigating the 
effect of thiazide diuretics on both BMD and TBS could provide new and important 
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insights into the mechanism by which the decreased risk of osteoporotic fractures in 
thiazide diuretics users can be explained.
To the best of our knowledge, the effect of thiazide diuretics on TBS has not been 
studied before. In view of the frequent use of thiazide diuretics and the high preva-
lence of osteoporosis in the ageing population 31,32, it is important to evaluate the as-
sociation between thiazide diuretics and several aspects of bone strength. Therefore, 
our objective was to investigate the association between thiazide diuretics use and 
both BMD and TBS as well as the association between thiazide diuretics use and bone 
formation estimated by serum osteocalcin levels, in a large, population-based cohort 
study.
MATERIALS AND METHODS
Study design and population
This cross-sectional analysis was conducted in individuals who participated in the 
Rotterdam Study, an ongoing prospective population-based cohort study. The design 
and rationale of the Rotterdam Study have been described elsewhere in detail 33. 
In brief, the Rotterdam Study originated in 1990 and was designed to investigate 
chronic diseases in the elderly. The study started with 7,983 participants aged 55 
years and older, living in Ommoord, a suburb of Rotterdam, The Netherlands. This 
original cohort (RS-I) was extended with a second cohort (RS-II) in 2000 and a third 
cohort (RS-III) in 2006, adding 3,011 (aged ≥ 55 years) and 3,932 (aged ≥ 45 years) 
participants, respectively. This resulted in a total study population of 14,926 par-
ticipants aged 45 years and older. All participants were examined at baseline and 
asked to participate in follow-up examinations every 3-4 years. For this analysis, 
we studied participants from the fourth visit of RS-I (RS-I-4, 2002-2004), the second 
visit of RS-II (RS-II-2, 2004-2005), and the first visit of RS-III (RS-III-1, 2006-2008) for 
whom there was both a LS-BMD and a LS-TBS measurement available. In total, 6,601 
participants gave written informed consent to participate in the study. Ever users of 
bisphosphonates and current users of loop diuretics were excluded from the study. 
Ever users of bisphosphonates were excluded because previous literature suggests 
that the effect of bisphosphonates might persist for years after discontinuation of use 
29. Loop diuretics have been suggested to influence BMD, however, to the best of our 
knowledge, literature about the persistence of the effect after discontinuation of use 
is lacking. Therefore, we only excluded current users of loop diuretics. The Rotterdam 
Study has been approved by the Medical Ethics Committee of the Erasmus Medical 
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Center and by The Dutch Ministry of Health, Welfare and Sports. The approval has 
been renewed every five years.
Assessment of thiazide diuretics use
Information about thiazide diuretics exposure was obtained through linkage with the 
pharmacies in Ommoord which use one shared computer network. The drug exposure 
period was calculated by dividing the total number of units per dispensed prescription 
by the prescribed daily number of units. The daily dose was expressed in ‘defined 
daily dose’ (DDD), as defined by the World Health Organization (WHO) 35. When a 
renewed prescription was filled within seven days after ending the previous one, it 
was considered as one continuous episode of drug use. The number of days between 
the last episode of drug use and the date of the DXA scan was used to determine the 
time a participant was unexposed to the drug prior to undergoing the DXA scan. We 
defined three different groups of users: current users, past users and never users. If 
the date of the performed DXA scan was within the drug exposure period or when 
the participant had a drug exposure period within 120 days prior to the performed 
DXA scan, the participant was classified as being a current user. This cutoff was set 
because previous literature has shown that the protective effect of thiazide diuretics 
on hip fracture, one of the most important types of osteoporotic fractures, disap-
pears after 4 months of discontinuation of thiazide diuretics use 9. If the date of the 
performed DXA scan was not within the drug exposure period but when the participant 
had a drug exposure period in the past not within 120 days prior to the performed 
DXA scan, the participant was classified as being a past user. Participants for whom 
the date of the performed DXA scan was not within the drug exposure period and who 
did not have a drug exposure period in the past were considered as never users. We 
used the following WHO’s Anatomical Therapeutic Chemical codes for thiazide and 
thiazide-like diuretics: C03AA and C03BA; for the combination of thiazide diuretics 
and potassium-sparing agents: C03EA; for the combination of thiazide diuretics and 
beta blocking agents: C07BB; and for the combination of thiazide diuretics and ACE 
inhibitors: C09BA.
Measurement of BMD and TBS
As TBS is measured at the lumbar spine and in order to study BMD and TBS measure-
ments of the same skeletal site, measurements of lumbar spine BMD (LS-BMD) and 
lumbar spine TBS (LS-TBS) were used in the current study. These measurements were 
carried out with DXA using a GE Lunar Prodigy densitometer (Lunar Radiation Corp., 
Wadison, WI). DXA scans were analyzed with GE lunar software for LS-BMD and with 
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iNsight software version 4.0 for LS-TBS. LS-BMD values are expressed in g/cm2. LS-TBS 
values are expressed as a score. LS-TBS was calculated as the slope of the log-log rep-
resentation of a two-dimensional variogram, which is derived from gray-level differ-
ences on the DXA image. The higher the LS-TBS value, the higher the microstructural 
quality of the bones. The method of TBS measurement has been described elsewhere 
in detail 25. As measurements of LS-TBS were not reliable when having a body mass 
index (BMI) above 37, participants with a BMI above 37 were excluded.
Osteocalcin measurements
As measurements of osteocalcin were not available for RS-I-4 and RS-II-2, osteocalcin 
measurements from the third visit of RS-I (RS-I-3, 1997-1999) and the first visit of 
RS-II (RS-II-1, 2000-2001) were used in the current analysis. In addition, measure-
ments of osteocalcin from RS-III-1 were available and added to the analysis as well. 
In total, 8,707 participants were included in the osteocalcin analysis. Osteocalcin 
levels were measured in blood samples by the Department of Clinical Chemistry of 
the Erasmus Medical Center using the Roche/Hitachi cobas e411/e601/e602, Elecsys 
2010 and MODULAR ANALYTICS E170 analyzers (Roche Diagnostics, Indianapolis, IN, 
USA). Information about thiazide diuretics, bisphosphonates and loop diuretics use 
was obtained in the same way as described above. For the osteocalcin analysis, the 
participant was classified as being a user if the date of the blood sampling was within 
the drug exposure period. This definition of users is different from the definition 
of current users in the other analyses, because a change in osteocalcin by thiazide 
diuretics is expected to occur rapidly whereas it takes time to increase the bone 
mineralization and microarchitecture. Every participant who was not classified as 
being user, was classified as being a non-user. Current users of bisphosphonates and 
loop diuretics were excluded from the analysis.
Assessment of covariables
Information on bisphosphonate, loop diuretic and oral glucocorticoid use was ob-
tained in the same way as information about thiazide diuretics was obtained. Ever use 
of bisphosphonates was defined as having at least one current or past drug exposure 
period. Current use of loop diuretics and oral glucocorticoids was defined in the same 
way as current use of thiazide diuretics, in order to be consistent in the definitions 
of use. Information on alcohol intake, smoking and physical activity was acquired 
using home interviews. Alcohol intake was measured continuously in g/day and cat-
egorized into three categories, based on quantiles of use: none, low, medium, and 
high. Smoking was expressed categorically as never, past, and current smoker. BMI 
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was calculated by dividing the weight in kilograms by the height in meters squared. 
Physical activity was expressed in total metabolic equivalent (MET) hours per week. 
Ascertainment methods for diabetes mellitus (DM), stroke and coronary heart disease 
(CHD) have been previously described in detail 31-33. In short, history of DM, stroke 
and CHD were assessed during the baseline home interviews and verified by reviewing 
medical records. Subsequently, DM, stroke and CHD were assessed during follow-up in 
the Rotterdam Study using information from general practitioners’ records, hospital 
records, and lab measurements of serum glucose for DM. Serum vitamin D, serum 
calcium, serum sodium, serum potassium, serum magnesium, and serum phosphate 
were measured in blood samples by the Department of Clinical Chemistry of the 
Erasmus Medical Center using standard methods. Season of blood sample collection 
was divided in two categories based on possible sunlight exposure: 1) autumn and 
winter and 2) spring and summer.
Statistical analyses
Continuous variables were expressed as means and standard deviations (SD), while 
categorical variables were expressed as frequency and percentage or valid percentage. 
Univariable and multivariable linear regression were used to examine the relationship 
of the use of thiazide diuretics with LS-BMD and LS-TBS. Furthermore, categories 
were created based on the mean defined daily dose (DDD) of thiazide diuretics to 
study the effect of dosage of thiazide diuretics on LS-BMD and LS-TBS. This resulted 
in two categories: <1 DDD and ≥ 1 DDD. To study the effect of the duration of thiazide 
diuretics use, three different categories of use were created: 1-120 days, 120-365 
days and more than 365 days. The higher cut-off of 365 days was chosen because of its 
clinical relevance: it has been shown that the use of thiazide diuretics for more than 
365 days was associated with a reduced risk of osteoporotic fractures 9,13 and that the 
protective effect of thiazide diuretics on femur fractures is largest among those using 
the medication for > 365 days 39. In addition, it is shown that the protective effect 
of thiazide diuretics on hip fracture disappears after 4 months of discontinuation of 
use 9, which implies that bone needs 4 months to remodel after a change in thiazide 
diuretics use. Subsequently, we hypothesized that the effect of thiazide diuretics on 
bone will only appear after 4 months of thiazide diuretics use and, therefore, the 
lower cut-off of 120 days was chosen. In both the DDD and the duration analyses, 
never use of thiazide diuretics was used as the reference category. Subsequently, both 
univariable and multivariable linear regression was used to examine the relationship 
of the DDD and duration of medication use with LS-BMD and LS-TBS. For all analyses, 
we used four models. The first model was adjusted for Rotterdam Study cohort, age 
and sex, whereas the second model was additionally adjusted for BMI, vitamin D 
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level, serum calcium, serum sodium, serum potassium, serum magnesium, serum 
phosphate, alcohol intake, smoking and, diabetes mellitus. The third model was ad-
ditionally adjusted for LS-TBS in the models where LS-BMD was the outcome, and vice 
versa. In addition, in a fourth model, we investigated if additional adjustment for 
season of vitamin D measurement, corticosteroids use, physical activity, stroke and 
coronary heart disease significantly changed the results. A p for trend was calculated 
across both the 3 categories of duration of use and the two categories of DDD of use, 
and the reference category.
In case of a significant association between thiazide diuretics use and LS-BMD or LS-
TBS, we tested interactions of thiazide diuretics use with age, sex and BMI. Interaction 
terms were considered to be significant when the p for interaction was below 0.10.
Serum osteocalcin levels for current users and non-users of thiazide diuretics were 
expressed as means and SD. Linear regression analysis was used to examine the 
relationship of the use of thiazide diuretics with serum osteocalcin levels. For this 
analysis, we used two models: the first model was unadjusted and the second model 
was adjusted for Rotterdam Study cohort, age and sex.
Multiple imputation was performed to impute missing values in the covariables, using 
the ‘Multivariate Imputation by Chained Equations’ package in R 40. The number of 
imputed datasets was based on the average percentage of missing values per variable 
41. The average percentage of missing values in the total population was 3.2%. Round-
ing to a value which is a multiplication of 5, generated a total number of 5 imputed 
datasets. The number of iterations was increased with 5 at a time until convergence 
was achieved. With the exception of the characteristics of the study population, 
results are reported for imputed data.
A two-sided p-value below 0.05 was considered as statistically significant. Data were 
analyzed using R version 3.4.4 (R Foundation for Statistical Computing, Vienna, Aus-
tria) and SPSS Statistics for Windows, Version 24.0 (IBM, Armonk, NY, USA).
RESULTS
Population characteristics
The flowchart of the study population is shown in Figure 1. A total number of 6,640 
participants were eligible for the current study as there was both a LS-BMD and a 
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LS-TBS measurement available. Of the total study population, 41 participants were 
excluded because they did not provide written informed consent, resulting in an 
eligible study population of 6,599 participants. Subsequently, 503 participants were 
excluded because of ever use of bisphosphonates and/or current use of loop diuretics, 
resulting in a final study population of 6,096. This population could be further divided 
into 4,883 never users, 551 past users and 662 current users of thiazide diuretics.
Characteristics of the final study population as well as the characteristics of never, 
past and current users of thiazide diuretics, before imputation, are shown in Table 
1. Mean age of the total study population at the time of the performed DXA scan was 
65.5 years and 56.2% were female. A total of 662 participants (10.9%) were current 
users of thiazide diuretics.
Association between thiazide diuretics use and LS-BMD
Table 2. shows the association between the use, dosage and duration of use of thia-
zide diuretics and LS-BMD. The use of thiazide diuretics was found to be positively 
associated with LS-BMD in the fully adjusted model (model 3). Past use of thiazide di-
uretics was associated with a 0.021 g/cm2 (95% CI: 0.006;0.036) higher LS-BMD value, 
while current use of thiazide diuretics was associated with a 0.016 g/cm2 (95% CI: 
0.002;0.031) higher LS-BMD value, both compared to never use of thiazide diuretics.
When taking dosage into account, the use of <1 DDD of thiazide diuretics was associ-
ated with a decrease in LS-BMD of 0.0002 g/cm2 (95% CI: -0.021;0.021) compared 
to never users in the fully adjusted model (model 3), although this difference was 
not statistically significant. Conversely, the use of ≥1 DDD of thiazide diuretics was 
positively and significantly associated with LS-BMD (β = 0.028, 95% CI: 0.010;0.046, 
model 3). A significant trend within the DDD of use was found (p for trend = 0.004). 
Analysis of the duration of thiazide diuretics use showed a positive association be-
tween thiazide diuretics use and LS-BMD when using the medication for more than 
365 days (β = 0.033, 95% CI: 0.014;0.052). In addition, a significant trend within the 
duration of use was found (p for trend < 0.001).
Additionally adjusting the analyses for season of vitamin D measurement, cortico-
steroids use, physical activity, stroke and coronary heart disease did not change the 
results (data not shown).
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  Female sex, n(%) (n= 6,096) 3,423 (56.2) 2,639 (54.0) 353 (64.1) 431 (65.1)
  Age at DXA scan, years (n = 6,096) 65.5 ± 10.3 64.6 ± 10.2 69.9 ± 10.0 68.5 ± 10.0
Alcohol use, n(%) (n = 5,276)
  No alcohol use
  Light drinking
  Moderate drinking

















Smoking, n(%) (n = 6,021)
  Never smoker
  Former, non-smoker













  Physical activity, hours/week (n = 5,215) 78.0 ± 52.6 77.1 ± 53.3 84.6 ± 49.0 79.5 ± 50.0
Comorbidities and medication use
  Diabetes mellitus, n(%) (n = 5,632) 544 (9.7) 386 (8.5) 64 (12.9) 94 (15.4)
  Stroke, n(%) (n = 5,788) 68 (1.2) 45 (1.0) 15 (2.9) 8 (1.3)
  CHD, n(%) (n = 5,702) 232 (4.1) 174 (3.8) 28 (5.5) 30 (4.8)
  Oral corticosteroid use, n(%) (n = 6,096) 153 (2.5) 119 (2.4) 20 (3.6) 14 (2.1)
Measurements
  BMI, kg/m2 (n = 6,036) 27.1 ± 3.6 26.8 ± 3.5 28.2 ± 3.7 28.6 ± 3.7
  LS-BMD, g/cm2 (n = 6,096) 1.144 ± 0.2051.140 ± 0.2051.156 ± 0.2041.162 ± 0.205
  LS-TBS (n = 6,096) 1.319 ± 0.1031.324 ± 0.1031.299 ± 0.1031.305 ± 0.101
  Systolic blood pressure, mmHg (n = 6,075) 142 ± 22 140 ± 21 153 ± 24 152 ± 23
  Diastolic blood pressure, mmHg (n = 6,075) 81 ± 11 81 ± 11 83 ± 12 84 ± 12
Blood measurements
  Season of blood collection, summer  
and spring, n(%) (n = 5,874)
2,733 (46.5) 2,197 (46.6) 256 (48.8) 280 (44.4)
  Serum vitamin D, ng/ml (n = 5,086) 58.97 ± 27.42 60.15± 27.56 54.78 ± 26.8753.41 ± 25.78
  Serum calcium, mg/dl (n = 5,772) 2.4 ± 0.1 2.4 ± 0.1 2.4 ± 0.1 2.5 ± 0.1
  Serum sodium, mmol/L (n = 5,669) 142 ± 2 142 ± 2 142 ± 3 142 ± 3
  Serum potassium, mmol/L (n = 5,666) 4.4 ± 0.3 4.4 ± 0.3 4.3 ± 0.4 4.2 ± 0.4
  Serum magnesium, mmol/L (n = 5,657) 0.85 ± 0.06 0.85 ± 0.06 0.84 ± 0.06 0.83 ± 0.06
  Serum phosphate, mmol/L (n = 5,655) 1.11 ± 0.16 1.11 ± 0.16 1.12 ± 0.17 1.11 ± 0.16
Data are presented as number (%), number (valid %), or mean ± standard deviation. Values are 
shown for non-imputed data. For variables with missing data, valid % is given.
a Percentage of past users = 9.0%, percentage of current users = 10.9%
Abbreviations: n = number; DXA = dual-energy X-ray absorptiometry; CHD = coronary heart disease; BMI = 
body mass index; LS-BMD = lumbar spine bone mineral density; LS-TBS = lumbar spine trabecular bone score.
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Association between thiazide diuretics use and LS-TBS
Results of the linear regression analyses of the use, dosage and duration of use of 
thiazide diuretics and LS-TBS are shown in Table 3. No statistically significant result 
was found, neither in the model adjusted for Rotterdam Study cohort, age and sex 
only, nor in the fully adjusted models. Additionally adjusting for season of vitamin 
D measurement, corticosteroids use, physical activity, stroke and coronary heart 
disease did not change the results (data not shown).
Table 2. Univariable and multivariable linear regression of the use of thiazide diuretics, dosage 
and duration of thiazide diuretics use, and LS-BMD (in g/cm2) (n = 6,096)
Model 1 Model 2 Model 3
Beta (95% CI) Beta (95% CI) Beta (95% CI)
Thiazide diuretics use
Never users (n = 4,883) Reference Reference Reference
Past users (n = 551) 0.044 (0.026;0.061)a 0.025 (0.008;0.042)a 0.021 (0.006;0.036)a
Current users (n = 662) 0.047 (0.031;0.062)a 0.020 (0.004;0.036)a 0.016 (0.002;0.031)a
Dosage of thiazide diuretics
Never users (n = 4,883) Reference Reference Reference
Current users (n = 662)
  < 1 DDD (n = 274) 0.029 (0.005;0.052) a 0.004 (-0.019;0.028) -0.0002 (-0.021;0.021)
  ≥ 1 DDD (n = 388) 0.059 (0.039;0.079)a 0.031 (0.011;0.051)a 0.028 (0.010;0.046)a
P for trend <0.001a 0.003a 0.004a
Duration of thiazide diuretics use
Never users (n = 4,883) Reference Reference Reference
Current users (n = 662)
  1-120 days (n = 256) 0.014 (-0.010;0.039) -0.012 (-0.037;0.012) -0.008 (-0.030;0.014)
  120-365 days (n = 53) 0.059 (0.007;0.111)a 0.037 (-0.013;0.088) 0.025 (-0.021;0.070)
  >365 days (n = 353) 0.069 (0.047;0.091)a 0.042 (0.020;0.063)a 0.033 (0.014;0.052)a
P for trend <0.001a <0.001a <0.001a
Model 1: adjusted for Rotterdam Study cohort, age and sex; model 2: additionally adjusted for 
BMI, vitamin D level, serum calcium, serum sodium, serum potassium, serum magnesium, serum 
phosphate, alcohol intake, smoking, systolic blood pressure, diastolic blood pressure and, diabetes 
mellitus; model 3: additionally adjusted for LS-TBS. a p<0.05.
Abbreviations: LS-BMD = lumbar spine bone mineral density; CI = confidence interval; n = number; 
DDD = defined daily dose; BMI = body mass index; LS-TBS = lumbar spine trabecular bone score.
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Interaction terms
As a significant association between the use of thiazide diuretics and LS-BMD was 
found, interaction terms of age, sex and BMI with thiazide diuretics were tested. 
None of these interaction analyses showed a statistically significant interaction with 
thiazide diuretics (data not shown).
Serum osteocalcin levels in users and non-users of thiazide 
diuretics
Of the 8,707 eligible participants, 64 were excluded because they did not provide 
written informed consent and another 325 of current bisphosphonate and/or loop 
diuretics use, resulting in a total population of 8,318 participants. The mean level of 
serum osteocalcin was 20.2 ng/ml (SD 8.3) in users of thiazide diuretics and 22.5 ng/
ml (SD 17.0) in non-users of thiazide diuretics (p<0.001). Linear regression analyses 
Figure 1. Flowchart of the study population. Of the total population of 6,640 eligible par-
ticipants, 41 were excluded because of no informed consent, resulting in an eligible study 
population of 6,599 participants. Subsequently, 503 participants were excluded because of 
ever use of bisphosphonates and/or current use of loop diuretics. This resulted in a final study 
population of 6,096 participants. This population could be further divided into 4,883 never 
users, 551 past users and 662 current users of thiazide diuretics.
Abbreviations: n = number; LS-TBS = lumbar spine trabecular bone score; LS-BMD = lumbar 
spine bone mineral density.
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showed that the use of thiazide diuretics was associated with a 2.3 ng/l (95% CI: 
-3.5;-1.1) lower serum osteocalcin level in the unadjusted model and with a 3.2 ng/l 
(95% CI: -4.4.;-2.0) lower serum osteocalcin level when adjusted for Rotterdam Study 
cohort, age and sex, both compared to non-use of thiazide diuretics (table 4., figure 
2.). Excluding the outliers did not significantly change the results.
DISCUSSION
In this cross-sectional analysis of 6,096 participants from the Rotterdam Study, past 
and current use of thiazide diuretics were significantly associated with an increase in 
LS-BMD. Use of ≥1 DDD and use of thiazide diuretics for more than 365 days were posi-
Table 3. Univariable and multivariable linear regression of the use of thiazide diuretics, dosage 
and duration of thiazide diuretics use, and LS-TBS (n = 6,096)
Model 1 Model 2 Model 3
Beta (95% CI) Beta (95% CI) Beta (95% CI)
Thiazide diuretics use
Never users (n = 4,883) Reference Reference Reference
Past users (n = 551) 0.005 (-0.003;0.013) 0.005 (-0.003;0.013) -0.0007 (-0.008;0.006)
Current users (n = 662) 0.006 (-0.002;0.013) 0.004 (-0.003;0.012) -0.0002 (-0.007;0.007)
Dosage of thiazide diuretics
Never users (n = 4,883) Reference Reference Reference
Current users (n = 662)
  < 1 DDD (n = 274) 0.006 (-0.005;0.013) 0.005 (-0.006;0.016) 0.004 (-0.006;0.014)
  ≥ 1 DDD (n = 388) 0.005 (-0.004;0.017) 0.004 (-0.006;0.013) -0.003 (-0.011;0.005)
P for trend 0.17 0.33 0.66
Duration of thiazide diuretics use
Never users (n = 4,883) Reference Reference Reference
Current users (n = 662)
  1-120 days (n = 256) -0.003 (-0.015;0.008) -0.005 (-0.017;0.007) -0.002 (-0.013;0.009)
  120-365 days (n = 53) 0.014 (-0.010;0.038) 0.013 (-0.011;0.037) 0.005 (-0.016;0.026)
  >365 days (n = 353) 0.010 (0.0005;0.020) a 0.009 (-0.001;0.019) -0.00001 (-0.009;0.009)
P for trend 0.04a 0.08 0.95
Model 1: adjusted for Rotterdam Study cohort, age and sex; model 2: additionally adjusted for 
BMI, vitamin D level, serum calcium, serum sodium, serum potassium, serum magnesium, serum 
phosphate, alcohol intake, smoking, systolic blood pressure, diastolic blood pressure and, diabetes 
mellitus; model 3: additionally adjusted for LS-BMD. a p<0.05.
Abbreviations: LS-BMD = lumbar spine bone mineral density; CI = confidence interval; n = number; 
DDD = defined daily dose; BMI = body mass index; LS-TBS = lumbar spine trabecular bone score.
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tively and significantly associated with LS-BMD. In addition, a significant trend within 
the DDD and duration of use was found as well. On the other hand, no significant as-
sociation between the use, the DDD and the duration of use of thiazide diuretics and 
LS-TBS was found. Furthermore, analyses regarding the association between thiazide 
diuretics use and serum osteocalcin levels showed that the use of thiazide diuretics 
was significantly associated with lower serum osteocalcin levels.
The findings of our study regarding the association between current use of thiazide 
diuretics and LS-BMD are consistent with several previous studies which have shown 
a positive association between the use of thiazide diuretics and LS-BMD as well 1,5-7,42. 
However, we also found an unexpected positive association between past use of thia-
zide diuretics and LS-BMD. We hypothesized that the effect of thiazide diuretics on 
LS-BMD would disappear after four months of discontinuation of use and our definition 
of current use of thiazide diuretics derived from this hypothesis. Our hypothesis was 
based on an important finding of a previous study of our research group, namely that 
Table 4. Linear regression analysis of the use of thiazide diuretics and serum osteocalcin levels (in 
ng/ml) (n = 8,318)
Model 1 Model 2
Beta (95% CI) Beta (95% CI)
Use of thiazide diuretics -2.3 (-3.5;-1.1) -3.2 (-4.4.;-2.0)
Model 1: unadjusted; model 2: adjusted for Rotterdam Study cohort, age and sex
Figure 2. Serum osteocalcin levels in ng/ml in users and non-users of thiazide diuretics, ad-
justed for Rotterdam Study cohort, age and sex (estimate with standard error).
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the protective effect of thiazide diuretics on the incidence of hip fractures disap-
peared after four months of discontinuation of use 9. As known, the risk of hip fracture 
is predominantly related to femoral neck BMD and not to LS-BMD. Nevertheless, we 
expected similar effects of thiazide diuretics on the BMD of different skeletal sites. 
Our finding could imply that the effect of thiazide diuretics on BMD lasts longer than 
their effect on the risk of osteoporotic fractures, but it is also possible that the effect 
of thiazide diuretics on BMD differs per skeletal site. Another explanation for this 
unexpected association could be the presence of residual confounding. In addition, 
as we found a significant association between thiazide diuretics use and LS-BMD, 
interaction terms of age, sex and BMI with thiazide diuretics were tested. None of the 
tested interaction terms were statistically significant. This implies that the effect of 
thiazide diuretics on LS-BMD does not differ by age, sex and BMI.
Furthermore, we found that the use of ≥1 DDD was positively and significantly as-
sociated with LS-BMD, while the use of <1 DDD was not. Similarly, when studying the 
effect of the duration of thiazide diuretics use on LS-BMD, a positive effect of thiazide 
diuretics on LS-BMD is only seen when using the medication for more than 365 days. 
Furthermore, we showed a significant trend within the DDD and duration of use as 
well, suggesting that the positive effect of thiazide diuretics on LS-BMD increases 
with dosage and time of thiazide diuretics use. Thiazide diuretics stimulate osteoblast 
differentiation, bone formation and calcium uptake 19 by the bones. Higher dose and 
longer duration of thiazide diuretics use could stimulate those three processes to 
a greater extent, causing a larger increase in the LS-BMD value. To the best of our 
knowledge, we are the first showing this positive trend and further studies are needed 
to confirm this finding before implications for clinical practice can be made.
In order to study determinants of bone strength other than BMD, we investigated the 
association between thiazide diuretics use and bone microarchitecture, estimated by 
LS-TBS and measured using DXA. No statistically significant association between the 
use of thiazide diuretics and LS-TBS was seen, neither overall nor when categorized 
according to DDD or duration of thiazide diuretics use. This suggests that the use of 
thiazide diuretics is not associated with changes in LS-TBS. However, another explana-
tion for our findings could be that the measurement of LS-TBS by using DXA is not able 
to detect the small changes in bone microarchitecture caused by thiazide diuretics 
use and that more sophisticated techniques for measuring bone microarchitecture are 
needed. High-resolution peripheral quantitative computed tomography (HR-pQCT) is 
one of those techniques which has the potential to measure different aspects of bone 
quality, including bone microarchitecture.
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Bone is a dynamic tissue that is continuously remodeled in order to preserve its 
strength and integrity 43-45. In the normal bone remodeling process, bone resorption is 
coupled to bone formation, ensuring that the resorbed bone is completely replaced 
by new bone 46. Currently, several biochemical markers are available for the assess-
ment of bone turnover 16. In osteoporosis, the bone turnover rate is increased 16. 
However, bone resorption and bone formation will be partly uncoupled, causing bone 
resorption to exceed bone formation 47. Bone resorption will thus still be followed by 
bone formation in osteoporosis patients, only to a lesser extent, which results in an 
increase in both bone resorption and bone formation markers in osteoporosis. One of 
the important bone formation markers is osteocalcin 16 and the serum levels of this 
marker will be increased in osteoporosis patients. In the current study, we investi-
gated the association between the use of thiazide diuretics and serum osteocalcin 
levels. Previous literature investigating the effect of thiazide diuretics use on serum 
osteocalcin levels, has shown conflicting results. In 1993, it was reported that users 
of thiazide diuretics had lower levels of serum osteocalcin compared to non-users 
of thiazide diuretics 48. In addition, a randomized controlled trial investigating the 
effect of hydrochlorothiazide on rates of bone loss in 320 men and women, showed 
a decrease in serum osteocalcin levels in subjects treated with thiazide diuretics 6. 
In contrast, no significant change in serum osteocalcin levels was seen in a study of 
50 postmenopausal women treated for 7 days with bendroflumethiazide compared to 
postmenopausal women treated with placebo 49. Two years later, a study of the same 
research group was published, showing a dose-dependent increase in serum osteo-
calcin levels in users of bendroflumethiazide 50. In our study, we found that users of 
thiazide diuretics had a significantly lower mean serum osteocalcin level compared to 
non-users of thiazide diuretics. Furthermore, linear regression analysis showed that 
the use of thiazide diuretics was significantly associated with lower serum osteocalcin 
levels after adjustment Rotterdam Study cohort, age and sex. These findings suggests 
that the higher BMD in users of thiazide diuretics may be explained by a decrease in 
bone turnover.
In this study, there was an unexpected finding, namely a significantly lower vitamin D 
level in users of thiazide diuretics compared to non-users. A possible explanation for 
this result may be found in the indication for prescribing thiazide diuretics. Thiazide 
diuretics are one of the cornerstones in the treatment of hypertension, but are also 
used in the treatment of conditions related to volume-overload such as chronic kidney 
disease and heart failure 51. Both chronic kidney disease and heart failure can lead to 
impaired mobility 52,53, which can cause a possible decrease in vitamin D level due to 
a shortage of sunlight exposure in these patients.
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Our study has a number of strengths and limitations. The main strength of our study 
is that we are the first to investigate the effect of thiazide diuretics, including dosage 
and duration of use, on multiple aspects of bone strength, namely BMD as well as TBS 
and bone turnover. Another strength is that we used a large prospective population-
based cohort study to investigate our research question, which limits the chance 
of selection and information bias and creates a high level of generalizability of our 
results to the general population. The Rotterdam Study is conducted in the elderly 
population, which is an important population of interest when performing studies 
of bone strength and osteoporosis. The main limitation of our study is the fact that 
our study is cross-sectional and therefore, we could not study changes in LS-BMD 
and LS-TBS over time. As a consequence, we were not able to establish a causal 
relationship between thiazide diuretics use and markers of bone strength. Second, 
potential misclassification of the exposure could have occurred in our study. Users 
of thiazide diuretics were identified using filling data at the pharmacies, which does 
not disclose whether the patient took the medication as prescribed and does not give 
information about treatment adherence. However, this potential misclassification of 
the exposure would probably be non-differential, as the probability of the exposure 
being misclassified is independent of the LS-BMD and LS-TBS values of the partici-
pants. Third, confounding by indication could be a possibility in our study, as thiazide 
diuretics are prescribed for hypertension and hypertension is associated with a lower 
LS-BMD. However, we tried to address this confounding by indication by adjusting for 
both systolic and diastolic blood pressure. Fourth, the Rotterdam Study consists of a 
predominantly Caucasian population aged above 45 years of age, which could limit 
the generalizability of our results to other populations.
CONCLUSION
The results from our study suggest that thiazide diuretics exert positive effects on LS-
BMD, but not on LS-TBS in the general population. This could imply that the reduced 
risk of osteoporotic fractures in thiazide diuretics users is explained by an increased 
BMD without improving bone microarchitecture. However, it is also possible that the 
measurement of LS-TBS is not able to detect small changes in bone microarchitecture 
and that more sophisticated techniques such as high-resolution peripheral quanti-
tative computed tomography (HR-pQCT) are needed to investigate the association 
between thiazide diuretics use and bone microarchitecture. Furthermore, our study 
indicates that only a high dose and longer duration of thiazide diuretics use exert 
positive effects on LS-BMD. These results could be relevant for clinical practice when 
treating elderly individuals with both hypertension and osteoporosis.
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ABSTRACT
Loop diuretics (LD) may affect bone health by inhibiting renal calcium reuptake. 
However, whether vitamin D status and dietary calcium intake modify the association 
between LD and bone outcome is unclear. Therefore, this study aimed to evaluate 
whether vitamin D level or calcium intake modify the association between LD and 
various indices of bone health including bone mineral density (BMD), and Trabecular 
Bone Score (TBS). From The Rotterdam Study, a prospective population-based cohort 
study, we used data from 6,990 participants aged >45yr with a DXA scan (2002-2008); 
6,908 participants with femoral neck (FN)-BMD, 6,677 participants with lumbar spine 
(LS)-BMD and 6,476 participants with LS-TBS measurements. Use of LD was available 
from pharmacy dispensing records. Vitamin D (25(OH)D) level was measured in serum, 
and dietary calcium intake was measured with a validated food frequency question-
naire. Almost eight percent of the participants used LD. The association between 
LD (past-users compared to never-users) and LS-TBS was significantly different by 
25(OH)D concentrations (P for interaction=0.04). A significantly lower LS-TBS among 
LD past-users was observed for 25(OH)D ≥50 nmol/l compared to ≤20 and 20-50 nmol/l 
(β=-0.036, 95% CI -0.060; -0.013 versus β=-0.012, 95% CI -0.036; 0.013 and β=-0.031, 
95% CI -0.096; 0.034 respectively). However, no other significant effect-modification 
by 25(OH)D and dietary calcium intake was found in the associations between LD-use 
and bone health outcomes (P-interaction > 0.13). This study suggests that the as-
sociation between LD-use and indices of bone health is not consistently modified by 
vitamin D or dietary calcium intake.
Keywords
Loop Diuretics; Bone Mineral Density; bone geometry; Trabecular Bone Score.
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INTRODUCTION
In the past decade, recognition of the importance of food and drug interactions 
has been growing in clinical practice (1). Especially in older people, however, more 
knowledge is needed because of the frequent use of medications and polypharmacy 
and higher risk of poor nutritional status (2). Food-drug interactions may be relevant 
in older people using loop diuretics (LD). Diuretics are frequently prescribed in the 
treatment of heart failure and hypertension (3, 4), and they have been shown to 
influence calcium homeostasis and bone metabolism.
Thiazide diuretics have shown to have a protective effect in preserving bone mass and 
in decreasing the risk of fractures (5). Yet, these effects have been shown to vary in 
relation to dosage, duration of treatment and do not last long after discontinuation of 
treatment (6-8). In contrast, few studies have been carried out assessing the effect of 
loop diuretics (LD) on skeletal health. Some studies suggest that LD can have a negative 
impact on bone turnover by increasing urinary calcium excretion (9, 11-13) whereas 
other show no association between LD-use and bone health on long-term use (6-13).
These conflicting findings may be the result of differences in calcium intake and vita-
min D levels across the studied population, considering that bone mineral deposition/
formation and bone resorption can be relatively normal as long as serum calcium and 
phosphate and calciotropic hormone levels like vitamin D and parathyroid hormone 
(PTH) are normal (14). Vitamin D has a major role in calcium homeostasis through three 
mechanisms: I) increased intestinal absorption of calcium, II) reduced renal excretion 
of calcium by stimulating resorption of the distal tubules and III) deposition and mobi-
lization of calcium from bones (15). An inverse association between LD-use and serum 
25(OH)D level has been reported before (16). LD-users have a lower concentration of 
25(OH)D than non-users (17). As a result vitamin D deficiency may amplify any potential 
adverse effects of LD on bone health due to increased urinary calcium losses. Also, the 
use of LD may be harmful for bone health through increased plasma PTH and 1.25(OH)2D 
levels as a result of increased renal calcium losses (13). Higher calcium loss may increase 
bone turnover resulting in a negative calcium balance. Furthermore, in case of very 
low external calcium supply from diet or supplementation, high levels of 1.25(OH)2D3 
mobilise the bone calcium reservoir for serum calcium homeostasis at the (temporary) 
expense of bone mass and strength (18). Accordingly, in people with a low calcium 
intake, the effect of LD on bone loss and increased fracture risk may be enhanced (10).
Therefore, in view of the frequent use of LD and a high prevalence of osteopenia 
and osteoporosis in the ageing population, in combination with a higher risk of mal-
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nutrition and vitamin D deficiency in older individuals, it is important to evaluate 
whether vitamin D level or calcium intake may modify the association between loop 
diuretics and various indices of bone health including bone mineral density (BMD) and 
Trabecular Bone Score (TBS) in elderly population.
MATERIALS AND METHODS
Study Population
This study was embedded in the first three cohorts of The Rotterdam Study (RS-I, 
RS-II and RS-III), an ongoing, population-based cohort study in Ommoord, a suburb of 
Rotterdam, the Netherlands (19). Since January 1990 participants of 55 years and over 
were recruited for RS-I (N=7,983). In 2000, the study was extended to 3,011 partici-
pants (RS-II). Later in 2006, the study was extended with a third cohort of participants 
of 45 y and older (RS-III). Overall response for all three cycles at baseline was 72% 
(14,926 of 20,744) (19). Participants were interviewed at home by a trained research 
assistant, after which they were invited for a physical examination and dietary as-
sessment at the research center. The study has been approved by the institutional 
review board (Medical Ethics Committee) of the Erasmus Medical Center and by the 
review board of the Netherlands Ministry of Health, Welfare and Sports, and approval 
has been renewed every 5 years. From all subjects written informed consent was 
obtained. More details on the main objectives, design and diagram of examination 
cycles of the Rotterdam Study (RS) have been published elsewhere (19). Because of 
a possible persisting effect on bone, users of bisphosphonates were excluded from 
the study. For the current analysis, 6,908 participants with data available for femoral 
neck (FN)-BMD, 6,677 participants with lumbar spine (LS)-BMD and 6,476 participants 
with LS-TBS were included from the fourth examination of the first cohort (RS-I-4, 
2002-2004), the second examination of the second cohort (RS-II-2, 2004-2005) and the 
first examination of the third cohort (RS-III-1, 2006-2008) (Figure 1).
Dietary intake and serum 25(OHD) level
Dietary data were collected at baseline (between 1989 and 1993 in RS-I-1, between 
2000 and 2001 in RS-II-1 and between 2006 and 2008 in RS-III-1) using a validated 
semi-quantitative Food Frequency Questionnaire (FFQ) managed by a trained dieti-
cian, at the study center (20, 21). For RS-I-1 and RS-II-1, a two-stage 170-items FFQ 
was used (during first stage, participants mentioned on 170 food item, which foods 
they consumed at least twice a month in the preceding year, and in the second stage, 
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dietician identified how often and in which amounts the foods were consumed). For 
RS-III-1, a one-stage 389-items FFQ was used. Dietary intake of nutrients (incl. total 
energy and dietary calcium intake) was determined using the Dutch Food Composition 
Tables (NEVO) from 1993, 2001 and 2006, using standardized portion sizes (20, 22). 
Intake of calcium was adjusted for energy corresponding to the residual method (23). 
Serum 25(OH)D was measured in the blood collected at the same time as dietary data, 
between 1990 and 2008 using electrochemiluminescence immunoassay (COBAS, Roche 
Diagnostics GmbH). The sensitivity of the test was 10 nmol/L, the range of serum 
25(OH)D concentrations was from 7.5 nmol/L to 175 nmol/L, the within-run accuracy 
was less than 7.8%, and the intermediate precision accuracy was less than 13.1% (24, 
25). Vitamin D deficiency was defined as a serum 25(OH)D level ≤ 50 nmol/L according 
to the current recommendations for older adults aged >70 years by the Institute of 
Medicine and the Dutch Health Council (26). In addition, we used also a vitamin D 
deficiency threshold <20 nmol/L in our analysis and showed the stratification analysis 
in categories of <20 nmol/L, between 20-50 nmol/L and >50 nmol/L.
Loop diuretics
As of 1st January 1991, pharmacy records of prescriptions were collected via all 
pharmacies in the Ommoord region with details on product name, ATC-code, number 
of tablets/capsules in each prescription, and prescribed daily number (27). LD-use 
(ATC-code C03C) was determined from baseline to the date of the DXA scan [19] 
and defined in three different categories: current-users, past-users and never-users. 
Current-users were defined when the participant had a drug exposure period between 
the date of the DXA scan and 120 days prior to the performed DXA scan. Past-users 
were defined when the participant had a drug exposure period more than 120 days 
Figure 1. Flow-chart of sub-cohorts included in the study
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prior to the performed DXA scan. In addition, if the participants had no drug exposure 
from baseline till the DXA scan, the participants were considered as never-users. The 
duration of LD-use among current-users was categorized into 1-120 days, 120-365 
days, and more than 365 days. Never-use of LD was used as the reference category.
Assessment of co-variables
Co-variables related to lifestyle, body composition and socioeconomic status (SES) 
were included. Weight (kg) and height (cm) were measured at study entry. BMI was 
calculated as weight divided by height squared (kg/m2). During home interviews physi-
cal activity (PA) was assessed by means of the Zutphen Physical Activity Questionnaire 
(28). Metabolic equivalent of tasks were calculated (MET hours/week) according to 
time spent in categories of light, moderate and vigorous activity (28). Socioeconomic 
status variables (i.e., educational level and income level), smoking (yes/no), pack 
years, use of alcohol, prevalence of Coronary Heart Diseases (CHD), stroke and Dia-
betes Mellitus (DM) were assessed by home interview. Also the use of bisphosphonates 
was determined using pharmacy dispensing records in the same way as the use of 
LD. Serum calcium, magnesium and sodium were measured in blood samples by the 
Department of Clinical Chemistry of the Erasmus Medical Center using the Roche/
Hitachi cobas c501 analyzer (Roche Diagnostics, Indianapolis, IN, USA).
Outcome assessment
Femoral neck and lumbar spine BMD was measured at RS-I-4, RS-II-2 and RS-III-1 (be-
tween 2002 and 2008) by dual energy X-ray absorptiometry (DXA) using a ProdigyTM 
fan-beam densitometer (GE Lunar Corp, Madison, WI, USA for all participants (19). 
The DXA-derived Trabecular Bone Score (TBS), which is measured in the Lumbar Spine 
(LS-TBS) is a grey-level texture measurement that correlates with 3D parameters of 
bone micro-architecture, connectivity density, trabecular separation and trabecular 
number (29). LS-TBS predicts future fractures (all type) independent of areal BMD 
[30]. Moreover, recent studies have shown that LS-TBS may be an applicable measure 
of trabecular bone integrity to study in regard to lifestyle factors that are adaptable, 
such as a dietary intake (31, 32). LS-TBS was derived from the same lumbar DXA scans 
that BMD was obtained from and it was analyzed using TBS iNsight software (version 
1.9; Medimaps, Geneva, Switzerland) at the Bone Disease Unit of the University of 
Lausanne (Lausanne, Switzerland). LS-TBS was calculated for a subgroup of RS-I-4, 
RS-II-2 and RS-III-1 and represents the mean value of the individual vertebral mea-
surements from L1 to L4. Subjects with a BMI higher than 37 kg/m2 were excluded 
from the study since LS-TBS measurements in morbidly obese persons are not ac-
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curate. Furthermore, the LS-TBS was standardized according to sex using the residual 
method, due to technical differences between LS-TBS across sexes. The method of 
LS-TBS calculation has been described in detail elsewhere (32).
Statistical analyses
First, for all variables normal distribution was examined by visual check of histograms. 
When necessary, data were log transformed. Linear regression analysis (cross-section-
al) was used to assess the association between LD-use (past-, current-use and the 
duration of 1-120 days, 120-365 days and >365 days) and FN-BMD, LS-BMD and LS-TBS. 
All the analyses were adjusted for age and sex and cohort (model 1). Thereafter, the 
co-variables were added additionally to model 2, based on literature relevance as well 
as principles of causal inference combined with the change-in-effect-criterion of ≥10% 
(33, 34). Potential confounders were BMI, smoking (pack-years), alcohol intake (g/
day), SES (education and job), total physical activity (METhours/wk) and comorbidities 
(prevalence of CHD, stroke and DM). For the analysis of the duration (continuous), 
the model was additionally adjusted for the past-users. An earlier study showed that 
in subjects with osteopenia/normal BMD levels, TBS is significantly associated with 
vertebral fractures (35). Even though BMD and TBS are correlated, they present differ-
ent aspects of bone health (35). For that reason, as sensitivity analyses, we wanted to 
assess how the association between LD and BMD may depend on measures of bone ar-
chitecture (i.e. TBS) and how a potential association between LD and TBS is dependent 
on BMD. So, the association between LD and FN-BMD and LS-BMD were additionally 
adjusted for LS-TBS and vice versa (model 3). In addition, in all analyses, sensitivity 
analyses was performed with additional adjustment for serum vitamin D, season of 
blood collection of vitamin D: (winter (September till end of February) and summer 
(March till end of August)) serum calcium, magnesium and sodium concentrations.
To assess whether effect-modification by serum 25(OHD) level or dietary calcium intake 
was present in the association of LD (ever-use) on FN-BMD, LS-BMD and LS-TBS, we 
evaluated the effect-modification by serum 25(OH)D level and energy adjusted dietary 
calcium intake on FN-BMD, LS-BMD and LS-TBS in model 2 (P for interaction<0.10), 
since the beta did not changed after additional adjustment in model 3. Thereafter, we 
stratified the analyses of LD-use (LD never-use, current-use and past-use with never 
use as reference category) and bone outcomes according to serum 25(OH)D level, in 
subsequent categories of ≤20, between 20-50 and ≥50 nmol/L) and energy adjusted 
dietary intake of calcium in following categories: ≤950 mg/day, 950-1200 mg/day and 
≥1200 mg/day. The association between LD and LS-TBS, LS-BMD and FN-BMD was also 
evaluated by sex through effect-modification.
152 CHAPTER 4
To account for missing data in co-variables (varied from 1.6% to 66.8%), we used a 
multiple imputation approach (n=10 imputations, 10 iterations). Briefly, as described 
by Sterne et al, multiple imputation is created on the correlation between each vari-
able and missing values with other participant characteristics [36]. Linear regression 
analyses were then separately accomplished in each of the 10 datasets [36]. Beta’s 
were pooled by taking the average of the effect sizes of the 10 imputed datasets. 
The pooled standard errors and respective 95% Confidence Intervals (CI) were then 
calculated by using Rubin’s rules (37). For details of the multiple imputation, see 
supplement supplemental tables S1 and S2. The statistical software package of SPSS 
24.0 was used for the statistical analyses (SPSS Inc., Chicago, Illinois, USA). For all the 




Baseline characteristics are presented for the total population, LD-users and non-
users (Table 1) and baseline characteristics before and after multiple imputation are 
shown in supplemental table S2. The median age, on the DXA scan date, was 65.0 
years [57.0-99.0 IQR] for the total population (n=6,990). Of the total population, 7.8% 
(n=543) ever used LD from baseline till the DXA scan with a mean duration of 51.2 
days (325.1 SD). The median age of the 543 LD-users was 77.0 years [52.0-99.0 IQR] 
and 64.0 years [51.0-97.0 IQR] for the LD non-users (Table 1).
Table 1. Characteristics total population, users and non-users of LD
Total population 
(n=6,990)
LD ever users 
(n=543)








Age (years)b 65.0 [57.0-99.0] 77.0 [52.0-99.0] 64.0 [51.0-97.0] <0.001*
Sex (%women) 3,985 (57.0) 309 (56.9) 3,675 (57.0) 0.92
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Table 1. Characteristics total population, users and non-users of LD (continued)
Total population 
(n=6,990)
LD ever users 
(n=543)








Loop diuretics use (%ever use)










  <50 nmol/L






























Dietary calcium intake (mg/day)a
  Tertiles (%):
  <950.0 mg/day
  950-1200 mg/day














Lumbar Spine TBSa 1.24 (0.13) 1.17 (0.12) 1.25 (0.12) 0.32
Femoral Neck Bone Mass Density
(g/cm2)a
0.91 (0.15) 0.86 (0.15) 0.91 (0.15) 0.98
Lumbar Spine Bone Mass Density
(g/cm2)a
1.14 (0.21) 1.15 (0.22) 1.14 (0.20) 0.40
Smoking (%)
  Never smoker
  Current smoker






















Alcohol Intake (g/day)b 7.3 [0.8-20.0] 3.1 [0.1-15.7] 7.9 [0.9-20.0] 0.11
PA (MET hours/week)b 70.5 [39.4-103.9] 70.8 [47.6-100.1] 70.4 [38.5-104.4] 0.84
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The median serum 25(OH)D level of the LD-users was 42.3 nmol/L [28.8-62.3 IQR] and 
for LD non-users, 55.4 nmol/l [37.2-76.7 IQR]. LD-users showed a significantly lower 
serum 25(OH)D level than non-users (p<0.001). The mean dietary calcium intake of 
the LD-users was 1189 mg/day (394 SD) and 1121 mg/day (394 SD) for LD non-users. 
Results of the linear regression analysis of LD-use and indices of bone health are 
shown in table 2 and discussed below.
Loop diuretics and LS-TBS
Compared to LD never-use, current-use of LD was only associated with LS-TBS in the 
crude model (β=-0.018, 95% CI: -0.034; -0.001) and past-use of LD was associated 
with lower LS-TBS, in model 1 (β=-0.031, 95% CI: -0.044; -0.017). Adjustment for 
co-variates in model 2 attenuated the association somewhat whereby the effect size 
was 30% lower. The analysis of categories of the duration of LD-use among users and 
LS-TBS, showed no significant associations (Table 2).
Loop diuretics and LS-BMD
Current-use of LD in 210 participants was associated with significantly higher LS-BMD 
compared to never-use of LD in the crude model (β=0.037, 95% CI: 0.010; 0.065). Past-
use of LD was associated with higher LS-BMD compared to never-use of LD in the crude 
model, model 2 and fully adjusted model (model3) (β=0.048, 95% CI: 0.026; 0.071, 
β=0.029, 95% CI: 0.006; 0.052 and β=0.038, 95% CI: 0.016; 0.060). In the analyses of 
the duration of LD-use, current-use of LD between 121-365 days showed a significantly 
higher LS-BMD in fully adjusted model (β=0.075, 95% CI: 0.007; 0.143 table 2).
Loop diuretics and FN-BMD
LD current-users showed no significant association with FN-BMD compared to never-
use of LD. However, past-use of LD showed a significantly higher FN-BMD only in the 
crude model (β=0.016, 95% CI: 0.001; 0.031, table 2).
Additional adjustment for serum vitamin D, season of blood collection of vitamin D, 
serum calcium, magnesium and sodium did not change the results (data not shown).
Furthermore, we evaluated the association between LD and LS-TBS, LS-BMD and FN-
BMD by sex and found no evidence that the association between LD and LS-TBS was 
significantly different according to sex (P-interaction=0.83). However, the association 
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between LD and LS-BMD and FN-BMD was significantly different according to sex (P-
interaction for both=0.04) (Supplemental table S3).
Serum 25(OH)D level and dietary calcium intake in the association 
of the use of loop diuretics and FN-BMD, LS-BMD and LS-TBS
Effect-modification analysis of serum 25(OH)D level and dietary calcium intake in 
the association between LD-use on FN-BMD and LS-TBS are shown in tables 3 and 4. 
P-value for interaction terms varied from 0.04 to 0.99. Serum 25(OH)D level was an 
effect modifier in the association between LD use and LS-TBS (P for interaction=0.04). 
After stratification in model 2, the group of serum 25(OH)D level ≥50 nmol/L showed a 
significantly lower LS-TBS compared to serum 25(OH)D ≤20 nmol/L and between 20-50 
nmol/L for LD past-use (β=-0.036, 95% CI: -0.060; -0.013 vs. β=-0.012, 95% CI: -0.036; 
0.013 and β=-0.031, 95% CI: -0.096; 0.034, respectively, table 3).
There was no effect modification by serum 25(OH)D level on the association between 
LD-use and FN-BMD and LS-BMD (Table 3). After stratification, for the analysis of the 
association between LD and LS-BMD, participants with serum 25(OH)D level between 
20-50 nmol/L had a significantly higher LS-BMD compared to participants with serum 
25(OH)D level ≤20 and ≥50 nmol/l for LD current use, however there was no significant 
interaction (P for interaction=0.30) (Table 3).
No significant effect modification by dietary calcium intake was observed on the asso-
ciation between use of LD and FN-BMD, LS-BMD and LS-TBS (Table 4). After stratifica-
tion of dietary calcium intake in categories of intake ≤950, 950-1200 and ≥1200 mg/
day, no significant associations were found with FN-BMD, LS-BMD and LS-TBS (Table 
4).
DISCUSSION
In this study, we observed a modest increase in BMD of the lumbar spine and a modest 
decrease in TBS in LD past-users, therefore our study conclude that if any, LD use does 
not have a strong association with bone health, in a population with a high calcium 
intake. Furthermore, this study found effect-modification by serum 25(OH)D level in 
the association between LD and LS-TBS. However, after stratification on serum 25(OH)
D, no consistent findings were found in the association between LD-use and bone 
outcomes, suggesting no strong modifying effect of serum 25(OH)D on these associa-
tions. Additionally, no effect-modification was found by dietary calcium intake.
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In our study, current LD-use showed a negative association with LS-TBS, however not 
significant.
In contrast to the findings of the association between LD and LS-BMD, we found 
that a history of LD was associated with a decreased LS-TBS if LD was used in the 
past. To our knowledge there have been no studies on LD-use and LS-TBS. TBS is a 
measurement related to bone microarchitecture provides skeletal information that 
is not captured from the standard BMD measurements (31). Also, TBS might be an 
appropriate measure to study in regard to lifestyle factors that are adaptable, such 
as dietary intake (31, 32). Other studies have reported lower TBS among individuals 
with primary hyperparathyroidism (38). And as mentioned, LD’s increase the plasma 
PTH and 1.25(OH)2D levels as a result of increased renal calcium losses (11). Thus a 
possible explanation for our finding is that LS-TBS may be decreased by secondary 
hyperparathyroidism caused by long-time LD-use (13, 39). However, we could not 
confirm this possible pathway in our current study, since we do not have the avail-
ability of serum PTH. Other explanation for the opposite direction between BMD and 
TBS due to potential residual confounding (i.e. body composition and health status) 
in the association between LD and TBS. Further studies are needed to explore the 
association between LD and overall bone health, especially TBS.
Additionally, LD-use was not associated with a lower BMD. In contrast, it has been 
shown that LD increases renal calcium excretion (8-11), with a potential negative 
effect on BMD (10, 13, 38). We expected that LD-use would result in a lower FN-BMD 
and LS-BMD, because treatment with LD may induce secondary hyperparathyroidism 
with raised bone resorption resulting in a lower BMD (39, 40). This was, however, 
not confirmed by our findings. Current-use of LD showed a non-significant negative 
association with FN-BMD and a non-significant positive association with LS-BMD. 
Furthermore, the study of Rejnmark et. al. in 2005 showed also a non-significantly 
higher LS-BMD for the group with LD (who had been treated with a LD for at least 2 
years prior to inclusion in the study), compared with non-users (38). Another study 
of Rejnmark et. al. in 2006 showed a decrease in BMD for the LD-users compared to 
placebo treated for 1 year. The effect was however weakened after 6 months end of 
treatment. Unfortunately, we cannot confirm this result in our study. In our analysis 
of the association between the duration of LD and FN-BMD, we found a positive as-
sociation for LD-use between 1-365 days and a negative association with FN-BMD for 
longer use of LD (>365 days) compared to never-users of LD, nevertheless this was not 
significant. Also we found an increase in LS-BMD when LD was used for 121-365 days. 
This suggests that LD-use might be weakly associated with higher BMD but only for a 
short time period.
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Some studies have shown differences in vitamin D level according to LD-use. In line 
with our results, there is evidence that LD-users have a lower serum 25(OH)D level 
than non-users (34) and the inverse association between LD-use and serum 25(OH)D 
level has been reported before (16). To the best of our knowledge, information about 
the effect modification by serum 25(OH)D level on the association between LD-use 
and FN-BMD and LS-TBS as bone health parameters has not been reported earlier. In 
our study, stratified analyses did not show consistent patterns and the differences 
were not statistically significantly different between cut-offs of serum 25(OH)D level. 
However, we found evidence for potential effect modification (P-interaction<0.10) by 
serum 25(OH)D level for the association of LD past-use and LS-TBS. Stratified analyses 
showed a slightly stronger inverse association between past LD-use and LS-TBS in those 
with serum 25(OH)D level ≤20, however the association was not significant in strata 
of serum 25(OH)D level between 20-50 and above 50 nmol/L. This finding may imply 
that past-use of LD may have affected LS-TBS which can have a higher impact in those 
with extremely low 25(OH)D levels. However, because this effect-modification was 
not further confirmed by other categories of LD-use, further replication is needed.
Moreover, even though we adjusted our analysis for body fat mass, reduced vitamin D 
levels may still be confounded other measures of body composition and health status.
Our initial hypotheses was that an adequate serum 25(OH)D level and dietary calcium 
intake would counteract the potential adverse effects of LD on bone health. In con-
trast, we found no consistent significant differences between categories of dietary 
calcium intake, in the association between LD and FN-BMD, LS-BMD and LS-TBS. Thus, 
given that LD increases the renal excretion of calcium (40), the effects of LD on bone 
health showed unexpected results. This is in contrast with earlier studies, showing 
that a higher dietary intake of calcium prevented the expected decrease of FN-BMD 
in LD-users (38, 41, 42). Potentially, the lack of calcium modifying the association 
between LD and bone health in our study may result from the fact that in our study 
calcium intake was higher than in other studies.
Strengths and limitations
A strength in our study is the availability of data on dietary intake of calcium, serum 
25(OH)D level and LD-use, and the different indices of bone health (i.e. FN-BMD as 
well as LS-BMD and LS-TBS). Our study also adds data to the quite unexplored field of 
nutrient-drug interactions in a population of community-dwelling older persons, who 
are at risk of musculoskeletal diseases, malnutrition and consequences of polyphar-
macy. However, some limitations need to be taken into account when interpreting our 
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results. These include the observational study design and potential residual confound-
ing (for example, underlying disease), which prevents us from drawing conclusions re-
garding causality and the direction of the effect size of the association. Furthermore, 
as all our analyses were hypothesis-based, we did not adjust for multiple comparisons. 
With regard to possible type I errors, stringent interpretation of p-values should be 
made with caution. Likewise, potential misclassification of LD-use using pharmacy 
records may occur because data regarding actual compliance was lacking. Also, di-
etary calcium intake was assessed using self-reported dietary assessment, which is 
subject to bias and measurement error. Also, dietary intake was measured only once 
(at baseline) and as a result we were unable to account for differences in dietary 
habits over time (e.g. due to disease or medication use). Moreover, the complete 
data on calcium or vitamin D supplement use was not available, which could lead to 
an underestimation of dietary intake. In addition, vitamin D and calcium prescriptions 
was not analysed as exposure variable because of confounding by indication. Also, we 
did not have a comprehensive assessment of calcium homeostasis. For example, the 
free calcium concentration in plasma is strongly controlled through a complicated 
physiological system including the interaction of calcitrophic hormones such as PTH 
and 1,25(OH)D and only in extreme situations, will the serum calcium concentration 
deflect from the normal range (14). Since we did not have the availability of serum 
PTH, we could not investigate potential pathways between the use of LD and calcium 
intake and vitamin D level. Finally, our result of inconsistent effect modification by 
serum25(OH)D and dietary calcium intake on the associations between LD and the 
parameters of bone health could be explained by managing the parathyroid hormones 
(PTH) and 1.25 (OH)D that maintain calcium homeostasis, especially when serum 
calcium is reduced (43).
In conclusion, this study does not support the hypothesis that the association between 
loop diuretic use and indices of bone health is modified by serum 25(OH)D level and 
calcium intake. However, because of polypharmacy effects and a higher risk of mal-
nutrition in elderly, further research and replication is warranted on nutrient-drug 
interaction on bone health (considering the subjects with osteopenia and osteoporosis 
and people with malnutrition), using other biomarkers as PTH and bone turnover 
markers as well as long term loop diuretic use.
Supplementary Materials: Table S1: Details of the multiple imputation modelling, 
Table S2: Basic characteristics before and after multiple imputation.
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SUPPLEMENTARY DATA
Table S1. Details of the multiple imputation modelling
Multiple imputation procedure
Software used SPSS 24.0 for Windows







imputed, used in 
model as predictor)
Calcium intake, vitamin D level, LD, LS-TBS, LS-BMD and FN-BMD
Covariates (imputed) BMI, scan age, smoking, METhours and comorbidities
Additional predictors Sex, cohort, packyears, alcohol, use of bisphosphonate







Number of missing for the variables imputed can be found in supplementary table S2.
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Table S2. Basic characteristics before and after multiple imputation
N Missing
(n)
Original data Imputed data
Age (years)b 6,990 0 65.0 [57.0-99.0] No missing
Sex (%women) 6,990 0 3,985 (57.0) No missing
BMI (kg/cm2)a 6,916 74 27.6 (4.1) 27.6 (4.1)
Loop diuretics use (%yes)
  Duration (days)a





  <50 nmol/L














Dietary calcium intake (mg/day)a
  Tertiles (%):
  <950.6 mg/day
  951-1234.7 mg/day
  >1235 mg/day
4,993 1,997 1126.5 (388.9) Not imputed
Lumbar Spine TBSa 6,476 514 1.24 (0.13) Not imputed
Femoral Neck Bone Mass Density (g/cm2)a 6,677 313 0.91 (0.15) Not imputed
Lumbar Spine Bone Mass Density (g/cm2)a 6,908 82 1.14 (0.21) Not imputed
Smoking (%)
  Never smoker
  Current smoker

















Alcohol Intake (g/day)b 6,990 0 7.3 [0.8-20.0] No missing
PA (MET hours/week)b 5,899 1,091 70.5 [39.4-103.9] 70.5 [39.4-103.9]



















apresented as mean (SD); bpresented as median [interquartile range]
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termβ (95%CI) β (95%CI)
LS-TBSb (6,476) 0.83
LD never-use Reference Reference
LD past-use (n=310) -0.030 [-0.050; 
-0.010]*
-0.011 [-0.029; 0.007]







termβ (95%CI) β (95%CI)
LS-BMD (n=6,677) 0.04*
LD never-use Reference Reference
LD past-use (n=321) -0.003 [-0.038; 0.033] 0.057 [0.028; 0.086]*







termβ (95%CI) β (95%CI)
FN-BMD (n=6,908) 0.04*
LD never-use Reference Reference
LD past-use (n=319) -0.0002 [-0.024; 0.023] 0.013 [-0.006; 0.033]
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Previous studies showed that high calcium intake may be associated with reduced 
colorectal cancer (CRC) risk, but results were inconclusive. We evaluated whether 
calcium intake from diet and supplements, as well as the calcium levels itself were 
associated with CRC risk in middle-aged and older individuals. Also we evaluated 
whether these associations were modified by genetic variation of calcium homeostasis.
Design
This study was embedded in The Rotterdam Study, a prospective cohort study among 
adults aged 55 years and older without CRC at baseline, from the Ommoord district of 
Rotterdam, The Netherlands (N=10,941). Effect modification by a pre-defined genetic 
risk score (GRS) from seven loci known to be associated with calcium concentrations, 
was evaluated.
Results
Relative to the recommended dietary calcium intake, only higher than the recom-
mended dietary calcium intake (≥1,485 mg/day) was associated with a reduced risk of 
CRC (HR: 0.66; 95% CI: 0.44 – 1.00). All seven loci for serum calcium concentrations, 
as well as the GRS, were not associated with CRC but showed effect modification by 
the GRS in the association between calcium intake and CRC (p for interaction=0.08). 
After stratification of GRS into low, intermediate and high, we found a lower CRC risk 
for low weighted GRS per increase in calcium intake.
Conclusion
The results from this study demonstrate that there is no consistent association be-
tween calcium indices on CRC. However, the association between calcium intake and 
CRC may be modified by genetic variation associated with serum calcium concentra-
tions that deserves further replication in other studies with different population.
Keywords: dietary calcium, calcium supplements, colorectal cancer, calcium SNPs, 
prospective cohort 
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INTRODUCTION
Colorectal cancer (CRC) is a growing public health concern worldwide, with over 
1.8 million new cases in 2018 globally (1). Several lifestyle factors such as physical 
inactivity, low dietary fiber intake, high red and processed meat intake and high 
alcohol intake are associated with an increased risk of developing CRC (2).
Previous studies have demonstrated that high dietary calcium intake (from dairy 
products) may be associated with reduced CRC risk, but the evidence for the associa-
tion for non-dairy calcium and CRC is still inconclusive (2). These differential results 
may be explained by differences in bioavailability, for example some of the green 
vegetables have a low bioavailability of calcium due to the presence of oxalate (3, 4).
Several biological mechanisms may explain a potential protective role of calcium in 
the development of CRC. For example, experimental studies in animals and humans 
showed that calcium may protect against CRC development by binding to bile acids 
and fatty acids in the gastrointestinal tract, and subsequently protecting the colon 
mucosa from these potentially toxic products (5, 6). Also, calcium may influence dif-
ferentiation and apoptosis of colonic epithelial cells and might reduce inflammation 
and oxidative damage in these cells (7).
Moreover, a potential role of the calcium-sensing receptor (CASR) in influencing 
carcinogenesis of colon epithelium and mediating antineoplastic effect of calcium 
was suggested (8). In this study, it was found that higher calcium intake was associ-
ated with a lower risk of CASR-positive tumours but not with CASR-negative tumours. 
Besides CASR, seven other Single Nucleotide Polymorphisms (SNPs) associated with se-
rum calcium have been identified (i.e. rs1801725, rs10491003, rs1550532, rs1570669, 
rs7336933, rs7481584, rs780094); these may be relevant in CRC etiology as well (9). 
However, inconsistent results on (colorectal) cancer have been reported for calcium-
related SNPs so far (e.g. related to CASR or Vitamin D Receptor (VDR) genes) (8, 10, 
11). Also, the association of these SNPs and CRC, and the effect modification of these 
SNPs on the association of calcium indices and CRC have not been investigated yet. 
Our working hypothesis is that higher intake of calcium could decrease the risk of 
CRC but that this depends on the genetic variability related to calcium homeostasis. 
Therefore, the aim of the present study was to determine whether calcium intake 
from diet and supplements as well as total calcium levels was associated with CRC risk 
in middle-aged and older individuals. Furthermore, we aimed to assess whether 7 loci 
for serum calcium concentration are associated with CRC and whether the association 
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between calcium indices and colorectal cancer risk differs according to pre-specified 
SNPs involved in calcium homeostasis.
Subjects and methods
The Rotterdam Study
This study was embedded in The Rotterdam Study, an ongoing prospective population-
based cohort study originally designed to investigate the occurrence and determinants 
of common age-related diseases (12). Briefly, The Rotterdam Study is composed of 
four cohorts. We used the existing data from the first and second cohort of The Rot-
terdam Study (RS-1 and RS-II). Individuals aged 55 years and older, who were living in 
the Ommoord district of Rotterdam, the Netherlands were recruited for RS-I, between 
1990 and1993 (n=7,983). The study was extended in 2001 with 3,011 participants in 
RS-II. Baseline data, were obtained by a home interview and two subsequent visits 
to the research center in Ommoord. Follow-up examinations were repeated approxi-
mately every three to four years, with a response rate of 78%, which is in line. Clinical 
outcomes such as morbidity and mortality were continuously monitored throughout 
the study period. All participants provided written informed consent, and ethical 
approval was obtained from the Medical Ethical Committee of the Erasmus Medical 
Center (12, 13).
Calcium
Dietary calcium intake data were obtained by using semi-quantitative food frequency 
questionnaires (FFQ) at baseline (between 1989 and 1993 in RS-I-1 and between 2000 
and 2001 in RS-II-1), managed by a trained dietician at the study center (12, 14). Por-
tion size of each food item was specified in standardized units, household measures or 
grams, and the frequency of each item was collected in times per day, week or month. 
Food items were coded using the corresponding NEVO-code (Dutch Food Composition 
Table) (15). Dietary intake of nutrients (incl. total energy and calcium) was calculated 
using the Dutch Food Composition database (NEVO) (15). Dietary calcium intake was 
adjusted for total energy intake using the residual method to adjust for measure-
ment error and residual confounding (16, 17). In a validation study (n=80) of The 
Rotterdam Study nutrient intake assessed with the FFQ was validated against multiple 
food records (18). The validation study showed a good correlation for calcium intake 
(Pearson’s correlation after adjustment for age, sex, energy intake, and within-person 
variation: 0.72) (18).
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In addition, drug use of participants of The Rotterdam Study was continuously moni-
tored since January 1, 1991, through computerized records from the pharmacies in 
the Ommoord district. The pharmacy data included the Anatomical Therapeutical 
Chemical (ATC)-code, the dispensing date, the total number of drug units per pre-
scription, the prescribed daily number of units, and product name of the drugs. 
On the basis of this information, the number of calcium dispensings was extracted 
(A12AA and A12AX) (19).
Serum calcium levels were determined at baseline using a cresolphthalein complexone 
method (Merck Diagnostica, Amsterdam, the Netherlands) with a Kone auto-analyser 
(Kone Diagnostics, Espoo, Finland) (12).
Single Nucleotide Polymorphisms (SNPs) selection
The Rotterdam Study RS-I and II consist of 8.448 DNA samples at baseline, and from all 
Rotterdam Study samples the genotypes of SNPs are being estimated using the basis 
Illumina 500 K SNP dataset configurations in each subject (12). The selection of SNPs 
in this study, was pre-specified using the seven loci (six new regions) known to be 
associated with serum calcium based on literature and based on our hypothesis only 
for the included participants of RS-I and RS-II (9). The selected SNPs were rs1801725, 
rs10491003, rs1550532, rs1570669, rs7336933, rs7481584, rs780094.
Colorectal Cancer (CRC)
Diagnosis of incident cancer was based on medical records of general practitioners 
(including hospital discharge letters) and furthermore through linkage with Dutch 
Hospital Data (Landelijke Basisregistratie Ziekenhuiszorg), histology and cytopathol-
ogy registries in the region (PALGA), and the Netherlands Cancer Registry. Cancer 
diagnoses were coded independently by two physicians and classified according to 
the International Classification of Diseases, 10th revision (ICD-10) (20). In case of 
discrepancy, consensus was sought through consultation with a physician specialised 
in internal medicine. In these analyses, only pathology proven CRC were used from 
baseline of the cohort until the end of follow up on December 31, 2014. Date of 
diagnosis was based on date of biopsy or—if unavailable—date of hospital admission 
or hospital discharge letter. Codes C18-C20 about malignant neoplasms of the colon, 
recto-sigmoid junction and rectum, were used to classify CRC diagnosis.
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Covariates
The following characteristics of the study population and other information were 
assessed during the home interviews and the visit to the research center at baseline 
of the cohort between 1990 and 2001: gender, age, education level, income, smoking 
status, other dietary variables (including intake of alcohol, dietary fiber and processed 
red meat), height, weight, waist circumference, history of diabetes mellitus type II, 
serum total cholesterol levels and serum total calcium levels. Level of education and 
net monthly household income were used as indicators of socioeconomic status. High-
est attained educational level was classified according to the International Standard 
Classification of Education using the following categories: primary education, lower/
intermediate general and lower vocational education, higher general and intermedi-
ate vocational education, and higher vocational education and university (21). For 
the present study, education level was categorized into two categories: low education 
(primary education solely) and intermediate to high education (secondary education 
and higher). Income of the participants was expressed in net monthly household in-
come. For the present study, income was categorized into low to intermediate income 
(<2,400 gulden/per month) and intermediate to high income (≥2,400 gulden/per 
month) based on net modal household income of the study population. Smoking status 
was categorized into two categories: never or ever smokers and current smokers.
Intake of energy (kcal/day), alcohol (g/day), dietary fiber (g/day) and processed red 
meat (g/day) were assessed with the FFQ as described previously. All dietary nutrient 
intake were adjusted for total energy intake using the residual method (17).
Height and weight were measured at the research center, and Body Mass Index (BMI) 
was calculated by weight in kilograms divided by the square of height in meters (kg/
m2) (22). Waist circumference was measured midway between the lowest rib and the 
iliac crest using a measuring tape (12). Diabetes mellitus type II was defined as fasting 
plasma glucose concentrations of ≥7 mmol/l or the use of glucose lowering drugs or 
insulin using the World Health Organization (WHO) and American Diabetes Federation 
(ADA) guideline (23, 24). Serum total cholesterol levels were determined with blood 
samples using an automated enzymatic procedure (25).
Physical activity and vitamin D level were obtained during the visit to the research 
center at the third follow-up visit of the cohort between 1997 and 2001. Physical 
activity was determined by means of an adapted version of the Zutphen Physical 
Activity Questionnaire (ZPAQ) (26). The ZPAQ was previously validated with a test-
retest reliability of 0.93. The correlation of ZPAQ with doubly labeled water which 
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is the golden standard measurement of physical activity was 0.60 (27). The adapted 
questionnaire consisted of questions about walking, cycling, gardening, diverse 
sports, hobbies and housekeeping. The Metabolic Equivalent of Task (MET) was used 
to express the intensity of physical activity of each activity. MET-values were based 
on the metabolic rate for that specific activity compared to the resting metabolic 
rate using the 2011 Compendium of Physical Activities (28). Vitamin D status was 
assessed with plasma concentrations of 25-hydroxyvitamin D (25OHD) (nmol/l) from 
non-fasting blood samples using electrochemiluminescence immunoassay (COBAS, 
Roche Diagnostics GmbH, Germany (12).
Statistical Analyses
Continuous variables with a normal distribution were expressed as mean with its 
standard deviation (SD), and continuous variables with a skewed distribution were 
expressed as median with its interquartile range (IQR). Categorical variables were 
presented in frequencies and relative percentages.
Cox regression analyses were performed to determine the associations between 
calcium diet, supplements, calcium level andCRC risk separately. Follow-up time (in 
years) was used as underlying timescale in the analyses. The proportional hazard 
assumption was explored by performing an interaction test of exposure with time in 
the Cox proportional hazard models. The proportional hazard assumption is assumed 
to hold when the P-value of the interaction between exposure and time is >0.05 
(29). The association between prescribed calcium supplement intake and CRC was 
analyzed using Cox regression analysis with prescribed calcium supplement intake as a 
time-dependent covariate. In these analyses the prescriptions of calcium supplement 
was compared with non-prescriptions of calcium supplements at the same time point. 
Time since first calcium dispensing was used as underlying timescale (30).
Dietary calcium intake was first analyzed continuously (per 200 mg). Subsequently, 
dietary calcium intake was analyzed as a categorical variable after stratification into 
four categories on the basis of the Recommended Dietary Allowance (RDA) for dietary 
calcium intake in the Netherlands (1,100 mg/day) (31) ± standard deviation (SD) of 
the study population. The category that included the RDA was used as reference 
group for further analyses. To assess linear trends between dietary calcium intake and 
CRC risk, tests for trend were calculated using the categorical variable as a continu-
ous variable in the Cox proportional hazard models. In addition, prescribed calcium 
supplement intake were analyzed continuously (per each prescription of calcium 
supplements) and dichotomously (yes/no) for the analyses. The category that included 
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no prescribed supplement intake was used as reference group for the dichotomous 
analyses. Because calcium homeostasis is affected by albumin concentrations, serum 
total calcium level was adjusted for serum albumin level in a subgroup (available only 
in RS-I) with the use of the following formula: 0.8 (4.0 – serum albumin level) + serum 
calcium level (32). Serum total calcium level was analyzed continuously (per each 
mmol/L) and in quartiles (first quartile as reference).
Potential confounders were added to the sex- and age-adjusted model (Model 2). 
We also included another model in which we additionally adjusted for BMI and waist 
circumference (Model 3).
The weighted Genetic Risk Score (GRS) was calculated from seven SNPs for calcium 
concentration (80% of variance is explained by these SNPs) by multiplying with the 
effect estimate of each SNP from GWAS on calcium concentration (9). After that, we 
summed all the scores of all seven SNPs (33). The association between seven SNPs 
separately as well as the GRS was analyzed by a Cox proportional hazard model. 
Furthermore, we tested the effect modification by weighted GRS on the association 
between calcium intake and CRC (P-value for statistically significantly interaction 
<0.10). Additionally, the associations of calcium level and calcium intake were tested 
(in Model 3) for effect modification by serum 25(OH)D level. The associations were 
stratified by 25(OH)D level (< 50 and ≥ 50 nmol/l) if the interaction term was below 
0.10.
To reduce bias associated with missing data, the multiple imputation procedure ac-
cording to the fully conditional specification method was used (n=10 imputations) 
(Supplemental tables S1 and S2) (34). The percentage of missing data of variables 
varied from 5.1% for smoking status to 42.8 % for history of diabetes type II (Supple-
mental table S2).
Results are presented as hazard ratios (HRs) and 95% confidence intervals (Cis). The 
pooled results from the multiple imputation procedure are given for all analyses. 
Statistical significance was set at P < 0.05. All analyses were performed with IBM SPSS 
Statistics version 25 for Windows.




Baseline characteristics of the study population are presented in table 1. Of the 
10,941 subjects included in the study (figure 1), 427 subjects (3.9 %) were diagnosed 
with CRC. The incidence rate was 2.9 per 1,000 person-years. The median age of the 
study population was 67.4 [IQR: 61.0-76.0 years]. The mean intake of dietary calcium 
intake was 1,116.7 (±390.0) mg/day (unadjusted for energy). Dispensed calcium 
supplement intake was reported by 17.3% of the study population. The mean of serum 
total calcium level was 2.4 (±0.1) mmol/L. As shown in table 1, the median (IQR) 
serum 25(OH)D level of the study population was 45.8 [IQR: 29.2-67.7].
Dietary calcium intake and CRC risk
Associations between dietary calcium intake and CRC risk are shown in table 2. 
Dietary calcium was only significantly associated with higher CRC risk in the crude 
model, when analyzed continuously (HR: 0.93; 95% CI: 0.87-0.99). When analyzed the 
dietary calcium intake in categories with using the RDA as reference, lower risk was 
found for high dietary calcium intake (≥1,485 mg/day), compared to the RDA (≥1,100-
















Excluded: participants with history 
of CRC (n=53)
Participants included in the 
study (n=10,941)
 
Participants included in The 
Rotterdam study (n=10,994)
 
Participants included in the 
study for the GRS analysis 
(n=8,814)
 
Figure 1. Flowchart of the included study participants
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Prescribed calcium supplementation and CRC risk
Associations between dispensed calcium supplement intake and CRC risk are shown in 
table 3. No associations were found between dispensed calcium supplement and CRC 
risk when analyzed continuously or dichotomously (Table 3).
Table 1. Baseline characteristics of the study population (n=10,941)
Characteristics





Women, n (%) 6,543 (59.8)
Education level, n (%)  
 Primary solely 6,094 (55.7)
 Secondary and higher 4,847 (44.3)
Income, n (%)  
 Low to intermediate (<2,400) 5,049 (46.1)
 Intermediate to high (≥2,400) 5,892 (53.9)
Total energy intake, kcal/d 1,954.5 (552.4)
Total dietary calcium intakeb, mg/d 1,116.7 (393.0)
Total dietary fiber intakeb, g/d 26.3 (79.4)
Total processed red meatb, g/d 101.1 (79.4)
Total alcohol intake g/d 9.7 (14.9)
Smoking status, n (%)  
 Never/ever 8,679 (79.3)
 Current 2,262 (20.7)
History of diabetes mellitus type II, n (%) 1,326 (12.1)
Physical activitya, MET hours per week 80.8 (44.4)
Body mass index, kg/m2 26.5 (3.9)
Waist circumference, cm 91.4 (11.5)
25(OH)D statusa, nmol/l, medianc 45.8 [29.2-67.7]
Serum total cholesterol levels, mmol/l 6.4 (1.2)
Serum total calcium level, mmol/l 2.4 (0.1)
Prescribed calcium supplement intake, n (%)




Values presented as means (SD), unless noted otherwise
a Measured during the third follow-up, not at baseline
b Adjusted for energy intake
c Median [IQR]
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Table 2. The association between dietary calcium intake and CRC risk








322 0.93 (0.87-0.99)* 0.95 (0.89-1.02) 0.95 (0.89-1.02)
Dietary calcium intake (mg/day) in categories
Category 1 (≤ 715) 59 1.47 (1.06-2.04)* 1.32 (0.93-1.89) 1.33 (0.93-1.89)
Category 2 (715-1,100) 120 0.85 (0.65-1.10) 0.83 (0.63-1.09) 0.82 (0.62-1.09)
Category 3 (1,100-1,485) 111 Reference Reference Reference
Category 4 (≥ 1,485) 31 0.65 (0.44-0.97)* 0.66 (0.44-0.99)* 0.66 (0.44-1.00)*
P-trendd 0.01* 0.06 0.07
Continuous: per each 200 mg
Categories: on the basis of the Recommended Dietary Allowance and standard deviation
aModel 1 was adjusted for cohort, age (years) and sex
bModel 2 was adjusted for age (years), sex, education (primary solely, secondary or higher), income 
(low to intermediate, intermediate to high), history of diabetes type II (no/yes), smoking status 
(never/ever, current), alcohol intake (g/day), dietary fiber intake (g/day), red meat intake (g/
day), serum total cholesterol levels (mmol/l) and physical activity (hours/day)
cModel 3 was additionally adjusted for BMI (kg/m2) and waist circumference (cm)
dTest for trend were carried out by entering the categorical variables as continuous variables in 
Model 3 of the Cox’s proportional hazard models
*p-value of < 0.05




















Continuous (prescribed calcium intake): per each prescription of calcium supplements
Dichotomous: yes/no
aModel 1 was adjusted for cohort, age (years) and sex
bModel 2 was adjusted for age (years), sex, education (primary solely, secondary or higher), income 
(low to intermediate, intermediate to high), history of diabetes type II (no/yes), smoking status 
(never/ever, current), alcohol intake (g/day), dietary fiber intake (g/day), red meat intake (g/
day), serum total cholesterol levels (mmol/l) and physical activity (hours/day)
cModel 3 was additionally adjusted for BMI (kg/m2) and waist circumference (cm)
*p-value of < 0.05
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Calcium concentration and CRC risk
The association between total serum calcium level and CRC in RS-I and RS-II is de-
picted in table 4. Total serum calcium level were not associated with CRC risk (Table 
4), and no linear trend was found (P-trend value >0.19). However, in the sensitivity 
analysis in RS-I population, where serum total calcium level was adjusted for serum 
albumin level in a subgroup (RS-I), we found a statistically significantly reduced CRC 
risk for total serum calcium level and a significantly increased CRC risk for higher 
albumin-adjusted calcium level (Supplemental table S3).
Effect modification by calcium concentrations SNP’s
The association between 7 SNPs separately as well as GRS is shown in table 5: we 
found no statistically significantly associations.
After evaluating the effect modification by weighted GRS from the calcium concentra-
tions SNPs, we found effect modification with dietary calcium intake by the GRS on 
CRC risk (p=0.08). No statistically significant effect modification by SNP with serum 









Serum total calcium level
- Continuous
257 0.49 (0.19-1.25) 0.47 (0.14-1.51) 0.48 (0.15-1.57)
Serum total calcium level
- Categorical
Quartile 1 (≤ 2.31) 63 Reference Reference Reference
Quartile 2 (2.31-2.39) 56 0.82 (0.59-1.15) 0.81 (0.57-1.15) 0.82 (0.58-1.16)
Quartile 3 (2.39-2.46) 40 0.85 (0.60-1.21) 0.80 (0.55-1.16) 0.81 (0.55-1.14)
Quartile 4 (>2.46) 48 0.84 (0.60-1.18) 0.77 (0.53-1.13) 0.78 (0.54-1.14)
P-trendd  50 0.35 0.19 0.21
Continuous: per each mmol/l
Categorical: quartiles (mmol/l)
aModel 1 was adjusted for cohort, age (years) and sex
bModel 2 was adjusted for age (years), sex, education (primary solely, secondary or higher), income 
(low to intermediate, intermediate to high), history of diabetes type II (no/yes), smoking status 
(never/ever, current), alcohol intake (g/day), dietary fiber intake (g/day), red meat intake (g/
day), serum total cholesterol levels (mmol/l) and physical activity (hours/day)
cModel 3 was additionally adjusted for BMI (kg/m2) and waist circumference (cm)
dTest for trend were carried out by entering the categorical variables as continuous variables in 
Model 3 of the Cox’s proportional hazard models
*p-value of < 0.05
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calcium level and calcium supplementation for CRC risk was found (P for interaction 
0.56 and 0.98, respectively). After stratification of GRS in low, intermediate and high 
weighted GRS in the association between dietary calcium intake and CRC risk, we 
found a significant lower CRC risk for the participants with lower GRS (HR= 0.78 per 
increase in calcium intake; 95%CI: 0.67-0.92, table 6).
Serum 25(OH)D level was a significant effect-modifier in the association between 
calcium intake and CRC (p=0.001) and in the association between calcium level and 
CRC (p=0.04). After stratification for serum 25(OH)D level, dietary calcium intake 
was associated with lower risk of CRC in subgroup of 25(OH)D level <50 nmol/l, and 
calcium level was associated with lower risk of CRC in subgroup of 25(OH)D level ≥ 50 
nmol/l. (Supplemental table S4).
The association of calcium concentration and calcium supplementation with CRC risk 
was not modified by serum 25(OH)D level (P for interaction 0.13 and 0.72, respec-
tively). Finally, a list of results from this study and comparison with literature has 
been added on supplemental table S5.
Table 5. The association between GRS, 7 SNPs for calcium concentrations and CRC risk (Cox 
analysis in Model 3)
 SNPs of calcium concentration HR (95% CI)
rs1801725 1.06 (0.78; 1.32)
rs1550532 1.06 (0.87; 1.30)
rs780094 0.96 (0.80; 1.16)
rs10491003 0.93 (0.68; 1.28)
rs7336933 1.14 (0.90; 1.45)
rs1570669 1.13 (0.93; 1.38)
rs7481584 0.99 (0.81; 1.20)
GRS 0.42 (0.02; 7.68)
Table 6. The association between dietary calcium intake and CRC risk, stratified by GRS score 
(low, intermediate and high GRS) (n=8,814)
Dietary calcium intake CRC cases HR (95% CI)
Low GRS 108 0.78 (0.67-0.92)*
Intermediate GRS 124 0.94 (0.82-1.08)
High GRS 109 1.05 (0.94-1.18)




In this prospective population-based cohort study, we did not find a consistent as-
sociation between calcium intake from diet or supplements or total serum calcium 
level and CRC risk. However, our findings suggest that the association between dietary 
calcium intake and CRC risk may be modified by the weighted GRS for SNPs for calcium 
concentrations, with calcium intake associated with a lower CRC risk for those with 
a low GRS.
Comparison with literature
Our results regarding dietary calcium intake and CRC risk are not fully in line with 
previous studies. Some prospective cohort studies found inverse associations of di-
etary calcium intake on CRC risk (8, 35). Moreover, results of combined prospective 
cohort studies showed a linear association; each 300 mg/day intake of total calcium 
was inversely associated with approximately 8% reduced CRC risk (36). In our study, 
we found an inverse association between dietary calcium intake and risk of CRC (Table 
2). The discrepancy between our results and those from previous studies may be ex-
plained by differences in average dietary calcium intake. The average intake of total 
calcium intake was below 800 mg/day for the previously studies (8, 16, 36), whereas 
our study population had a relatively high dietary calcium intake (1,116.7) mg/day).
In contrast to previous findings of studies of the association between dietary intake of 
calcium and CRC, a meta-analysis of randomized trials found no association between 
calcium supplement intake and CRC risk over a period of four years (3). It may be ar-
gued that the duration of the included trials was too short and probably lacked power 
to detect effects on CRC risk. As we know, calcium from diet mainly contains calcium 
phosphate, whereas calcium from supplements generally contains other compounds 
such as calcium citrate malate. Calcium from supplements has a higher bioavail-
ability than calcium from diet (10).The duration in our study was longer, however, the 
percentage of calcium prescriptions was around 17%, which is also low powered to 
discover any association. Moreover, we had no reliable data of the dosage, frequencies 
of the prescribed supplementation and over-the-counter calcium supplementation.
In our study, serum total calcium level was also not associated with CRC risk. Most 
studies on serum calcium levels and CRC have been conducted in selected patient 
group, where hypercalcemia is a well-known characteristic of various malignancies 
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(19). One previous study showed that serum total calcium levels were associated 
with a slightly higher risk of CRC risk in women (37). Another study showed that lower 
serum calcium levels may be a prognostic factor for CRC development (38). Most 
of the previous studies were conducted using serum calcium levels uncorrected for 
albumin. Sensitivity analysis in this study showed interestingly a higher risk for CRC 
for albumin-adjusted calcium levels, which is an important result and were also found 
in another study (37). This finding suggests that the true association between calcium 
and colorectal cancer may depend on other factors regulating calcium homeostasis. 
Differences may also be explained by suggested potential role of SNPs of calcium 
concentrations in influencing carcinogenesis of colon epithelium and mediating an-
tineoplastic effect of calcium (8). CASR could be associated with CRC survival (39); 
however, others showed no statistically significant effect modification investigating 
genome-wide SNPs, associated with calcium level and risk of CRC (40). In the pres-
ent study, we evaluated whether the seven loci known to be associated with serum 
calcium concentration, discovered from genome-wide study (9), were associated with 
CRC. In our study, we found no association between seven SNPs as well as weighted 
GRS score with CRC risk. Furthermore, only effect modification by the weighted GRS 
score in the association between total dietary calcium intake and CRC risk was found, 
suggesting that the protective effect may differ according to different genetic vari-
ability for altered calcium levels .
Additionally, the association of dietary calcium intake or calcium level with CRC risk 
was modified by 25(OH)D status. It is well known from previous evidence that vitamin 
D can modify the association between calcium level and CRC (41, 42). Previous study 
showed that 25-hydroxyvitamin D levels were associated with reduced CRC risk for 
concentrations of >80 nmol/l (43). Stratification by 25(OH)D status, showed that the 
association between dietary calcium intake and CRC risk appeared to be lower in 
subjects with a serum 25(OH)D level below 50 nmol/l suggesting that high calcium 
intake may inhibit the adverse impact of vitamin D deficiency. Besides, the association 
between calcium level and CRC risk was lower in subjects with a serum 25(OH)D level 
above 50 nmo/l. Vitamin D and calcium are interrelated. As described previously, 
vitamin D is important for the absorption of calcium in the gut (41). Like calcium, 
vitamin D plays an important role in growth restraining, controlling differentiation 
and apoptosis in cells of the intestines (41). Based on this, the association between 




We hypothesized that calcium may be associated with CRC risk through several 
mechanisms. First, calcium may influence cell growth. Calcium has growth inhibiting 
properties on normal and tumor intestinal cells and may thereby influence CRC devel-
opment (5). Also, in vivo and in vitro studies on human colonic epithelial cells showed 
that calcium suppresses proliferation and induces apoptosis in the lining of the colon, 
and thereby protects against CRC development (5, 42). Furthermore, experimental 
studies in animals and humans showed that calcium may bind to bile acids and fatty 
acids in the gastrointestinal tract, forming insoluble complexes, such as calcium soaps 
that protect the lining of the colon, and thereby reduces the risk of CRC (5, 6).
Moreover, we hypothesized that individual common genetic variants of calcium con-
centrations do modify the association between dietary calcium intake and CRC risk, 
and indeed we observed such an effect modification by the GRS on the association of 
calcium intake with CRC. To investigate effect modification by other genetic variants, 
larger studies with sequence data and genome-wide studies of calcium and CRC risk 
are needed.
Strengths and limitations
Our study has several strengths and limitations. One of the strengths is the prospec-
tive study design, which minimizes recall bias associated with CRC diagnosis. Also, 
this study had a long follow-up period, which is important because of the long latency 
period of CRC (44) and it may reduce the influence of reverse causation. Another 
strength of this study is the large study sample from a population-based setting, 
which increases the generalizability of the results.
Several potential limitations of our study need to be considered. First, information on 
dietary intake was obtained by self-report and at baseline of the study. Although diet 
in middle-aged and older individuals remains fairly consistent over time (45) and we 
adjusted our analyses for total energy intake to reduce potential measurement error 
(18), misclassification in calcium intake may still have occurred. Also, measurement 
error may have occurred since not all dietary supplement intakes were specified in 
dosages and frequency of usage. Furthermore, calcium homeostasis is affected by 
i.e. albumin concentrations. Unfortunately, we were only able to perform albumin-
adjusted calcium level analysis in a subgroup. Finally, the association between cal-
cium intake and CRC risk may differ in parts of the colon or rectum (46), we could not 
evaluate potential differences because of a limited number of CRC cases.
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CONCLUSION
In this prospective population-based cohort study, we did not find a consistent asso-
ciation between calcium intake from diet , supplements or total serum calcium levels 
and CRC risk. However, on the basis of SNPs related to calcium concentrations, we 
observed effect modification of the weighted GRS on the association between dietary 
calcium intake and CRC risk, with lower risk of CRC by increasing calcium intake in 
subjects with low weighted GRS score. Considering the increasing incidence of CRC, it 
is important to further investigate other factors regulating calcium homeostasis and 
its role on CRC etiology.
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SUPPLEMENTARY DATA
Table S1. Details of the multiple imputation modelling
Multiple imputation procedure
Software used SPSS 25.0 for Windows





Exposures and outcomes 
(not imputed, used in 
model as predictor)
CRC, calcium level and dietary calcium intake
Covariates (imputed)
Additional predictors Sex, cohort, packyears, alcohol, smoking







Number of missing for the variables imputed can be found in supplementary table S2.
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Table S2: Basic characteristics before and after multiple imputation
Characteristics N Missing (n) Original data Imputed data
CRC cases, n (%) 10,941 0 427 (3.9) No missing
Follow-up, years
Age, yearsc
10,941 0 13.6 (7.5)
67.4 [61.0-76.0]
No missing
Women, n (%) 10,941 0 6,543 (59.8) No missing
Education level, n (%) 8,263 2,687  
 Primary solely 4,348 (39.7) 6,094 (55.7)
 Secondary and higher 3,915 (35.8) 4,847 (44.3)
Income, n (%) 8,912 2,029  
 Low to intermediate (<2,400) 3,808 (34.8) 5,049 (46.1)
 Intermediate to high (≥2,400) 5,104 (46.7) 5,892 (53.9)
Total energy intake, kcal/d 6,638 4,303 1,968.7 (549.7) 1,954.5 (552.4)
Total dietary calcium intakeb, mg/d 6,188 4,753 1,116.7 (393.0) Not Imputed
Total dietary fiber intakeb, g/d 6,207 4,734 26.3 (75.9) 26.3 (79.4)
Total processed red meatb, g/d 6,207 4,734 101.1 (78.0) 101.1 (79.4)
Total alcohol intakeb, g/d 6,404 4,537 9.9 (15.0) 9.7 (14.9)
Smoking status, n (%) 10,379 562  
 Never/ever 8,217 (75.1) 8,679 (79.3)
 Current 2,162 (19.8) 2,262 (20.7)
History of diabetes mellitus type II, n 
(%)
6,263 4,678 827 (7,6) 1,326 (12.1)
Physical activitya, MET hours per week 7,273 3,668 80.8 (44.4) 80.8 (44.4)
Body mass index, kg/m2 9,545 1,396 26.6 (3.9) 26.5 (3.9)
Waist circumference, cm 8.954 1,987 91.4 (11.5) 91.4 (11.5)
25(OH)D statusa, nmol/l, medianc 6,269 4,672 49.1 [32.4-71.1] 45.8 [29.2-67.7]
Serum total cholesterol levels, mmol/l 9,591 1,350 6.4 (1.2) 6.4 (1.2)
Serum total calcium level, mmol/l 6,636 4,308 2.4 (0.1) Not Imputed
apresented as mean (SD); bpresented as median [interquartile range]
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Table S3. The association between serum total calcium level (unadjusted and adjusted for 
albumin level) and CRC risk in RS-I









356 1.03 (0.95-1.11) 1.11 (1.00-1.23)* 1.11 (1.00-1.23)*
Total serum 
calcium level
356 0.44 (0.16-1.22) 0.24 (0.06-0.94)* 0.26 (0.06-1.03)* (p=0.054)
Continuous: per each mmol/l
aModel 1 was adjusted for age (years) and sex
bModel 2 was adjusted for age (years), sex, education (primary solely, secondary or higher), income 
(low to intermediate, intermediate to high), history of diabetes type II (no/yes), smoking status 
(never/ever, current), alcohol intake (g/day), dietary fiber intake (g/day), red meat intake (g/
day), serum total cholesterol levels (mmol/l) and physical activity (hours/day)
cModel 3 was additionally adjusted for BMI (kg/m2) and waist circumference (cm)
*p-value of < 0.05
Table S4. The association between dietary calcium intake and CRC risk stratified by serum 
25(OH)D (< and ≥ 50 nmol/l)
Dietary calcium intake CRC 
cases
HR (95% CI) P=0.001**
25(OH)D <50 nmol/l 299 0.88 (0.79-0.97)*
25(OH)D ≥50 nmol.l 181 1.01 (0.90-1.12)
Calcium level P=0.04**
25(OH)D <50 nmol/l 299 0.94 (0.21-4.25)
25(OH)D ≥50 nmol.l 181 0.06 (0.01-0.65)*
Continuous: per each 200 mg
*p-value of < 0.05 **p-value of <0.10
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Table S5. List of Results from literature
Results from our study In line with the following 
studies
In contrast to the following 
studies
Low CRC risk for high dietary 
calcium intake (≥1,485 mg/
day), compared to the RDA 
(≥1,100-1,485 mg/day)
Garland et al., 1985 (1)
Flood et al., 2005 (2)
Abid et al., 2014 (3)
Park & Kim, 2015 (4)
Zhang et al., 2016 (5)
Yang et al., 2018 (6)
Meng et al., 2019 (7)
No association between 
dispensed calcium supplement 
and CRC risk
Bristow et al., 2013 (8) Flood et al., 2005 (2)
Barry et al., 2019 (9)
No association between serum 
calcium level and CRC risk
Fuszek et al., 2004 (10)
A higher CRC risk for higher 
albumin-adjusted calcium 
level in a subgroup analysis
Proctor et al., 2010 (11)
Wulaningsih et al., 2013 (12)
No association between 7 SNPs 
separately as well as GRS and 
CRC risk
Mahmoudi et al., 2014 (1 of 
the SNPs) (13)
Jacobs et al., 2010 (some of 
the SNPs) (14)
Zhu et al., 2017 (some of the 
SNPs) (15)
Effect modification by 
weighted GRS from calcium 
concentrations SNPs were 
found on the association 
between dietary calcium 
level and CRC risk. After 
stratification, a lower CRC risk 
was found for the participants 
with lower GRS
Park & Kim, 2015 suggest that 
gene-diet interactions may 
possibly alter the associations 
among dietary intake, genetic 
polymorphisms, and CRC risk 
(4)
Figueiredo et al., 2011 (16)
Serum 25(OH)D was also 
an effect-modifier in the 
association between calcium 
intake and calcium level and 
CRC. After stratification for 
serum 25(OH)D level, dietary 
calcium intake was associated 
with lower risk of CRC in 
subgroup of 25(OH)D level <50 
nmol/l, and calcium level was 
associated with lower risk of 
CRC in subgroup of 25(OH)D 
level ≥ 50 nmol/l.
Ng et al., 2014 (17)
Park et al., 2007 (18)
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GENERAL DISCUSSION
As the usage of dietary supplements grows worldwide, especially among older people, 
the objective of this thesis was to understand more about the role of micronutrients 
in health and diseases in the older population. The micronutrients that were the 
main topic of this thesis were folic acid, vitamin B12, vitamin D and calcium because 
they are widely used as dietary supplements, and have pleiotropic effects on several 
age-related diseases.
The association between vitamin D and body composition was studied, as well as the 
effect of folic acid and vitamin B12 on body composition (Chapter 2). The long-term 
effects of folic acid and vitamin B12 supplementation (the B-PROOF study) on common 
age-related diseases as such as cancer, fractures and cardiovascular diseases was 
assessed (Chapter 3). Lastly, the role of micronutrients on bone health and colorec-
tal cancer in interactions with diuretics and genetic variation on bone health and 
colorectal cancer, respectively was assessed (Chapter 4). This chapter provides an 
overview and discussion of the main findings of this thesis, followed by an outline 
of the clinical and public health implications and suggestions for potential further 
research.
MAIN FINDINGS AND COMPARISONS WITH 
RECENT STUDIES
Micronutrients and body composition
The prevalence of micronutrient deficiencies is increased in people with obesity, 
which is expressed as having a BMI >30. However, obesity is a multifaceted physiologi-
cal phenomenon leading to changes in body composition and is sometimes difficult to 
assess in an ageing population. Therefore, BMI as a measure may underestimate the 
prevalence of obesity among older adults. In studies involving this population group, 
measuring fat mass and fat-free mass as aspects of this changing body composition 
provides a better insight into the actual body composition and the prevalence of 
obesity. Therefore, the association between micronutrients and body composition (by 
measuring body fat percentage next to BMI) in an older population was assessed. We 
found that a higher BMI and higher body fat percentage were both significantly as-
sociated with lower serum 25(OH)D levels. In this study we confirmed that overweight 
older persons and those with a higher percentage of body fat were at risk of vitamin 
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D insufficiency (Chapter 2.1). This finding corresponds with other studies involving 
various populations (1, 2).
This association can be due to a decreased bioavailability of vitamin D due to its 
deposition in adipose tissue (3). But to assess the causality and the direction of the as-
sociation between the level of serum 25(OH)D and the change in BMI and fat percent-
age, one can use vitamin D supplementation studies and Mendelian Randomization 
studies. Mendelian randomisation studies suggested that vitamin D is causally related 
to markers of obesity, e.g. adiponectin (4). In the B-PROOF intervention trial with B 
vitamin supplements, all participants were also given vitamin D supplementation, 
therefore whether vitamin D supplementation might change body composition could 
not be assessed. Neither did we have any information on serum 25(OH)D levels after 
the intervention. However, a recent RCT showed that vitamin D supplementation had 
no effect on body composition (5). Yet, a systematic review and meta-analysis of RCTs 
showed that obesity reduced the effect of vitamin D supplementation on vitamin D 
level (6, 7). In addition, evidence from RCTs has also shown that optimal vitamin D 
supplementation may benefit obesity-related disorders (3). Altogether these results 
suggest that increase in overweight and fat mass seems to reduce serum 25(OH)D 
level and that obese people may need a higher doses of vitamin D to achieve the 
normal range of 25(OH)D compared to non-obese people. Further RCTs on the role of 
vitamin D supplementation in obesity-related disorders are needed (see implications 
and future research).
Another aspect that was evaluated in this thesis, was the effect of folic acid and 
vitamin B12 supplementation on body composition. In chapter 2.2 we observed that 
higher serum folate was associated with a lower BMI, and a higher vitamin B12 status 
was associated with a higher Fat Mass Index (FMI) from observational data, which was 
partly in line with previous studies (8). However, this association was not confirmed as 
causal, because the intervention with folic acid and vitamin B12 supplementation in 
the B-PROOF study had a null-effect on body composition, suggesting that B-vitamins 
may not have a role in the aetiology of obesity or changes in body composition in 
older individuals. Neither was the causal role of a lower vitamin B status in obesity 
supported in a Mendelian randomisation study of genetic determinants of vitamin 
B12 (9). However, a relatively strong association has been observed between the 
pleiotropic Fucosyltransferase 2 (FUT2) gene variant rs602662 and serum vitamin B12 
(9). FUT2 is thought to be involved in interactions between host factors and gut 
microbiome composition, which is involved in production of vitamin B12. Therefore, 
it can be hypothesized that differences in the gut microbiome composition might lead 
to the observed associations with obesity and body composition, and the concomitant 
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vitamin B12 changes might be a by-stander effect (10). Other recent studies support 
the causal role of obesity on vitamin B12 status by finding an association between FTO 
gene variants (which are associated with obesity (11)), and serum vitamin B12 levels 
(12). On the basis of these findings it can be concluded that obesity may influence 
B-vitamin status, but not the other way around.
Long-term effect of micronutrients on cancer
In the B-PROOF trial, the combination of vitamin B12 and folic acid supplementa-
tion was observed to be associated with an elevated risk of cancer, and especially 
colorectal cancer (Chapter 3.1). Previous studies on the association between folic 
acid and vitamin B12 supplementation and cancer risk were inconclusive, with some 
studies showing a null-effect or even a reduced risk of cancer after supplementa-
tion (13). The proposed underlying mechanism is that the carbon group of folic acid 
supplementation contribute to cell proliferation through purine nucleotide synthesis 
that accelerate the process of cell growth or by the provision of methylgroup donors 
to influence the process of DNA methylation and expression of genes that may be 
involved in carcinogenesis. Indeed, in a follow-up study of the B-PROOF study, when 
assessing genome wide methylation patterns on 450.000 CpG sites in genomic DNA of 
circulating blood cells using the Illumina array, variations in DNA-methylation were 
observed in several genes involved in carcinogenesis (14) in the intervention group.
One explanation for the opposing outcomes of several trials compared to our findings 
is that most studies on the effects of B vitamins on cancer have examined the effect of 
folic acid supplementation only, rather than in combination with vitamin B12 supple-
mentation. Since vitamin B12 also plays a role in the one-carbon mechanism, it might 
also play a role in the aetiology of cancer. The VITamins and Lifestyle cohort-study 
(VITAL), assessed the association of vitamin B12 supplementation and showed a higher 
risk of lung cancer in men between 50 and 76 years with a higher use of vitamin B12 
supplements (15).
However, studies on the association between cancer on the one hand and dietary 
intake or plasma levels of these B vitamins on the other hand, have shown conflicting 
results. Results from observational studies have suggested that the intake of these mi-
cronutrients individually is associated chiefly with a decreased risk of several cancers 
(16-18). However, studies of plasma levels of folic acid and vitamin B12 did not find an 
association with an increased risk of several cancers (19, 20). For example, in a study 
of subjects in UK primary care, having higher plasma B12 levels was found to be as-
sociated with an increased one-year cancer risk compared to normal B12 levels (21). 
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In a nested case-control study including a Mendelian randomisation approach based 
on 8 genetic variants for circulating vitamin B12, an increased risk of lung cancer was 
found to be associated with an increase in circulating vitamin B12 concentrations 
suggesting a causal effect of B vitamins on cancer risk (22).
Taken the results of previous studies, the B-PROOF study and RCT together, it seems 
that folic acid and/or vitamin B12 supplements, due to higher dose and higher bio-
availability, might potentially increase the risk of cancer in older persons (such as the 
participants in the B-PROOF study) (23). This could be due to individual effect of folic 
acid or vitamin-B12, or due to an interactive effect of both folic acid and vitamin-B12 
combined, and that this effects could be due to changes in DNA methylation patterns.
Effects of B vitamins on fractures, CVD and stroke
With regard to the findings of the B-PROOF trial during a prolonged follow-up pe-
riod on the main pre-specified outcome, no effect on fracture risk was observed, 
and neither an effect on cardiovascular disease was seen (Chapter 3.2). Similar to 
B-PROOF, another long-term RCT by Stone et al. found that vitamin B12 and folic 
acid supplementation had no effect on the risk of fractures in women (24). One of 
the limitations of B-PROOF could be the limited power to detect any effect of the 
B-vitamin supplementation due to relatively low incidence of events in the limited 
follow period. We therefore extended the follow-up period (of 2-3 years) of the initial 
B-PROOF trial to 6-9 years to capture more events, and evaluated the long-term 
effect of the intervention. A questionnaire was sent to the participants with informed 
consent for contacting in the future. In this extended study of the B-PROOF trial, 
however, only 90 new fractures were captured. We hypothesize that this may be an 
underestimation due to high loss to follow-up, mainly due to the high morbidity and 
mortality rates in these older adults (with a median age of 76 years when contacted 
in this extended follow-up study). During the second follow-up questionnaire, extra 
information was documented on the non-responders shown in the flow-chart below 
(Figure 1). In contrast with B-PROOF extended follow-up, a recent study showed 
that higher intake of vitamin B12 (≥ 30 vs < 5 µg, diet and supplements) in a longer 
follow-up period (of 20.9 years), was associated with increased fracture risk (25). This 
study documented 2304 cases with hip fracture of 75 864 included in women nurse 
health study with lower intake of vitamin B12 than B-PROOF study. Nevertheless as 
this study has a cohort design of the study, residual confounding may be present and 
thus randomized controlled trials with a larger follow-up are needed to establish 
adverse effects in the long run.
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In the B-PROOF trial, which selected and included participants with elevated homo-
cysteine levels, B-vitamin supplementation was observed to may have been beneficial 
in reducing fractures, but only in individuals with high total homocysteine concentra-
tions (Chapter 3.2). This suggests that in subgroups of older persons or those with a 
higher risk of a deficiency of B-vitamins, supplementation may decrease the risk of 
fracture. However, it was a subgroup analysis and because of the low number of cases 
(n= respectively 16, 31, 23) in the stratified analysis of different levels of homocysteine 
levels (≤ 13.2, 13.2-15.1 and ≥15.1 mmol/l), these findings should be interpreted with 
caution. Similarly, in the study by Stone et al., the number of participants was too 
low to study the effects of B-vitamin supplementation among women with deficiency 
in the Women’s Antioxidant and Folic Acid Cardiovascular Study (WAFACS) (24). Thus, 
replication is needed to test the effect of B-vitamin supplementation especially in the 
deficient individuals. Potentially there is benefit of supplementation and the effect of 
B-vitamins on fracture risk in this deficient older persons.
With regard to the long-term follow-up effect of B-vitamin intervention in the B-PROOF 
trial on CVD and stroke, no effect was observed from analysis of the self-reported 
data. Systematic reviews on homocysteine-lowering with B-vitamins, showed only a 
Figure 1. Flow-chart showing an overview of reasons for non-response of participants in the 
secondary analysis of the B-PROOF trial (Chapter 3.2).
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decrease in stroke risk and not in the risk of other cardiovascular diseases, identical 
as the outcomes of the initial B-PROOF study (26, 27).
Interplay between micronutrients, Single Nucleotide Polymorphisms 
(SNPs) and drugs on disease
Diuretics and bone health
In the Rotterdam Study (RS), a positive association was observed between thiazide use 
(past and current) and bone mineral density at the lumbar spine (LS-BMD) but not with 
lumbar spine trabecular bone score (LS-TBS), a DXA-derived measure of bone micro-
architecture and quality. This relation was observed in the general population and in 
particular in participants older than 65 years, compared to participants younger than 
65 years (Chapter 4.1). In line with this observation, other studies showed a lower 
fracture risk with the use of thiazide diuretics (TDs) (28). This is further supported by 
another study among women that showed that TD users had a slower annual change in 
femoral neck and spine BMD compared to non-users, which suggests that BMD loss was 
lower in TD users, confirming the results observed in RS (29). Thus, the possible pro-
tective effects in relation to fracture risk could be explained by an increase in BMD, 
which increased with the dosage and duration of thiazide use, without improving bone 
microarchitecture. The increased BMD in TD users may be explained by estimated 
decrease in osteocalcin level, a marker of osteoblast activity, bone formation, and 
bone turnover (30) the expression of which might be influenced by TD use (Chapter 
4.1).
In contrast to thiazide diuretics, loop diuretics (LDs) may adversely affect bone health 
by inhibiting calcium reuptake. Indeed, in the Rotterdam Study, TBS was found to be 
only decreased if LDs were used in the past and LDs seem to be weakly associated with 
higher BMD when used for a period of 121-365 days, compared to never users, but the 
results were not consistent (Chapter 4.2). The potentially harmful effect of LDs on 
bone were more firmly confirmed in other studies (31-33). Because of the common use 
of LDs among older persons and the high prevalence of osteopenia and osteoporosis, 
we investigated the effect-modification of vitamin D and calcium on the association 
between LDs and bone health. Yet, in this study, no consistent associations were found 
between LD use and bone outcomes after stratification by serum 25(OH)D levels. Even 
though the analyses were adjusted for body fat mass, residual confounding may have 
biased the association between serum 25(OH)D levels and bone health caused by 
other co-morbidities, such as other measures of body composition, physical activity, 
lifestyle and health status.
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Calcium and cancer
In chapter 4.3, we studied the association between the intake of calcium (dietary 
and supplements), serum calcium level, and colorectal cancer (CRC). In this study, an 
association was only found for a higher calcium intake (≥ 1,485 mg/day), compared 
to an average calcium intake (1,100-1,485 mg/day), which suggests that normal 
intake of dietary calcium is not associated with higher risk of CRC. This association 
was also not seen between calcium supplement use and CRC, and neither between 
calcium levels and CRC risk. In addition, we found no statistically significant linear 
trend between dietary calcium intake and CRC, perhaps suggesting a threshold effect. 
From previous studies, calcium intake from dairy products may be associated with 
reduced CRC risk while the association for non-dairy calcium intake and CRC risk is 
still inconclusive (34).
The different results from this and previous studies may be explained by differences in 
bioavailability of calcium (35). After adjusting serum calcium levels for albumin in a 
subgroup, circulating serum calcium levels were observed to be positively associated 
with an increased risk of CRC. This supports the observation of the relation between 
calcium dietary intake with increased CRC risk. However, these observations do not 
necessarily indicate a causal relationship. Calcium is partly (around 40%) bound to 
albumin (36) and it is known that calcium serum level is under close homeostatic 
control (under normal circumstances), and disturbed calcium homeostasis is often 
found in diseases including cancer (37). Studying genetic determinants of calcium 
concentrations, as a stable proxy, could give more insight into calcium homeostasis. 
This is possible because through GWAS several such genetic determinants have been 
found (38), which are combined into a so-called polygenic risk score, or polygenetic 
risk score (PRS), which can explain a certain percentage of the variance in calcium 
levels in the population. Therefore, we also studied the interaction between calcium 
intake, levels and supplementation and a PRS of calcium concentrations, in relation 
to colorectal cancer risk (Chapter 4.3). Indeed, the associations between dietary 
calcium intake or serum calcium levels and CRC, were modified by the calcium PRS, 
with a lower CRC risk for subjects with a lower PRS, compared to subjects with a 
higher PRS. Taken together, results of the calcium PRS analysis suggest a relationship 
between circulating calcium and risk of cancer, but further replication in other stud-
ies with different population are needed.
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METHODOLOGICAL AND ETHICAL 
CONSIDERATIONS
Influence by a case of scientific misconduct?
For this thesis specifically the methodological and ethical considerations relevant to 
the B-PROOF trial concern two complexities: data integrity in the community of sci-
ence, and secondary post-hoc analyses as an approach for analysis of the unexpected 
adverse events, which we will discuss in this section.
The design of the B-PROOF study was based on findings of earlier observational studies 
on the association between homocysteine levels and osteoporotic fractures, includ-
ing those in the Dutch study populations of the Rotterdam Study and LASA (39-41). 
Interestingly, an intervention trial appeared, soon after these initial epidemiological 
association studies, to show that B-vitamin supplementation had a beneficial effect 
on fracture risk, which was the study by Sato et. al. (42). Many other trials, including 
the B-PROOF trial, have since been carried oud to investigate the effect of B-vitamin 
supplementation on bone health, but have not been able to replicate the results of 
the RCT by Sato et al. Therefore, around 10 years after publication of Sato’s RCT, 
concern was expressed regarding the integrity and scientific validity of Sato’s study 
(43). In the meantime, due to the null-findings of the primary results of the B-PROOF 
trial and concerns regarding the possible adverse effect of B-vitamin supplementation 
on cancer risk, the researchers in the B-PROOF trial were interested in conducting 
a meta-analysis including Sato’s trial. However, the authors did not respond to this 
opportunity despite numerous attempts to get in touch with them. At the same time, 
a study to evaluate the validity of the results reported by the Journal of the American 
Medical Association had begun, and as a result, the article by Sato et al. was retracted 
along with 21 (of 33) of his other articles due to scientific misconduct and concerns 
about data integrity (44). Unfortunately, the results published by Sato et al. had -by 
that time- already resulted in several large-scale intervention trials being conducted, 
based in part on the spurious results of Sato’s work.
The question therefore arises whether the B-proof study would have been conducted 
if the study by Sato et al. had not been published. Because of the positive results 
of other observational studies on the association between homocysteine level and 
osteoporotic fractures and the limited evidence from RCTs, the B-PROOF trial was 
designed to study the effect of homocysteine-lowering intervention through B-vitamin 
supplementation on osteoporotic fractures irrespective of Sato et al. Thus, most 
likely the B-PROOF study would still have been designed and conducted given the 
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order of events and available evidence at that time. Nevertheless, the power analysis 
of the B-PROOF trial was based on Sato’s publications, and if the study by Sato et al. 
had not been published, the power analysis based on the observational studies would 
have resulted in recruitment of a larger number of study participants and/or a longer 
follow-up.
Importantly, the question also arises if unnecessary harm could have been prevented 
if the Sato et al. study was not published. The dosage of the B-vitamin intervention 
of the initial B-PROOF trial was chosen also based on safety considerations, since 
there were already concerns regarding the adverse effects of pharmacological doses 
of vitamin B supplementation. Furthermore, individuals with a five-year history of 
cancer were excluded from the study, and if any participant reported a cancer diag-
nosis during the study, they were advised to discontinue the supplementation, while 
follow-up of the other outcomes continued. Participants were advised to discontinue 
supplementation when reached high dosage of folic acid and vitamin B12 (beyond 
recommended daily intake) when combined with the intervention. Moreover, half 
way through the study, we compared the number of incident cancer cases with the 
incidence of cancer in the general population, without de-blinding the intervention, 
and observed these figures to be similar at that point in time. As mentioned, at the 
end of the B-PROOF trial and de-blinding, there were further concerns about the 
possible adverse effect of folic acid and or vitamin B-12 supplementation on cancer 
risk based in results from the B-PROOF trial. This was studied further in a secondary 
analysis, by linking the B-PROOF data to data of the national cancer registration. 
Subsequently, the concerns were confirmed by indeed showing an adverse effect for 
these B-vitamins on incidence of cancer overall, and colorectal cancers in particular. 
So, taken together it is unlikely that unnecessary harm was inflicted on B-PROOF 
subjects by including the Sato et al. study, and all required precautions were taken to 
prevent such harm from happening.
Thus, even without the RCT conducted by Sato et al., the B-PROOF trial would have 
been designed and performed, however, probably with a different power calculation.
Lessons learned
Because we cannot turn back time, we can learn a great deal from this, one of sci-
ence’s major scandals, which by now has been widely publicized. This was however 7 
years after B-PROOF was initiated.
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Negative results are important
First of all, the number of publications is increasing, but the number of retracted 
papers is also increasing. Currently, the pressure to publish positive and novel results 
in science is high due to pressure on citation numbers in order to secure prizes and 
funding (45). Previous work has also shown that statistically significant results are 
more likely to be published than papers with null results. This could feed scientific 
misconduct, as was the case with Sato’s RCT, and potential publication bias (i.e., 
leading to distortion of the scientific literature and misleads health professionals, 
and policymakers in their decision-making (46)). It is therefore essential to be able 
to publish the negative results, too. A change in mind-set is needed when it comes 
to accepting negative papers, such as the follow-up B-PROOF manuscript with its 
null-findings on the risk of fractures and cardiovascular disease.
Secondary analyses are informative
A second methodological consideration in this thesis was the secondary post hoc analy-
sis of the long-term effect of primary and secondary outcomes as well as the adverse 
events. Most of the studies focusing on the effect of B-vitamins on the relevant health 
outcomes (fracture or cancer) are secondary analyses alongside other outcomes (such 
as cardiovascular disease), which are the primary outcome. Selection bias and sample 
size calculations are some examples of issues that need to be taken into account with 
respect to interpreting these findings. Being aware of this, in future studies, issues 
of selection- and information bias and confounding can be dealt with in the design.
For the analysis of the long-term effect of the intervention on primary and secondary 
outcomes and the adverse events in the extension of the B-PROOF study, participants 
with informed consent for future studies from the B-PROOF trial were selected. Luck-
ily as there were no differences between the intervention and the control group in 
the selected population, the randomisation was still intact. Another issue to address 
in secondary analyses is sample size. However, for studies on the unexpected adverse 
effects of supplementation such as our initial B-PROOF trial, or studies involving rare 
diseases as an outcome, it is maybe difficult to predict the correct sample size in 
advance, but assumptions are possible. It is important to report clearly that the study 
is a secondary analysis or an extended follow-up. Also, the methods of the secondary 
analysis and the number of participants which were included in the analysis derived 
from the primary trial should be reported. The recommendation of Hopewell et al. 
(2013) (47) is adapted from the 2010 CONSORT Statement, and states which informa-
tion should be included in these reports in order to enable readers to evaluate the 
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validity and reliability of the results of the secondary analysis, and ultimately to use 
these to assess the scientific implications. Possible biases should also be mentioned, 
as well as their potential effects. In the secondary analysis of the B-PROOF in chapter 
3.1, all these items are mentioned.
Longer follow up is beneficial
Moreover, a post-trial follow-up of a randomized controlled trial can provide valuable 
information about the long-term effect of the intervention on the primary outcomes 
of the trial, especially in this age category (48). Most of the RCTs are designed as 
short-term trials, but a longer follow-up time could help to detect persistent effects 
in the years following the intervention and identify the latency-effect of the interven-
tion. We expected the primary outcomes of the B-PROOF trial to detect the persistent 
effects on fracture years after the intervention, and to detect the latency-effect 
of the intervention on CVD as in the baseline and at the end of the first follow-
up, a follow-up questionnaire was used for the post-trial follow-up. Unfortunately, 
given the older age group the prolonged follow-up period resulted in a high loss to 
follow-up, resulting in limitations of the generalizability of the results. In light of this 
knowledge, prolonged follow-up is preferably already taken up in the initial study 
design. For example through patient consent forms a route could be to secure ac-
cess to routine health records in order to access data on detailed health information 
relating to these participants using diagnostic codes (e.g. ICD-10), including mortality 
data and the cause of death in follow-up participants, where relevant. Of course, 
valid informed consent at the baseline would need to be in accordance with the 
new privacy guidelines. In the Netherlands, the electronic patient record (EPD) is 
useful but sometimes difficult to obtain information source and at the time of data 
collection the use of the EPD as researcher would have let to unanticipated regulatory 
issues. Additionally, from the mortality data and the cause of death, a cause-specific 
mortality analysis can provide more information on the effect of the intervention, 
since for example several studies have indicated that cancer patients may have a 
higher risk of CVD mortality (49).
Better documentation of supplement use helps interpretation
The examination of the supplement use (over the counter or additional supplementa-
tion on top of the intervention) of the participants in the B-PROOF trial and the Rot-
terdam study was based on self-reported data, which could result in misclassification 
of supplement use due to insufficient recall problems. The use of supplementation 
also varies over the years. Another method of monitoring dietary supplement use 
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more truthfully, was used in the study by White et al.. In this study, researchers 
collected the supplements data by repeated questionnaires and then calculated an 
high validity and reliability compared with questionnaire at baseline, three months 
after, supplement inventory and to the biomarkers of the nutrients (50). In the future, 
better monitoring of the supplement use will be necessary (see below, implications 
and future research).
Dosage counts matter
Another point of discussion that needs mentioning, is the dosage of the intervention. 
For the B-BROOF study, a dosage of 500 µg/day for vitamin B12 and 400 µg/day for 
folic acid was chosen. For vitamin B12, the dosage was higher than the recommended 
daily intake (51). However, this dosage was chosen based on a dose-finding study 
which showed that a dose of 647 µg/day for four months is sufficient in an older 
population with mild deficiency to normalize vitamin B12 status (52). The majority of 
dietary supplements contains a high level of micronutrients. For some micronutrients, 
such as folic acid, there is an upper intake limit, but this is not yet the case for 
vitamin B12 (51). As some colleagues showed previously, dietary intake of vitamin B12 
is significantly associated with vitamin B12 biomarkers (53). Furthermore, the associa-
tion between total vitamin B12 intake (from diet and supplements) showed a stronger 
association with vitamin B12 biomarkers, probably due to the higher bioavailability 
and higher absorption of the free vitamin B12 from supplements (54).
Other micronutrients are also important
As we mentioned previously, other nutrients are also involved in one-carbon mecha-
nism, such as choline and methionine, and these are also relevant to the study of 
the effect of micronutrients on health. For example, choline metabolism disruption 
could affect DNA methylation (55). Additionally, high methionine is associated with 
methionine/transmethylation metabolism, which could increase DNA damage and 
carcinogenesis (56). However, more studies on the restriction of methionine and the 
prevention of cancer are needed. Unfortunately, there is no data available on these 
nutrients, but it is important to evaluate these mechanisms. However, given the fact 
that the B-PROOF trial was randomized and no major differences in baseline charac-
teristics were observed between the intervention and control group, we assume that 
the effect of the B-vitamin intervention is not explained by differences in the intake 
of other methyl donors. On the other hand, for the cross-sectional analysis of the 
B-PROOF trial and in The Rotterdam Study, other nutrients involved in one-carbon 
mechanism could have played a role. Unfortunately, these were not available.
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IMPLICATIONS AND FUTURE RESEARCH
What determines deficiency
The most common deficiencies in Western Europe are iron, vitamin D, folate and 
vitamin B12 (57). These nutrient deficiencies are fairly easy to detect, diagnose with 
laboratory tests and treat with the appropriate supplements. However, subclinical 
deficiency is difficult to recognize and can still result in pathological changes, which 
may subsequently lead to clinical diseases. It is therefore important to recognize the 
‘at-risk’ population and to treat them appropriately (for example by a dietician) in 
order to prevent clinical diseases due to the depletion of micronutrients. Community-
dwelling older persons are at risk of vitamin B12 deficiency induced anaemia that 
may be masked by the use of high dosages of folic acid (58). These potential un-
derdiagnoses that can cause neurological complications needs further investigation. 
General Practioners should therefore be alert to the correct diagnosis of vitamin B12 
deficiency, such as for example by assessing serum methylmalonic acid analysis (MMA) 
(59).
As well as the method of measuring deficiencies, the cut-off for some biomarkers is 
also under debate. For example, for vitamin D the Endocrine Society (ES) uses the cut-
off of 75 nmol/L (60) and the Institute of Medicine (IOM) uses a cut-off of 50 nmol/L 
(61) for 25(OH)D concentrations. Yet, also based on the studies presented here it is 
highly recommended that a different cut-off for deficiency should be used for each 
age group due to different nutritional needs in different stages of life, particularly 
among older age persons, and due to physiological variations, the pathological ageing 
process, the role of medication and how it influences nutritional biomarkers (62).
Body composition
Since the studies in this thesis demonstrated that body composition, and in particular 
obesity, may have an effect on micronutrient status, future studies should focus on 
the effect of changes in body composition and the mechanisms that underlie their 
potential effects on micronutrient status. For example, in a meta-analysis of studies 
that measure the changes in the body composition and changes in B-vitamin levels 
along with the interaction of the genes associated with body composition and B-
vitamins. Furthermore, due to the possible risks of unnecessary supplementation with 
high doses of B-vitamins (and possibly vitamin D) (63), a meta-analysis is needed to 
examine the differences in vitamin D and B-vitamin status in an obese population and 
whether vitamin D influences obesity-associated health risks over the short and long 
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term. The prevention of obesity (especially in early life) could be an important public 
health strategy for reducing metabolic syndrome and obesity-associated health risks.
Aspects of micronutrient research
Certain other important questions remain unanswered, including the following. Is it 
the structure of B-vitamins that makes the difference in the effect on cancer (cells), 
or the amount of intake regardless of the source of the folate/folic acid and vitamin 
B12? Is there a cut-off point for these micronutrients, after which they cease to 
be preventive and start to be harmful? What is the effect of these supplements in 
deficient people? Future research is required to understand the potential beneficial 
and adverse effects of micronutrient supplementation in more detail. Ideally, ran-
domized controlled trials would provide more insight into the negative effects of 
dietary supplements but, due to potential ethical issues, this is not possible. Analysing 
the potential harm in the relevant subgroups within a meta-analysis of all the trials 
that have measured the effect of B-vitamins and vitamin D and accurately addressing 
adverse event reports, would therefore be a better solution. It is necessary to report 
adverse events in randomized controlled trials like the B-PROOF study, but trials in 
Good Clinical Practice (GCP)-based pharmaceutical settings have stricter rules for 
monitoring of adverse effects. In the future, there should be better monitoring of the 
use of dietary supplementation and adverse effect in the general population, including 
all age groups, similar to the clinical trials used to test the (new) drugs. A mandatory 
improved report on adverse effects, drafted in accordance with the International 
Conference on the Harmonisation of Good Clinical Practice (ICH GCP) guidelines (64), 
should cover all adverse effects and analyse the risks of dietary supplements in ran-
domized controlled trial studies. However, clinical trials are not always feasible (due 
to earlier mentioned potential ethical issues), and so a population-based cohort such 
as the Rotterdam Study, with improved repeated measurement of the use of dietary 
supplements by the participants (including the use of over-the-counter supplements), 
could also provide valuable information and facilitate the analysis of the adverse 
effects of micronutrients (from food and dietary supplements). This type of study 
(population-based cohort) may also have better generalizability to the community-
dwelling population as a whole (65).
Disentangling cause and effect
However, it is important to note that, in population-based studies, the reliability 
of the results derived from association analysis, whereby the direction of the as-
sociation is not certain, i.e. potential ‘reverse causation’, is not always adequate. 
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Moreover, residual confounding is a problem in observational studies, and therefore 
Mendelian randomization (MR) could provide a solution, because this method is less 
likely to be affected by reverse causation or confounding. This method provides evi-
dence about assumed causal relationships between a modifiable risk factor and the 
outcomes of interest, by using genetic variations as natural experiments. In our case, 
the genetic variants could be that for homocysteine to support causal inferences 
regarding the effect of cardiovascular disease (modifiable risk factors) (66). It should 
be noted that this method depends on assumptions for a valid instrumental variable: 
the relevance assumption (the instrumental variables should associate with the risk 
factor of interest); the independence assumption (the instrumental variables should 
share no common cause with the outcome); and the exclusion restriction assumption 
(the instrumental variables should do not affect the outcome except through the risk 
factor). Together this means that pleiotropy, i.e., one gene and/or variant of a gene 
can have multiple biological functions, can be a problem here, and will need to be 
addressed in future MR studies.
The challenge of drug-nutrient interactions
In our aging society prevalence of medications use is high and continues to rise, 
with accompanying polypharmacy. Furthermore, older age is an important risk factor 
for nutritional status, thus also prevalence of poor nutritional status is rising. As 
such, recognition of the importance of food and drug interaction has been growing in 
clinical practice (67). Diuretics are frequently prescribed in the treatment of heart 
failure and hypertension (68, 69), and they have been shown to influence calcium 
homeostasis and bone metabolism. As mentioned previously, the association between 
the use of diuretics and trabecular bone score has not been investigated previously, 
and the possible changes in bone microarchitecture need more detailed research using 
more refined techniques, such as high-resolution peripheral quantitative computed 
tomography (HR-pQCT). Further studies are needed to investigate the association 
between loop diuretics and general bone health, especially trabecular bone score. 
Moreover, research and replication is needed on nutrient-drug interactions with bone 
health, using other biomarkers such as PTH and bone turnover markers. Nutrient-drug 
interactions are largely understudied. The knowledge about this subject is scarce and 
awareness of potential adverse effect of nutrient-drug interaction, and also training 
for clinicians is needed (67). Guidelines for the prevention of bone loss due to use of 
loop diuretics might also be helpful. Future research should also focus on the associa-
tion between polypharmacy and nutritional status in the older population due to the 
higher use of medication among this group and the possible association with reduced 
intake of some nutrients and potential food-drug interactions (70).
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An early recognition of (colorectal) cancer
Clinical trials are not always achievable, as mentioned before. Thus to assess the 
effect of the B-vitamin supplementation on cancer an early diagnosis of malignant 
neoplasm is appreciated. Biopsies are the standard methods for diagnosis of lesions 
(71, 72), which are often invasive methods for the patient. Currently, research into 
microRNA (miRNA) and cancer is being conducted and has shown that the expression 
of miRNAs is dysregulated in different tumours and miRNAs is suggested as a potential 
biomarker for diagnostic and also prognostic targets in cancer (73, 74). In the follow-
up to B-PROOF, we could have measured such potential biomarkers in order to detect 
a variety of common cancers earlier; however, due to budget constraints we were 
unable to do this, so we linked our data to data of the national cancer registration 
for the diagnosis of cancer. In other studies, the role of the miRNAs has been shown 
in the diagnostic and treatment of colorectal cancer (75), which could be used to 
investigate the effect of B-vitamin supplementation on cancer risk in the future.
Is folic acid fortification universally good ?
As we know, fertile women are advised to take folic acid pre- and peri-conceptionally 
in order to reduce the risk of neural tube defects (76). For this reason, folic acid 
fortification (folic acid added to enriched grain products) has been introduced in 
some countries. Due to fortification, the National Health and Nutrition Examination 
Survey Data determined a higher folic acid intake, which exceeded the upper limit 
intake (77). Now that we suspect a possible adverse effect of excess folic acid and/
or vitamin B12 intake among older persons (presumably with malignant cells), the 
question arises as to whether it is still appropriate to add folic acid to food, since the 
majority of the population does not need extra folic acid or other micronutrients. On 
the other hand, there may be arguments that the older population may also benefit 
from fortification (due to their higher likelihood of deficiencies because of inadequate 
diet and changes in the absorption and excretion of micronutrients (78)). A recent 
study evaluated the effect of voluntary fortification of vitamin B12 and folic acid, and 
showed that in older adults, fortification was not an effective manner of preventing 
deficiencies (79). The B-PROOF study evaluated the effect of folic acid and vitamin 
B12 supplementation, and this study provides a further insight into the potential 
adverse effect of these micronutrients in the older population and contributes to 
evaluation and decision-making around the fortification of food. The suggestion from 
work presented in this thesis is not to stimulate widespread use but to limit the ad-
vice to consume micronutrients (through supplements) to pre- and peri-conceptional 
women and others who need additional micronutrients, such as those with a proven 
General discussion & summary 217
5
deficiency. However, although it is conceivable that deficient individuals may be more 
likely to benefit from supplementation (80), studies addressing the specific subpopu-
lations who may or may not benefit from supplementation are scarce.
Again, the B-PROOF study showed an adverse effect of vitamin B12 (and/or folic acid) 
on cancer, especially on colorectal cancer, and another recent study showed a poten-
tial association between higher vitamin B12 level and higher mortality, which has to be 
confirmed in other studies (81). Nevertheless, the adverse effects of high vitamin B12 
is the subject of debate (with respect to both intake and level), and therefore, it can 
be argued that setting a maximum upper intake level for vitamin B12 (from supple-
ments) is preferable in order to avoid the excessive intake of this micronutrient.
CONCLUSION
To conclude, the community-dwelling older population with obesity or excess body 
weight is at increased risk of deficiency in several micronutrients including vitamin D, 
vitamin B12 and folate. Those with obesity may need a higher intake of micronutri-
ents. However, considering the potentially adverse effects of B-vitamins and the risks 
with respect to health outcomes, including more acute life-threatening ones such as 
cancer, dietary supplements may not always be beneficial to health in this popula-
tion. Consequently, I do not recommend using B-vitamin supplementation for older 
persons as a population group, and micronutrients should preferably be obtained from 
a balanced diet. On the basis of the findings of this thesis it is suggested that supple-
ments are recommended in case of proven deficiency but, even then, not in excessive 
amounts. The optimum dosage for supplementation needs to be further investigated. 
Furthermore, the use of micronutrients should be monitored carefully and the poten-
tial risks and adverse effects of dietary supplements should be investigated thoroughly. 
Possible nutrient-drug interactions also need to be explored in greater depth.
Finally, due to the impact of “frailty”, i.e., the combined effect of several chronic 
disabling and degenerating phenomena in elderly, in a community-dwelling older 
population, future interventions should focus on addressing factors that may ac-
celerate the ageing process and exacerbate nutritional status, as described in the 
introduction. Such factors include quality of nutrition and improving physical activity 
to prevent frailty in the ageing population. Good quality of nutrition includes simply 
following the official guidelines for healthy nutrition and an achievable, personalized 
physical activity/exercise regime that suits the daily life of the ageing population 
under the supervision of a dietician.
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The growing interest in the role of micronutrients in optimizing health and prevention 
of diseases results in increasing in use of dietary supplements. Ageing is associated 
with higher risk on fracture, coronary heart disease, stroke, cancer and frailty. How-
ever, there is limited evidence to evaluate the role of the micronutrients in health and 
disease among older adults. Common used micronutrients are B-vitamins, calcium and 
vitamin D. Consequently, it is essential to identify the role of these micronutrients 
on the most common diseases in the ageing population. In this thesis we addressed 
the effect of these micronutrients on body composition, fractures, cardiovascular 
diseases and cancer. Furthermore, the role of the interaction of calcium and vitamin 
D in the association between diuretics and bone health, and the interaction of SNPs 
in the association between calcium and colorectal cancer is described in this thesis. 
Chapter 1 provides a general introduction on B-vitamins in the one carbon mechanism, 
calcium and vitamin D, the role of these micronutrients on health and disease and a 
description of the studies based in this thesis.
In all age categories, prevalence of overweight is growing, including the older popula-
tion (1). Overweight has been associated with several diseases, such as increased 
risk of coronary heart disease, type 2 diabetes, strokes and certain types of cancers 
(2, 3). In chapter 2, we examined the association between vitamin D, B-vitamins 
and body composition in the B-PROOF study. We observed that a higher BMI and fat 
percentage were associated with lower serum 25(OH)D levels in older population. 
Also that overweight persons and persons with a higher fat percentage were at risk of 
vitamin D insufficiency. B-vitamins were associated with body composition, however, 
we found no effect of the B-vitamins intervention on body composition. This suggests 
that B-vitamins may not have a role in the etiology of obesity or changes in the body 
composition in this population.
In chapter 3 we showed that treating older persons with moderately increased homo-
cysteine concentrations with combined folic acid and vitamin B12 supplementation 
was associated with a mild excess risk of overall cancer and statistically significant 
increased risk for colorectal cancer when compared with control group. This effect 
was even more pronounced in compliant participants. Furthermore, we assessed the 
long-term effect of micronutrients on other disease outcomes and found neither an 
effect on fracture risk, nor on cardiovascular disease in older individuals in the ex-
tended follow-up study of the B-PROOF trial. Individuals with high total homocysteine 
concentrations, probably with a higher chance of deficiency of B vitamins, might have 
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a decrease risk of fracture after supplementation. However, due to the low number 
of cases in the stratified analysis these findings should be interpreted with caution.
The interplay of micronutrients, SNPs and drug on diseases was evaluated in chapter 
4. A positive association was shown between thiazide use (past use and current use) 
and LS-BMD and no association was found between thiazide use and LS-TBS. The 
associations were seen in participants older than 65 years old. In contrast to the 
thiazide use, we showed a decrease in LS-TBS if LD use was for a longer period and an 
increase in LS-BMD if LD use was for a short time period. Hence, our study prevents 
any strong conclusion on the impact of LD-use on bone health. Moreover, we found no 
consistently modified effect by vitamin D or dietary calcium intake in the association 
between LD-use and indices of bone health.
Finally we evaluated the association between calcium (intake and level) and 
colorectal cancer with the interplay of SNPs for calcium level in these associations. 
Dietary calcium intake higher than 1.485 mg/day compared to average calcium intake 
(1.100-1.485 mg/day) seems to be protective for CRC. However, after adjusting in a 
subgroup for albumin, we found an increased risk of CRC for dietary calcium intake. 
The weighted genetic risk score (GRS) from the calcium level SNPs were significant in 
the interaction analysis between calcium intake and calcium level and CRC risk. After 
stratification, we observed a lower CRC risk for subjects with a lower GRS. Overall, 
calcium homeostasis could contribute in other disease processes, i.e. neoplasms, and 
since other factors could play a role in calcium homeostasis and CRC risk which should 
investigated in the future.
Based on the results of this thesis, dietary supplementation is recommended for 
people with proven deficiencies and not above recommended daily doses. The optimal 
dose for dietary supplementation should be further investigated. Furthermore, the 
use of micronutrients should be monitored for the potential risks. Negative effects of 
supplementation should be investigated in the future. Also, the interaction between 




Door de grote interesse in de rol van micronutriënten bij het verbeteren van gezondheid 
en het voorkomen van ziektes, is het gebruik van voedingssupplementen toegenomen 
in de laatste jaren. De meest gebruikte micronutriënten zijn B-vitaminen, calcium 
en vitamine D.Veroudering is geassocieerd met een hoger risico op botbreuken, hart- 
en vaatziekten, kanker en andere problemen bij kwetsbare ouderen. Uit de geringe 
bewijzen uit de wetenschap is het lastig om de rol van micronutriënten bij gezond-
heid en ziekte(-ontwikkeling) van ouderen vast te Hierdoor is het belangrijk om de 
rol van micronutriënten (specifiek B-vitaminen, calcium en vitamine D) op de meest 
voorkomende ziektes bij ouderen te onderzoeken. In dit proefschrift behandelen we 
het effect van deze micronutriënten op lichaamssamenstelling, botbreuken, hart- en 
vaatziekten en kanker. Daarnaast, beschrijven we de rol van de interacties van calcium 
en vitamine D in de associatie tussen diuretica en botgezondheid, en de interactie van 
de SNPs in de associatie tussen calcium en colorectaal kanker. Hoofdstuk 1 bevat een 
algemene introductie over B-vitaminen in het ‘one-carbon’ mechanisme, calcium en 
vitamine D. Daarnaast gaat hoofdstuk 1 nader in op de rol van deze micronutriënten 
op gezondheid en ziekten, en wordt een beschrijving gegeven van de studies die in dit 
proefschrift aan de orde komen.
In alle leeftijdscategorieën, zien we overgewicht toenemen, zo, ook bij ouderen. 
Overgewicht is geassocieerd met ziekten zoals een verhoogd risico op hart- en vaat-
ziekten, type 2 diabetes, beroerte en sommige kankersoorten. In hoofdstuk 2 hebben 
we de associatie tussen vitamine D en B-vitaminen en het lichaamssamenstelling 
onderzocht in de B-PROOF studie. In de populatie van de B-PROOF studie, vonden we 
dat een hogere BMI en een hoger vetpercentage geassocieerd zijn met lagere 25(OH)
D waarden. Daarnaast zagen we dat mensen met overgewicht en een hoog vetpercen-
tage mogelijk vitamine D insufficiënt waren. Overigens vonden we dat B-vitaminen 
geassocieerd waren met lichaamssamenstelling, maar we vonden geen effect van 
de interventie met de B-vitaminen op lichaamssamenstelling. Dit suggereert dat B-
vitaminen mogelijk geen rol hebben in de etiologie van obesitas of veranderingen in 
lichaamssamenstelling van personen binnen deze populatie.
In hoofdstuk 3 hebben we laten zien dat de oudere populatie met een mild verhoogde 
homocysteïne concentratie, die foliumzuur en vitamine B12 suppletie hadden gekre-
gen (de interventie groep), een mild verhoogd risico hadden op ontwikkeling van alle 
kankersoorten en een statistisch significant verhoogde kans op colorectaal kanker, 
vergeleken met de controle groep. Dit effect was zelfs meer aanwezig bij trouwe 
deelnemers, die de suppletie bijna elke dag innamen. Verder hebben we het lange 
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termijn effect van micronutriënten op andere ziekte-uitkomsten onderzocht. In de 
verlengde follow-up van de B-PROOF studie vonden we geen effect van de interventie 
op zowel botbreuken als op hart- en vaatziekten binnen de oudere populatie. In de 
groep ouderen met verhoogde homocysteïne concentratie (>15.1 mmol/l), die waar-
schijnlijk een hogere kans hebben op B-vitamine deficiëntie, vonden we dat suppletie 
risico op botbreuken mogelijk vermindert. Echter, door het lage aantal botbreuken 
in de gestratificeerde analyse, moeten deze bevindingen voorzichtig geïnterpreteerd 
worden.
De wisselwerking tussen micronutriënten, SNPs en medicatie op ziektes is geëvalueerd 
in hoofdstuk 4. Een positieve associatie tussen het gebruik van thiazide medicatie 
(zowel gebruik in het verleden als het huidig gebruik) en LS-BMD was gevonden. 
Daarnaast is er geen associatie gevonden tussen thiazide gebruik en LS-TBS. Deze 
associaties werden gezien bij participanten ouder dan 65 jaar. In tegenstelling tot 
thiazide gebruik, hebben we een verlaging in LS-TBS laten zien voor een andere 
diuretica, namelijk lis diuretica (LD), als deze voor een langere periode gebruikt 
was. Daarentegen, zagen we een verhoging van LS-BMD indien LD voor een kortere 
periode werd gebruikt. Daarom kunnen we met onze studie geen sterke conclusies 
trekken over de invloed van LD gebruik op botgezondheid. Daarnaast hebben we geen 
consequent effect modificatie van vitamine D, of inname van calcium gevonden in de 
associatie tussen LD gebruik en diverse metingen van botgezondheid.
Als laatst in hoofdstuk 4 hebben we de associatie tussen calcium (gemeten naar in-
name en via bloedwaarde) en colorectaal kanker geëvalueerd, rekening houdend met 
de wisselwerking van SNPs (die belangrijk zijn voor calcium in het bloed) in deze 
associatie. Hierin vonden we dat calcium inname uit voeding hoger dan 1.485 mg/
dag mogelijk beschermend werkt tegen colorectaal kanker, dit vergeleken met de 
gemiddelde calcium inname (1.100-1.485 mg/dag). Echter, na de correctie voor de 
albumine waarden in een subgroep analyse, vonden we juist een verhoogd risico op 
CRC bij een hogere calcium inname uit de voeding. De gewogen genetische risico 
score van de 7 SNPs voor calcium waarden waren significant in de interactie analyse 
tussen calcium inname, calcium uit het bloed en CRC risico. Daarin vonden we een 
lager CRC risico bij mensen met een lagere GRS. Het lijkt dat er andere factoren, 
die een rol spelen in de calcium homeostase, betrokken zijn bij de associatie tussen 
calcium en het risico op colorectaal kanker. Dit vraagt om nader onderzoek.
Op basis van de bevindingen van dit proefschrift, wordt het innemen van voedings-
supplementen enkel aangeraden bij een bewezen deficiëntie worden gebruikt, en 
bovendien niet in grote hoeveelheden. De optimale dosis voor voedingssupplementen 
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zou nog onderzocht moeten worden. Daarnaast dient het gebruik van micronutriënten 
nauw gemonitord te worden. Het potentiële risico en de negatieve effecten van 
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and Rotterdam. From 2010 on she started at Erasmus MC as a research assistant for 
the B-PROOF trial (a multi-center study with Wageningen University and VU University 
Medical Center), helping with the inclusion of participants and other practical work. 
In the meantime she wrote her first published paper. After the end of the B-PROOF 
trial, Sadaf worked between 2013 and 2014 at the department of Neuroscience and 
Surgery, where she worked together with colleagues on systematic reviews on music 
intervention in surgery.
In 2015 she started a PhD project as a part-time job at the department of Internal 
Medicine at Erasmus MC on micronutrients in health and diseases. Sadaf worked 
mainly on the follow-up study of the B-PROOF study, and the Rotterdam Study (a large 
prospective cohort study in Rotterdam Ommoord). Since April 2020, Sadaf works as 





Gedurende afgelopen 10 jaar bij het Erasmus MC, heb ik veel mensen leren kennen 
en heb met ze samen kunnen werken. Laat me beginnen bij het begin toen ik voor 
het eerst bij het Erasmus MC ben komen werken. Dankzij Sandra Smits en Nathalie 
van der Velde ben ik bij de B-PROOF familie terecht gekomen. Dank voor deze kans 
om in een onderzoekswereld met alles erop en eraan binnen te wandelen. In de loop 
van die jaren heb ik naast Anke, Suzanne en Annelies mogen ervaren hoe het zou zijn 
om te promoveren. Bedankt voor jullie steun en begeleiding en fijn om bij te dragen 
aan de dataverzameling. Lieve Sandra, Anke, Suzanne en Annelies, wat vind ik het 
leuk dat we nog steeds contact hebben en dat ik van tijd tot tijd in mijn agenda kan 
zetten: etentjes met de ‘ex-B-PROOF-crew’. Nadat B-PROOF ‘afgelopen’ was, heb ik 
de mogelijkheid gekregen van Nathalie, Prof. Uitterlinden en Prof. Stricker om mijn 
eigen promotie onderzoek te beginnen. Bedankt voor het geloof in mij en de kans om 
dit pad te mogen bewandelen.
Beste Prof Stricker, uw deur is altijd open geweest voor mij en het was fijn om in de 
buurt te kunnen komen werken in het NA gebouw. Beste Jessica, ik ben jou enorm 
dankbaar voor je begeleiding en dat je mijn (co)promotor wilde zijn. Wat heb ik geluk 
gehad om met jou te mogen samenwerken en over mijn papers en andere zaken te 
discussiëren. Inmiddels ben je hoogleraar geworden. Jij was (en bent) mijn inspiratie 
om door te gaan wanneer het mij moeilijk werd.
Beste promotiecommissie, Prof. dr. Francesco Mattace Raso, Dr. Joyce van Meurs, 
Prof. dr. Ellen Kampman, Prof. dr. Paul Lips en Prof. dr. Jacobijn Gusseklo, ik wil jullie 
hartelijk bedanken voor het opponeren en de tijd die jullie hebben genomen om mijn 
proefschrift te beoordelen.
Even een tussenstapje/uitstapje in mijn carrière, namelijk de periode vlak vóór 
mijn promotie traject. Dankzij Prof. Oscar Franco ben ik terecht gekomen bij Prof. 
Hans Jeekel, dank daarvoor beste Prof. Franco. Beste Prof. Jeekel, dank voor de 
mogelijkheid om bij te dragen aan een systematische review binnen een heel leuk en 
leerzaam project, namelijk ‘Music as Medicine’. Marianne, ik vond het altijd gezellig 
om met jou samen te werken. Ook al was je vaak in Zuid Afrika voor je eigen promotie 
onderzoek, we hebben wel een leuke tijd gehad samen in het Z-gebouw. Beste prof. 
Monique van Dijk en Prof. Myriam Hunnik, van jullie heb ik veel geleerd over het 
schrijven en analyseren van een systematische review, bedankt daarvoor. Ik heb in die 
periode ook samengewerkt met Martine Busch van het Praag Instituut en Miek de Jong 
van het Louis Bolk Instituut (in samenwerking met ZonMW) aan het project ‘integra-
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tive medicine’. Ik vond het een zeer leerzame ervaring, bedankt beste Martine en 
Miek dat ik hier deel van mocht uit maken.
In de loop van de jaren heb ik in verschillende gebouwen van Erasmus MC gewerkt 
en mede door de nieuwe flexplekken, heb ik veel verschillende PhD studenten leren 
kennen. Laat me beginnen met de EPI-IPCI ‘gang’: Kiki, Linda, Natalie, Leila, Esmée, 
Eliza, Emmely, Christel, Marlies, Jesse, Fariba, Remy en Maarten, maar ook latere 
studenten Cynthia, Ross, Johnmary, Banafsheh, Fereshteh, Negin, Aniek en Tom. Dank 
voor de gezelligheid, steun, feedback, tripjes, etentjes, sinterklaas- en kerstavonden. 
Hierna ben ik zeker nog van plan om in ieder geval sinterklaas met jullie te blijven 
vieren hoor! Ik wil graag ook alle post-docs en begeleiders in deze groep bedanken 
voor de adviezen tijdens mijn presentaties.
، چقدر خوب که من تنها ایرانی نبودم لیال، فریبا، بنفشه، فرشته و نگین جان





Lieve Kiki en Linda, wat fijn dat we nog steeds in contact zijn met elkaar en vaak 
kunnen afspreken voor etentjes. Linda, jij bent al mijn maatje met kickboksen, leuk 
dat Kiki ook soms mee komt om lekker los te gaan op de zak. Dankzij onze appgroep 
kunnen we alle frustraties en leuke nieuwtjes met elkaar delen. Leuk dat jullie mijn 
paranimfen willen zijn en bij deze wil ik jullie erg bedanken voor al jullie hulp.
Daarnaast wil ik graag de Nutrition & Lifestyle ‘gang’ bedanken: Trudy, Mirjam, Kim, 
Anh Nhi, Michelle, Marlou, Amy, Eralda, Monica, Macarena, Yuchan, Carolina, Niels, 
Noreen, Maria en Zhangling. Bedankt voor de leuke en leerzame meetings, uitjes en 
het gezelschap als tijdelijke kamergenootjes. Kim en Anh Nhi, leuk om met jullie naar 
Nutrition 2019 geweest te zijn, en Washington en Baltimore te ontdekken. Hopelijk 
kom ik jullie en de rest van de Nutrition ‘gang’ nog tegen bij de activiteiten van de 
NAV (Nederlandse Academie van Voedingswetenschappen).
Laura, leuk dat ik je heb leren kennen en bedankt voor o.a. je steun tijdens mijn 
presentaties bij de NAV. Ik vond het heel gezellig als ik mijn overleggen met Jessica in 
Den Haag kon combineren met koffie dates met jou. Veel succes met je promotie en 
hopelijk komen we elkaar vaak tegen in de toekomst.
Af en toe zat ik ook nog bij de werkoverleggen van de genetica groep. Hier heb ik, ook 
al is mijn kennis beperkt in dit domein en gaat mijn thesis niet over dit onderwerp, 
veel van geleerd. Wederom bedankt Prof. Uitterlinden dat ik bij de gezellige jaarlijkse 
kerstdiners aanwezig mocht zijn.
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Caroline dank voor je inzet voor de B-PROOF studie, ik kreeg elke keer een bericht dat 
er een vragenlijst bij jullie terecht was gekomen en jij zorgde dat het goed terecht 
kwam. Eline, dank voor de praktische hulp en ondersteuning. Je bent altijd attent en 
lief voor iedereen, en misschien kunnen we ooit samen de vioollessen weer oppakken.
Alle co-auteurs van mijn manuscripten over botgezondheid, Fernando, Kate, Fjorda 
en Carola bedankt voor jullie input en kennis hierover. Ook wil ik de rest van de co-
auteurs bedanken voor jullie input en bijdrage aan mijn manuscripten, zonder jullie 
was dit niet mogelijk.
Lieve 2919 B-PROOF deelnemers en daarnaast nog 3323 geïnteresseerden, dank voor 
jullie deelname en inzet. Zonder jullie deelname en interesse zou B-PROOF niet 
hebben bestaan. Ook hartelijk dank voor het vertrouwen in mij om jullie te mogen 
prikken voor de bloedafnames ondanks mijn geringe ervaring hierin. Ik vond het heel 
leuk om met jullie te kletsen tijdens de inclusie en metingen. Wat waren jullie al-
lemaal geïnteresseerd en positief toen ik vertelde dat ik uit Iran kom. Ook wil ik alle 
studenten die B-PROOF hebben geholpen met de praktische taken bedanken.
Lieve collega’s van het Flevoziekenhuis, dank voor jullie steun tijdens de laatste 
loodjes van mijn proefschrift. 
Mijn lieve Iraanse vriendinnetjes, Azadeh, Farnoush, Mandana, Elnaz, Pegah, Reihaneh, 
Bita, Nastaran, Nasrin, Shahrzad en Mariam, bijna Iraanse vriendinnetje, jullie wil ik 
ook bedanken voor jullie steun, etentjes, feestjes, het bieden van een luisterend oor 
en de afleidingen die ik nodig had tijdens mijn promotie traject. Fijn dat ik deze fase 
van mijn leven kan vieren met jullie. Love you all.
Lieve Rubella en Marleen, mijn middelbare school vriendinnetjes, wat ben ik blij dat 
we nog steeds contact met elkaar hebben en nu ieder met eigen gezinnetje. Samen 
met Roberto en Nico waren jullie heel lief en behulpzaam voor mij toen ik amper 
Nederlands kon praten. Ik vind het grappig dat jullie elke keer zeggen dat ik de 
enige ben, die jullie van die tijd kennen, die gaat promoveren. Daarnaast ook mijn 
Vu studiegenootjes Jedidja en Lu, ook al zien we elkaar niet heel vaak, maar als we 
afspreken, is het altijd als vanouds! Hopelijk houden we nog heel lang contact met 
elkaar, ook al wonen we heel ver van elkaar.
Lieve schoonfamilie, bedankt voor al jullie steun, gezelligheid en liefde voor mij. Ik 
bof enorm met jullie om me heen en voel me zeer welkom bij jullie.
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Mijn ouders wil ik ook bedanken dat ze een enorme stap hebben gezet om naar 
Nederland te komen om een meer zekere toekomst voor ons te kunnen bieden. Ook 
al was het niet zo makkelijk voor jullie om dit stap te kunnen zetten. Door jullie 
doorzettingsvermogen en liefde ben ik nu waar ik nu ben.
هلند، یک مامان و بابای عزیز، ممنون برای همه چیز. ممنون که مارو آوردید 
کشور غریب، با اینکه برای خودتون خیلی سخت بود و هنوز هست. بدونید که به 
هر جا که رسیدم تا االن مدیون شما هستم و بهتون افتخار میکنم. امیدوارم 
 سایتون همیشه باال سر ما باشه. دوستتون دارم.
 
Siavash, lieve broer, wat ben ik trots op jou met je creatieve (zie de cover) en lieve 
eigenschappen (ook al laat je het niet vaak zien). Ik hoop dat je kunt bereiken wat 
je in je dromen hebt. Je bent de leukste en liefste oom voor Nila die ze kan wensen, 
dooset daram.
Lieve Bram, dank voor je steun en geduld. Jij was en bent er altijd voor mij en voor 
Nila. Jij bent de allerliefste en grappigste echtgenoot en papa. Ik ben trots op je en 
hoop dat we samen heel oud worden. Lieve Nila, mijn allerliefste dochter, wat ben ik 
trots op jou en wat ben ik blij dat ik je mama ben. Jij hebt veel meegemaakt vanaf 
je geboorte, maar je bent nu al heel sterk. In mijn moeilijke tijden, was het alleen 
al genoeg om naar je te kijken. Jij maakt samen met papa mijn dag en mijn leven 
altijd veel beter. Ik geniet samen met jullie en daar gaat het uiteindelijk om ♥ Ik houd 




  متخود لد دق رب ابق دنچ
  متخورفا درخ غارچ دنچ
 
 تسین شیرارق هک ار کلف ریپ
 متخومآ بجعلتوب سب شدرگ
 
 نم نامهم دمآ مرک جنگ
  متخوت مرک ز ناریقف ماو
 
 تسین شیب منخس هس نیا زا لصاح
 متخوس و متخوس و متخوس
 
 زابکاپ نم معمش لثم رب
  متخودنا هک لخد نآ متخیر
 
 ناج یسیع هتکن یسب هک سب
 متخوپسا رخ شوگ رد و لد رد
 
 هصقن اند مت اذا هک سب
مت خوش منص دیوگنب ات  
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